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CHAPTER 1
General IntroductIon
w. boorsma
This thesis focuses on the role of insulin secretion and insulin sensitivity in the patho-
physiology of type 2 diabetes and its main complication, cardiovascular disease. In this 
introduction we present the main working hypotheses and list the main research questions 
addressed in this thesis. First we discuss the research questions related to hyperglycaemia, 
followed by those related to cardiovascular disease.
 
DiabETES mElliTuS; “a glObal burDEN”
Diabetes mellitus, a disease known from ancient times, has reached epidemic proportions 
in the previous decade, with 194 million affected people worldwide in 2003 1. Diabetes 
mellitus is clinically distinguished by two forms. Type 2 diabetes mellitus is characterised 
by a relative shortage of insulin and accounts for some 90% of the adult onset diabetes. 
The remaining 10% (type 1 diabetes), is a compilation of monogenic forms such as matu-
rity onset diabetes of the young 2 and mitochondrial diabetes 3 or late onset auto-immune 
diabetes 4. Type 1 diabetes is characterised by an absolute shortage of insulin.
Type 2 diabetes is not very likely to disappear in the near future. Global estimations predict 
a further increase of more than 50% for the year 2030, with the greatest increase in the 
developing countries of Africa, Asia and South America 5. In more developed countries 
the prevalence of diabetes is now around 6% in the general population (most prevalent in 
middle aged and elderly). In the Netherlands the prevalence of type 2 diabetes was found 
to be 3,8% in 2003 6. However, because of the increasing prevalence of overweight and 
obesity, type 2 diabetes is now also prevalent in  obese adolescents; in the US 4% of these 
persons have been found to have diabetes while 25% had abnormal glucose tolerance 7. 
A large part of the medical and socio-economic burden of the disease, which can be as 
high as 10% of the total health care expenditure in many countries 1 8, is mainly caused by 
the diabetes associated complications. Cardiovascular disease (CVD) morbidity and mor-
tality are 2 to 4 fold greater in type 2 diabetic patients compared to non-diabetic people 9 
for a great part due to accelerated athero-genesis. Micro-vascular complications include 
renal disease, retinopathy and neuropathy 10. 
The incremental costs of  patients with type 2 diabetes tend to start 8 years earlier than the 
actual time of diagnosis 11.  This can be explained by the obesity related clustering of CVD risk 
factors, as for example hypertension and abnormal lipid levels (see metabolic syndrome), 
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which often precedes the clinical development of hyperglycaemia by at least 7-10 years. 
Among non-diabetic persons two other forms of hyperglycaemic state are distinguished 
(table 1); impaired glucose tolerance (IGT) and impaired fasting glucose (IFG). They are 
considered pre-diabetic states, because persons with IGT or IFG carry a high risk for the 
development of type 2 diabetes 12 13.  Furthermore, they share with type 2 diabetes, the 
tendency to cluster cardiovascular risk factors 14. 
 
Diagnosis of type 2 diabetes, impaired glucose tolerance and impaired fasting glucose.
Type 2 Diabetes, impaired glucose tolerance and impaired fasting glucose are diagnosed in 
accordance with the World Health Organization (WHO) and International Diabetes Federa-
tion (IDF) recommendations from 1999 & 2006 15 16, using both fasting and post glucose 
load (75 g) values of plasma glucose (Table 1).         
Table 1. biochemical criteria (venous plasma) for normal glucose tolerance and the diagnosis of diabetes 
mellitus, impaired glucose tolerance and impaired fasting glucose*
Glucose concentration,  
mmol l-1 (mg dl-1)
(Venous plasma)
normal glucose tolerance (nGT):
fasting and
2-h post glucose load
< 6.1 (< 110)
< 7.8 (< 140)
diabetes mellitus (T2dM):
fasting and/or
2-h post glucose load
≥ 7.0 (≥ 126)
≥ 11.1 (≥ 200)
Impaired glucose tolerance (IGT):
fasting (if measured)
and 2-h post glucose load
< 7.0 (< 126)
≥ 7.8 (≥ 140 ) and < 11.1 (< 200)
Impaired fasting glucose (IFG):
fasting and (if measured)
2-h post glucose load
≥ 6.1 (≥ 110) and < 7.0 (< 126)
< 7.8 (< 140)
       
*adapted from “definition,diagnosis and classification of diabetes mellitus and its complications, who geneva, and the “international 
diabetes federation igT/ifg consensus statement” 15;16. Venous plasma, venous whole blood and venous capillary values are given in 
the original reports.
riSk faCTOrS fOr TypE 2 DiabETES
GEnETiC FACTORs
Both genetic predisposition and environmental factors are involved in the pathogenesis of 
type 2 diabetes. A positive family history confers a 2 to 4 fold risk for type 2 diabetes and 
15-25% of first degree relatives of patients with type 2 diabetes develop impaired glucose 
tolerance or diabetes 17. The prevalence of type 2 diabetes in offspring is estimated to be 
60% by the age of 60 years 18. Already several genes have been identified to be associated 
with an increased risk of type 2 diabetes 19. Development of type 2 diabetes is also depen-
dent on ethnicity: the prevalence among African-Caribbean and South Asian people is 3 to 
5 fold higher in western societies as compared to the Caucasian population 20. 
EnviROnmEnTAL FACTORs
Besides the ageing of the populations, which is strongly associated with the increase in 
type 2 diabetes, there are other environmental factors that contribute to the development 
of type 2 diabetes.  High availability of energy dense food and a more sedentary lifestyle 
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have led to an increased prevalence of overweight and obesity 21, which are strong determi-
nants of type 2 diabetes 22. In particular android (upper body) fat distribution is associated 
with an unfavourable metabolic and cardiovascular disease risk profile in both men and 
women 23-32. Another factor which recently receives a lot of attention is sleep deprivation 
(which links glucose metabolism to the brain) 33-35.
 
 
CurrENT paThOphySiOlOgiCal hypOThESiS;
GLuCOTOxiCiTy, LiPOTOxiCiTy And TyPE 2 diABETEs
Glucose homeostasis
Glucose is the premium fuel of human body cells and is therefore very important. Normal-
ly, glucose levels are sustained within a very narrow range (Table 1). This normoglycaemia 
is maintained by the balanced interplay between insulin secretion of the beta-cells in the 
pancreas and the insulin sensitivity of the target cells of muscle, liver and fat tissue. The 
pancreas adapts to changes in insulin sensitivity by enhancing secretion when the sensi-
tivity to insulin decreases, and vice versa (fig 1). The interplay between beta-cell function 
and insulin sensitivity, determining glucose tolerance, can be expressed in the so-called 
disposition index 36. Deviation from the “normoglycaemia” hyperbola, as in patients with 
type 2 diabetes or impaired glucose tolerance status occurs when the compensatory in-
crease of insulin secretion becomes insufficient for the given level of insulin sensitivity. 
Insulin sensitivity and insulin resistance
Insulin sensitivity fluctuates during life, with insulin resistance being observed primarily 
in puberty 37, pregnancy 38 with ageing 39, obesity and in poor quality sleep 34. Normal 
insulin sensitivity is seen in persons with a healthy lifestyle 40 41. Insulin resistance is pres-
ent when biological effects of insulin are less than expected for both glucose disposal in 
skeletal muscle and suppression of endogenous glucose production in the liver 42. Insulin 
resistance is strongly associated with obesity, especially with abdominal adiposity 23 31 32 43. 
Insulin resistance at the level of the beta-cell might have a role in the pathogenesis of 
defective insulin secretion 44.
Hyperglycemia and glucotoxicity
When insulin secretion becomes insufficient to maintain normoglycemia for a given level of 
insulin resistance, glucose levels gradually rise. Persisting hyperglycaemia damages the inte-
rior of blood vessels, as well as the beta-cells themselves 45 46. Reactive oxygen species formed 
during energy metabolism are normally detoxified by catalase and superoxide dismutase. 
Since beta-cells are equipped with a relatively low amount of these enzymes 45 compared 
to other cells, they are more vulnerable in states of oxidative stress, as for example during 
persisting hyperglycaemia. The defect in insulin secretion resulting from this glucotoxicity, 
among other processes (see lipotoxicity i.e.) might have its own deleterious actions on the 
metabolism 47. Decreased insulin secretion could result in disordered regulation of glucose 
levels by decreasing suppression of hepatic glucose production and reducing the efficiency 
of glucose uptake in insulin sensitive tissues. Impaired insulin secretion could also (further) 
impair adipocyte metabolism, resulting in increased lipolysis and elevated non-esterified 
fatty acid (NEFA) levels. Simultaneously raised glucose and NEFA levels are deleterious to 
islet health 48 49. This slow forward feeding mechanism could result in type 2 diabetes. Mild 
impairments in insulin secretion may also have central effects on metabolic homeostasis. 
Decreased insulin action in the hypothalamus (where insulin acts to regulate food intake 
and body weight 50) could result in weight gain and aggravation of insulin resistance. 
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Figure 1. The disposition index 
remains the same while moving 
along the hyperbola. only when 
“falling” from the ngT hyperbola, 
progression to another glucose 
tolerance state is possible and the 
di changes. di = disposition index  
ngT = normal glucose tolerance 
T2dm = type 2 diabetes
Lipid metabolism and”lipotoxicity”
Although there is now general acceptance of the concept that obesity and central distri-
bution of body fat are important determinants of insulin resistance and therefore type 
2 diabetes, the exact pathophysiological mechanisms are only partly elucidated. We do 
now know that adipocytes very actively regulate the storage and mobilisation of fat in 
a highly coordinated manner, communicate through cytokines and hormones and are 
even under direct control of the brain through recently discovered nerves 51-55. Under 
normal conditions excess fuel, both carbohydrates and fat (in the form of triglycerides), 
can be stored in fat cells, and can be mobilised again in the form of NEFA during fasting 
conditions or during exercise, through lipolysis. An increased mass of stored triglycer-
ides however, especially in adipocytes in visceral or deep subcutaneous adipose tissue 
depots, leads to large adipose cells, which become resistant to the ability of insulin to 
suppress lipolysis.  This leads to increased release and circulating levels of NEFAs which 
aggravates insulin resistance (decreases glucose uptake and oxidation) in skeletal mus-
cle and liver 56-58.  When these NEFAs accumulate in  other organs than the adipose tissue 
(ectopic fat storage), they further promote insulin resistance in liver and muscle cells 
and damage the beta-cells in the pancreas 59 60. This is known as “lipotoxicity”. The link 
between intra-hepatic lipids in non-alcoholic fatty liver disease (NAFLD) and hepatic 
insulin resistance seems tight as well 61 62. The excess of NEFAs also promotes hepatic 
triglyceride production and therefore the dyslipidemia usually seen in type 2  diabetes. 
 
 
ThE hOOrN igT-STuDy (ChapTErS 2 aND 3)
Although there was already data available on the development of type 2 diabetes in groups 
of persons defined by a certain ethnicity or carrying an increased risk for type 2 diabetes 
(Pima Indians i.e. or Mexican Indians), there was not much information available on type 
2 diabetes development in a population of Caucasian confirmed IGT subjects at the time 
when the present study was initiated. There was growing evidence that insulin secretion 
and insulin resistance equally contributed to the development of type 2 diabetes in for ex-
ample Pima Indians. However, we wanted to know if this is true for Caucasian IGT subjects 
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Figure 2. The metabolic syndrome with the clustering of cVd risk factors around insulin resistance and it’s physiological antagonist; 
hyperinulinemia. whr= waist to hip ratio, bmi = body mass index, ma = microalbuminuria , Tg = triglycerides, hdl = hdl-cholesterol,  
crp = c-reactive protein, sbp = systolic blood pressure, dbp = diastolic blood pressure. 
as well. Our hypothesis was that beta-cell dysfunction; expressed in a low DI, would be the 
best predictor for type 2 diabetes development. 
The main research questions are;
 1: Is insulin secretion a better predictor for conversion to type 2 diabetes than 
           insulin sensitivity? 
 2: What happens to the insulin secretion in relation to the insulin sensitivity 
     during 3 years of follow up?
 3: What determines the change of insulin secretion and insulin sensitivity in IGT 
     subjects?
Subcutaneous fat, visceral fat and inflammation
There are differences in metabolic, genetic and hormonal characteristics between subcuta-
neous and visceral fat tissue. When compared with visceral adipocytes (fat cells), subcuta-
neous adipocytes have low catecholamine stimulated lipolysis rates and are more 
sensitive to insulin 63-66. It has been suggested that subcutaneous adipose tissue acts as a 
‘metabolic sink’, metabolizing and storing excess free fatty acids in both fasting 67 68 and 
postprandial states 69. This may prevent ectopic fat accumulation in liver, muscle and beta-
cell and thus eventually prevent insulin resistance, impaired insulin secretion, impaired 
glucose metabolism, hyperlipidemia and increased CVD risk. In addition, it is known that 
visceral fat contains more macrophages, which are both more active and secrete more 
Interleukin-6 and Tumour Necrosis Factor-α than subcutaneous fat, which increases the 
C-reactive protein levels. This produces a chronic low inflammatory state which adds to 
the CVD risk 70.
 
Microalbuminuria
Albumin is a relatively large negatively charged protein which is usually secreted in small 
amounts in the urine (less than 20 μg/min). Microalbuminuria  71 is a state of slightly in-
creased urinary albumin excretion of 20-20 μg/min or 30-300 mg/24h 72. Microalbuminuria 
is thought to be the consequence of an increased albumin leakage through the glomerular 
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capillary wall due to increased permeability of the capillary wall, or due to increased intra 
glomerular pressure or both 73 74. Microalbuminuria is a known risk marker for cardiovas-
cular and renal disease in type 2 diabetic patients 75 76 and in non-diabetic persons 76-78. The 
risk for cardiovascular disease is independent of renal function, hypertension and diabetes 
and is already present at very low levels of microalbuminuria 76 79 80. The evidence is even 
suggesting that urinary albumin-creatinine ratio (ACR) is a continuous CVD risk factor 76 78-80. 
Known CVD risk factors associated with microalbuminuria are; age, hypertension, type 
2 diabetes, obesity, high LDL, low HDL, smoking and hyper-homocysteinemia, but they 
explain only a small part of the association between microalbuminuria and CVD. New can-
didates (or mediating mechanisms) for the explanation of the remaining part of the excess 
of CVD risk in subjects with microalbuminuria are; insulin resistance, hyper filtration 81, 
autonomic dysfunction 82 and low grade inflammation 83 84.
The Metabolic syndrome
People with diabetes or inter-mediate hyperglycemias often suffer from a condition, which 
is known as “The Metabolic Syndrome”, or MS. MS is the clustering of risk factors in 
people with insulin resistance (fig 2). The general idea behind the concept of MS is that 
the whole is more than the sum of its parts and that the MS-definition is a better predictor 
of CVD than the individual risk factors.  In order to identify people at risk for CVD, several 
suggestions have been made through the years to define MS, by several organizations and 
committees such as World Health Organization (WHO), Adult Treatment Panel (ATP) and 
IDF. Altered glucose metabolism (high fasting glucose, insulin resistance, hyperinsuline-
mia), an altered lipid metabolism (low HDL-cholesterol, high Triglycerides), hypertension 
and abdominal obesity, can all be a part of MS depending on the definition 85-87. In the 
1999 WHO definition of MS, microalbuminuria was part of the definition 15. Classifications 
above poorly agree with each other and there is still no consensus of which one should 
be used 88. On one hand ethnical differences ask for different thresholds but on the other 
hand it just proves to be very difficult to define thresholds for 3 factors at once or more. 
Another disadvantage is that continuously distributed data lose information when trans-
formed into dichotomous variables. Furthermore the “superior” prediction of CVD by MS 
is almost gone when adjustments have been made for classical risk factors. And, finally, 
there is almost no clinical relevance using MS because it does not alter the doctor’s deci-
sions on therapy in clinical practice.
What is the rationale behind MS?
It was hypothesized that the underlying factor of the clustering of CVD risk factors as ob-
served in conditions like the metabolic syndrome, impaired glucose tolerance and type 2 
diabetes is insulin resistance. In 1988 when Reaven 89 postulated the metabolic syndrome, 
albeit in a slightly different definition and form, he already hypothesized a causal relation-
ship between insulin resistance and the development of hypertension. Since then more 
and more evidence has been generated suggesting that insulin resistance is the driving 
force for the concomitant occurrence of a decompensating glucose metabolism, dyslipi-
demia and cardiovascular disease.  However, the possibility of insulin resistance being the 
consequence rather than the cause has not been ruled out by previous studies and there-
fore this paradigm is still being questioned today 90. This produced the rationale for the 
RISC Study 91 (fig 3).
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Figure 3. rationale of the risc study to determine the role of insulin resistance in the pathogenesis of cardio-vascular disease. does a 
direct link exist? The research in this thesis is based on the baseline measurements of the risc study 91.
ThE riSC STuDy  (ChapTErS 4, 5 aND 6)
The main research questions are;
	 •	Can	insulin	sensitivity	explain	the	relationships	between	body	fat	distribution	 
    and cardiovascular disease risk?
	 •		Is	insulin	sensitivity	associated	with	ECG	abnormalities,	independent	of	other	 
     CVD risk factors?
	 •		Is	insulin	resistance	independently	associated	with	microalbuminuria?
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ABsTRACT
 
CONTExT In persons with impaired glucose tolerance (IGT), both impaired insulin se-
cretion and insulin resistance contribute to the conversion to type 2 diabetes (T2DM). 
However, few studies have used criterion standard measures to asses the predictive value 
of impaired insulin secretion and insulin resistance for the conversion to T2DM in a Cau-
casian IGT population. 
ObjECTivES To determine the predictive value of measures of insulin secretion and in-
sulin resistance derived from a hyperglycemic clamp, including the disposition index, for 
the development of T2DM in a Caucasian IGT population.
DESigN, SETTiNg aND parTiCipaNTS The population based Hoorn IGT-study con-
sisted of 101 Dutch IGT subjects (aged < 75 years), with mean two-hour plasma glucose 
values, of two separate oral glucose tolerance tests (OGTTs), between 8.6 and 11.1 mmol/l. 
A hyperglycemic clamp at baseline was performed to assess first-phase and second-phase 
insulin secretion and insulin sensitivity. During follow up, conversion to T2DM was as-
sessed by means of six-monthly fasting glucose levels and yearly OGTTs. 
rESulTS   The cumulative incidence of T2DM was 34.7%. Hazard ratio for T2DM devel-
opment adjusted for age, sex and BMI was 5.74 (95% confidence interval [CI], 2.60-12.67) 
for absence of first insulin peak, 1.58 (95% CI, 0.60-4.17) for lowest versus highest tertile 
of insulin sensitivity and 1.78 (95% CI, 0.65-4.88) for lowest versus highest tertile of the 
disposition index.                                     
CONCluSiONS In these Caucasian persons with IGT, the absence of the first insulin peak 
was the strongest predictor of T2DM.
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Impaired glucose tolerance (IGT) is a strong risk factor for developing type 2 diabetes 
(T2DM). About one third of people with IGT develops T2DM in five to ten years time 1 2. 
The general idea is that insulin resistance precedes beta-cell dysfunction in the process of 
conversion to T2DM 3-7. Most evidence for the predictive value of insulin resistance and 
beta-cell function for T2DM was based on estimates derived from oral glucose tolerance 
tests (OGTTs), like fasting and two-hour post-load insulin levels, fasting pro-insulin levels, 
and the ratio between fasting pro-insulin and fasting insulin levels. However, the agree-
ment between these estimates and the criterion standards for insulin sensitivity and beta-
cell function are far from perfect 8 9. The criterion standards for assessing beta-cell function 
and insulin sensitivity are, respectively, the first (and second) insulin secretion phase of 
the hyperglycemic clamp and the M-value of the euglycemic hyperinsulinemic clamp 10.
Because of  the strong correlation between the M/I ratio of the hyperglycemic clamp and 
the M-value  11, the M/I ratio can also be used to assess insulin sensitivity. Clamp-studies 
are time-consuming, invasive, and labor-intensive and therefore difficult to use in large 
epidemiological studies. Therefore only few clamp studies have been performed. Only in 
populations with a high risk for developing T2DM, such as in Pima Indians, or in popu-
lations with IGT, have intravenous glucose tolerance tests (IVGTTs) or clamp-tests been 
used 3-6. In these studies, the first insulin secretion phase was the strongest predictor for 
developing T2DM 12. However, insulin resistance and beta-cell function have a close inter-
relationship, and this has not been taken into account in most of these studies. In general, 
insulin resistance is compensated for by an increase in  insulin secretion 7. Thus, high 
insulin production may be regarded as good beta-cell function, whereas in reality the in-
sulin production may already be impaired 13 14. This compensatory insulin secretion in the 
presence of insulin resistance is taken into account in the disposition index, the product 
of insulin sensitivity and insulin secretion. In this study, we analyzed the predictive value 
of measures, derived from a hyperglycemic clamp, of insulin resistance and insulin secre-
tion, including the disposition index, for the development of T2DM in a Caucasian IGT 
population.
 
 
mEThODS
sTudy POPuLATiOn 
The participants in our analysis came from two existing studies. The population-based 
cohort Hoorn Study, conducted in 1989–1991, analyzed the glucose metabolism of 2,484 
men and women of the municipality of Hoorn 15. During the 1996–1998 follow-up, we 
identified 55 patients with IGT, all of whom were under 75 years of age and had mean 
fasting plasma glucose levels of 6–7 mmol/l and mean two-hour post-load plasma glucose 
levels of  7.8–11.1 mmol/l. For the DAISI Study, conducted in 1994–1995, a random sample 
of 12,093 men and women, was also taken from the population register of Hoorn 16. From 
that sample, 6,651 participants underwent two OGTTs within two weeks. Of those, we in-
cluded the 108 participants who were under 70 years of age and had mean fasting plasma 
glucose levels of 5.5–7.8 and mean two-hour post-load plasma glucose levels of 8.6–11.1 
mmol/l. The coefficient of variation was 6.5% for fasting plasma glucose and for two-hour 
post-load plasma glucose was 16.7% (20). These 108 persons together with the 55 IGT 
persons from the Hoorn study (N = 163), were randomized in the DAISI-study 21. The in-
tervention group (acarbose, N = 54) was excluded from the present analysis. Finally, the 
study population for the present analysis consisted of 109 subjects. All participants signed 
written informed consents, and the study was approved by the Ethical Review Committee 
of the VU University Medical Center.
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mEAsuREmEnTs
OGTT: Blood samples were taken from all patients in a fasting state and two hours after a 
75g oral glucose load. We used a glucose hexokinase-method (Roche Diagnostics GmbH, 
Mannheim, Germany) to determine fasting and two-hour post-load plasma glucose levels. 
We determined insulin levels using a two-site immuno-radiometric test (Medgenix, Diag-
nostics, Fleurus, Belgium). This insulin-specific test does not show cross reactivity with 
pro-insulin and split products. Intact pro-insulin was determined by immuno-radiometric 
method based on antibodies (Dako, Cambridgeshire, UK). 
Hyperglycemic clamp: Participants underwent a hyperglycemic clamp after at least 12 
hours of fasting. Lying supine, patients received a priming infusion of saline (0.9%) and 
glucose (20%) in one arm. To sample blood, we cannulated a vein on the back of the hand 
of the opposite arm. The hand was placed in a thermo-regulated box at 45° C to arterial-
ize the venous blood. After infusing the patients with a bolus of glucose (150 mg/kg), we 
took immediate blood glucose measurements every 2.5 minutes with a glucose analyzer 
(Yellow Springs Instrument, Inc., OH, USA); we maintained blood glucose levels at a hy-
perglycemic level of 10 mmol/l for 180 minutes. We obtained insulin samples every 2.5 
minutes during the first ten minutes and at five-to-ten minute intervals for the remaining 
170 minutes. 
 
Clamp-derived estimates of insulin sensitivity 
Under stable conditions of constant hyperglycemia, the amount of glucose infused (mg/
kg/min) equals the amount of metabolized glucose (M). The amount of glucose infused 
was calculated by the area under the curve of the glucose infusion rate during the last 
20 minutes of the clamp using the trapezoidal rule. The M value divided by the average 
plasma insulin concentration (I) during the same interval, the M/I ratio, provides a meas-
urement of tissue sensitivity to insulin (mg/kg/min per mU/l).
Clamp-derived estimates of beta-cell function
Several measures of beta-cell function were obtained from the hyperglycemic clamp. The 
first insulin secretion phase was assessed in the first 15 minutes of the clamp. For the defi-
nition of the presence of a first insulin peak, we used the following procedure. By visual 
inspection, we selected 23 “flat” insulin curves. For each separate curve, we calculated 
the standard deviation of the insulin values. Next, from these 23 standard deviations, we 
calculated the pooled estimate (S
pooled) of the “typical” standard deviation of these “flat” 
curves. We considered an insulin peak present if the difference between two subsequent 
insulin levels exceeded 1.96∙√2∙(Spooled) (Figure 1).
Figure 1. difference 
between persons with 
and without a peak of 
insulin levels in the first 15 
minutes of the hypergly-
caemic clamp.
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Another measure for the first insulin secretion phase was the area under the curve (AU-
Cins0-10) of the insulin levels of the first ten minutes of the clamp, which were calculated 
using the trapezoidal rule. The second insulin secretion phase (160-180 minutes) was 
calculated by the mean insulin level of that period (ins160-180).
Other measurements: During the baseline medical examination, we measured weight, 
height, and waist and hip circumferences and calculated body mass index (BMI) and 
waist-hip ratio. We measured blood pressure twice on the right arm with a random-ze-
ro sphygmomanometer (Hawksley-Gelman Ltd, Lancing, UK) and used the mean in our 
analyses. 
Disposition Index 
The disposition index was calculated as the product of  M/I ratio (µg/kg/min per mU/l) 
and the AUCins0-10 (mU/l). 
Conversion to diabetes
When the study started, the World Health Organization (WHO) had in 1985 defined T2DM 
as a fasting plasma glucose value of  ≥7.8 mmol/l and/or a two-hour plasma glucose value 
of  ≥11.1 mmol/l 17. In 1999, during the study, the WHO lowered the fasting plasma glucose 
value criterion to  ≥7.0 (the two-hour plasma glucose value remained ≥11.1 mmol/l) 18. 
We used both sets of WHO criteria in separate analyses (not all WHO 1985 analyses are 
shown). For the analysis with the WHO 1999 criteria, participants with a fasting plasma 
glucose of  ≥7.0 mmol/l at the start of the study were excluded. 
In the participants of the DAISI Study fasting plasma glucose levels were measured every 
three months for three years and once a year thereafter. In the participants of  the Hoorn 
Study fasting plasma glucose was measured yearly. Participants underwent an OGTT if the 
fasting plasma glucose level reached a value of  ≥6.0 mmol/l, or at the end of the study. For 
subjects not developing T2DM, the follow-up time was calculated as years from the date of 
the baseline clamp to the end of the study, with a maximum of eight years. 
 
 
 
STaTiSTiCal mEThODS
Quantitative data are expressed as means with standard deviations (skewed variables as 
medians with inter quartile ranges) and categorical data as percentages. ANOVA was per-
formed to test for statistically significant differences between continuous variables, the 
skewed variables were log-transformed first. When variances were unequal among the 
groups to test (Levene’s test), differences were evaluated by Mann-Whitney-U test. χ2-
test was used tot test for categorical variables.  We calculated the cumulative incidence 
of T2DM using the 1999 WHO definition. The incidence was also calculated in tertiles of 
the clamp-derived measures of insulin resistance and beta-cell function and in tertiles of 
the disposition index, after which Kaplan-Meier Survival curves were plotted. Multivariate 
analyses were performed, adjusted for sex and age, using Cox Proportional Hazard analy-
sis. Insulin resistance and beta-cell function were first analyzed separately and subse-
quently combined in one model. The relative risk of the incidence of T2DM was calculated 
as a hazard ratio with a 95% confidence interval. All statistical analyses were performed 
with SPSS 12.0.1. A p <0.05 was considered to be statistically significant.
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1999 Who definition
no diabetes
mean  (Sd)
diabetes
mean  (Sd) p value
number 66 35
age (years) 62.7  (8.9) 61.3 (9.1) 0.45
sex (% men) 50 % 40 % 0.23
hba1c 5.5 (0.5) 5.7 (0.6) 0.10
bmi (kg/m2) 27.3 (3.7) 29.0 (4.4) 0.04
waist            women 92.2 (84.3-97.6) 98.0 (88.6-102.3) 0.14
                             men 95.4 (92.0 –99.0) 99.4 (95.7-106.3) 0.06
waist/hip ratio      women 0.88 (0.80-0.95) 0.90 (0.80-0.92) 0.19
                             men 0.94 (0.80-1.00) 0.90 (0.90-0.95) 0.43
oGTT measurements
fasting plasma glucose (mmol/l)             5.9 (0.7) 6.5 (0.6) 0.001
Two-hour post-load plasma glucose (mmol/l) 7.8 (2.0) 9.3 (1.1) 0.001
fasting specific insulin (mu/l) 9.0  (7.2-12.3) 11.4 (8.5-15.8) 0.04
fasting pro-insulin (mu/l) 2.3  (1.8-3.0) 2.8 (2.1-5.3) 0.06
hyperglycemic clamp measurements
peak (% present) 80 % 52 % 0.004
area under curve 0-10 min (mu/l min-1) 24.6 (16.7-34.1) 21.9 (15.4-39.4) 0.95
mean insulin 160-180 min (mu/l min-1) 48.1 (36.1-78.8) 47.9 (33.4-103.6) 0.75
m/i ratio (mg/kg/min) 11.2 (6.3-15.2) 9.8 (4.4-16.2) 0.29
disposition index 226.4 (147.5-349.9) 176.8 (137.4-307.6) 0.14
Values are means (sd) or medians (inter-quartile ranges) for skewed variables.
Table 1.  baseline characteristics of participants developing and not developing diabetes.
rESulTS
The cumulative incidence of T2DM according to 1999 WHO criteria was 34.7% (mean 
follow-up, 4.2 years; range 0.5–8.0 years). Table 1 presents the baseline characteristics 
for participants who did and did not develop T2DM.  The mean glucose level during the 
clamp was 10.2 mmol/l (standard deviation [SD] 1.07), the coefficient of variation (CV) of 
the glucose level during the clamp was 10,5%. The mean glucose level during the last 20 
minutes of the clamp was 9.9 (SD: 0.6), the CV 6.6%.
Figure 2 A. presence or absence of an 
insulin peak at baseline.
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Figure 2 B. insulin sensitivity in tertiles 
at baseline.
Figure 2 C. disposition index in tertiles 
at baseline
Figure 2 d. first phase insulin secretion 
tertiles at baseline
Figure 2. Kaplan-meier survival curves for either the presence of a first insulin secretion peak (a), insulin sensitivity (b), the disposition 
index (c) and first phase insulin secretion (d).
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Figure 2 shows Kaplan-Meier Survival curves for the presence or absence of the first in-
sulin peak and tertiles of the M/I ratio, disposition index and first insulin secretion phase. 
The absence of the first insulin peak was the strongest predictor for the development of 
T2DM development. 
   Model Who ‘85
hazard-ratio (95% CI)
Who ‘99
hazard-ratio (95% CI)
   Absence of  insulin peak (model 1) 6.47 (2.76-15.19)*** 5.74 (2.60-12.67)***
   Absence of  insulin peak (model 2) 7.26 (2.97-17.75)*** 5.68 (2.55-12.64)***
   AuC0-10 (model 1) :  tertile 1 vs tertile 3 2.09 (0.78-5.70) 0.71 (0.26-1.93)
                                     tertile 2 vs tertile 3 1.29 (0.46-3.61) 0.71 (0.30-1.69)
   AuC0-10 (model 2) :  tertile 1 vs tertile 3 4.10 (1.22-13.80)** 0.86 (0.29-2.57)
                                   tertile 2 vs tertile 3 1.53 (0.54-4.30) 0.75 (0.25-1.67)
   Ins160-180 (model 1) : tertile 1 vs tertile 3 1.05 (0.41-2.73) 0.64 (0.25-1.67)
                                   tertile 2 vs tertile 3 0.80 (0.30-2.13) 0.72 (0.30-1.71)
   M/I ratio (model 1) :  tertile 1 vs tertile 3 1.68 (0.55-5.10) 1.58 (0.60-4.17)
                                  tertile 2 vs tertile 3 1.62 (0.52-5.06) 0.96 (0.34-2.70)
   dI (model 1) :          tertile 1 vs tertile 3 4.95 (1.38-17.77)** 1.78 (0.65-4.88)
                                    tertile 2 vs tertile 3 1.72 (0.43-6.85) 1.20 (0.44-3.24)
**p < 0.01,*** p < 0.001. cox regression models; all adjusted for age, sex and bmi (model 1) and age, sex, bmi and insulin sensitivity 
(model 2). abbreviations: 95% ci : 95% confidence interval ; auc0-10 : area under insulin curve between 0-10 minutes of the 
hyperglycemic clamp; ins160-180: mean insulin level between 160-180 minutes of the hyperglycemic clamp; m/i ratio: insulin sensitivity 
measurement of the hyperglycemic clamp.  di: disposition index. 
Table 2.  cox proportional hazard analyses for diabetes, all models adjusted for age, sex and bmi.
Table 2 shows the results of Cox Proportional Hazards analyses of OGTT and clamp-
derived measures for the incidence of T2DM for both the 1985 and 1999 WHO criteria, 
adjusted for age, sex and BMI.  The highest hazard ratio was observed for the absence of 
the first insulin peak. The other variables were not as predictive of  T2DM development 
(1999 WHO criteria). First phase insulin secretion, insulin resistance, second phase insulin 
secretion and the  disposition index were not significantly associated with the risk of devel-
oping T2DM. When we applied the WHO 1985 criteria, however, the first insulin secretion 
phase and the disposition index, were both predictive of T2DM conversion. 
Table 3. comparison of the excluded T2dm (who 1999) at baseline with the new T2dm at the follow up.
variables T2dM excluded: T2dM follow up: 
number 8 35
age 57.8 (6.9) 63.0 (8.8)
sex (% male) 37.0 45.0
bmi 30.7 (3.2) 28.6 (4.5)
fasting plasma glucose (mmol/l) 7.3 (0.2) 6.5 (0.6)
Two-hour post-load plasma glucose (mmol/l) 9.7 (0.6) 9.3 (1.1)
peak (% present) 37.5 52.0
disposition index 128.4 (66.3-259.4) 176.8 (137.4-307.6)
m/i ratio 8.1 (2.5-18.1) 7.1 (3.8-10.0)
Values are means (sd) or medians (inter-quartile ranges) for skewed variables.
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Additional analyses in  the 8 persons with T2DM according to the WHO 1999 criteria,  thus 
excluded at baseline, demonstrated that their fasting and two hour plasma glucose values 
were higher  at baseline than in those who developed  T2DM at the follow up (table 3). 
They were younger and the percentage of women was higher among these 8 persons than 
in the group of new T2DM. They also had a higher percentage of absence of first insulin 
peak and a lower mean DI.
DiSCuSSiON
The incidence of T2DM in this confirmed IGT population was almost 35%, with a rela-
tively short mean follow-up period of four years. The absence of the first insulin peak 
was the strongest predictor of the development of T2DM. The second insulin secretion 
phase, insulin resistance and the disposition index did not independently predict T2DM. 
The participants were selected according to the 1985 WHO criteria, but during the study 
the WHO criteria for T2DM changed. For the 1999 WHO analyses, therefore, we excluded 
participants with a fasting plasma glucose >7.0 mmol/l.  The true criterion standard mea-
surement for insulin sensitivity is the M-value of the hyperinsulinemic euglycemic clamp 
19 20. Since, the M-value of the hyperinsulinemic clamp and the M/I value of the hyperg-
lycemic clamp are highly correlated 11, a hyperglycemic clamp was the most efficient way 
to analyze both insulin resistance and beta-cell function. We observed that AUCins0-10 as a 
measure of first phase insulin secretion did not predict the conversion to T2DM.  Prob-
ably this can be explained by the close relationship between the AUCins0-10, the  measure of 
insulin sensitivity. In our data AUCins0-10 was strongly correlated with the  M/I ratio derived 
from the hyperglycemic clamp (data not shown). Perhaps unexpected, insulin resistance 
did not emerge as a significant independent predictor of diabetes. This is likely to be due to 
the fact all participants had IGT, itself an insulin resistant state. Also previous studies have 
demonstrated that insulin resistance is only a predictor of conversion in persons with NGT 
at baseline 3 4. In persons with an adequate  betacell function the AUCins0-10 will be higher in 
insulin resistant persons, compared with persons with a normal insulin sensitivity. The re-
sulting DI and glucose tolerance will remain the same. In contrast, those who are not able 
to increase the (first) phase insulin secretion in response to insulin resistance, thus those 
with an absent first phase, will develop hyperglycaemia. Insulin resistance itself stimu-
lates insulin secretion, an adaptation of the beta cell for prevailing insulin resistance 21 22. 
The disposition index, reflects the interrelationship between  insulin secretion and insulin 
resistance. Alterations in the DI has been demonstrated to be predictive of changes  in glu-
cose tolerance status as reported by others 7 14 23 24. This study is one of the few prospective 
studies with measurements of the first insulin secretion phase in confirmed IGT persons 
and the first to report prospective analyses with the disposition index in a Caucasian IGT 
population 8. Impaired first insulin secretion phase as an independent predictor for the 
development of T2DM, independent of obesity and insulin resistance, has also been de-
scribed in a population in Sweden, in Pima Indians 4 25-29, and in Mexican-Americans 3. We 
found that the incidence of T2DM was predicted best by the absence of the peak of the first 
insulin secretion phase. In the prospective study in Pima Indians, the findings were very 
similar, although their estimate of  beta-cell function was acquired with an IVGTT 28. 
The disposition index, as an expression of the compensatory mechanism of insulin se-
cretion on decreasing insulin sensitivity, appeared to be an independent predictor of the 
incidence of T2DM, but only when we used the old WHO 1985 criteria. This is line with 
the notion that elevated fasting glucose (7.0-7.8 mmol/l) clearly indicates defective insulin 
secretion, and that fasting glucose levels <7.0 mmol/l indicates sufficient compensatory 
insulin secretion 24.
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In summary, the present study of Caucasian patients followed prospectively over several 
years showed that the absence of the first insulin peak, as an expression of a impaired 
acute insulin response to glucose, was a strongest predictor of incident T2DM. 
 
 
 
 
 
32 CHAPTER 2 The absence of an acuTe insulin response predicTs The onseT of Type 2 diabeTes  in a caucasian populaTion wiTh impaired glucose Tolerance (igT): The hoorn IGT-STudy.
rEfErENCES  
 1.  de Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ: Relation of 
impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. JAMA 
285:2109-2113, 2001
 2.  Nijpels G, Popp-Snijders C, Kostense PJ, Bouter LM, Heine RJ: Fasting proinsulin and 2-h post-load glucose levels predict 
the conversion to NIDDM in subjects with impaired glucose tolerance: the Hoorn Study. Diabetologia 39:113-118, 1996
 3.  Haffner SM, Miettinen H, Gaskill SP, Stern MP: Decreased insulin secretion and increased insulin resistance are indepen-
dently related to the 7-year risk of NIDDM in Mexican-Americans. Diabetes 44:1386-1391, 1995
 4.  Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, Knowler WC, Bennett PH, Bogardus C: Insulin resistance 
and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima 
Indians. N Engl J Med 329:1988-1992, 1993
 5.  Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Charles MA, Bennett PH: A two-step model for development of non-insulin-
dependent diabetes. Am J Med 90:229-235, 1991
 6.  Weyer C, Bogardus C, Mott DM, Pratley RE: The natural history of insulin secretory dysfunction and insulin resistance in 
the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787-794, 1999
 7.  Kahn SE: Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes. 
J Clin Endocrinol Metab 86:4047-4058, 2001
 8.  Ferrannini E, Mari A: Beta cell function and its relation to insulin action in humans: a critical appraisal. Diabetologia 
47:943-956, 2004
 9.  Mari A, Ahren B, Pacini G: Assessment of insulin secretion in relation to insulin resistance. Curr Opin Clin Nutr Metab 
Care 8:529-533, 2005
 10.  Defronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. 
Am J Physiol 237:E214-E223, 1979
 11.  Ruige, J. B. Fasting plasma glucose in impaired glucose tolerance is determined by betacell function.  1997. 
  Ref Type: Thesis/Dissertation
 12.  Kahn SE: The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 dia-
betes. Diabetologia 46:3-19, 2003
 13.  Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP, 
.: Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a 
hyperbolic function. Diabetes 42:1663-1672, 1993
 14.  Stumvoll M, Tataranni PA, Stefan N, Vozarova B, Bogardus C: Glucose allostasis. Diabetes 52:903-909, 2003
 15.  Mooy JM, Grootenhuis PA, de Vries H, Kostense PJ, Popp-Snijders C, Bouter LM, Heine RJ: Intra-individual variation of 
glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Cauca-
sian population: the Hoorn Study. Diabetologia 39:298-305, 1996
 16.  Ruige JB, Dekker JM, Nijpels G, Popp-Snijders C, Stehouwer CD, Kostense PJ, Bouter LM, Heine RJ: Hyperproinsulinaemia 
in impaired glucose tolerance is associated with a delayed insulin response to glucose. Diabetologia 42:177-180, 1999
 17.  World health organisation. World health organisation; Diabetes mellitus: report of a WHO study group. Geneva, World 
health org.,1985 (Tech. Rep. Ser. No 727).  1-1-1985. 
  Ref Type: Report
 18.   Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
  5. Diabetes Care 20:1183-1197, 1997
 19.  Defronzo RA, Ferrannini E: Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, 
dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194, 1991
 20.  Saad MF, Rewers M, Selby J, Howard G, Jinagouda S, Fahmi S, Zaccaro D, Bergman RN, Savage PJ, Haffner SM: Insulin 
resistance and hypertension: the Insulin Resistance Atherosclerosis study. Hypertension 43:1324-1331, 2004
 21.  Ahren B, Pacini G: Impaired adaptation of first-phase insulin secretion in postmenopausal women with glucose intoler-
ance. Am J Physiol 273:E701-E707, 1997
 22.  Bergman RN, Phillips LS, Cobelli C: Physiologic evaluation of factors controlling glucose tolerance in man: measurement 
of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 68:1456-1467, 
1981
 23.  Bergman RN, Ader M, Huecking K, Van Citters G: Accurate assessment of beta-cell function: the hyperbolic correction. 
Diabetes 51 Suppl 1:S212-S220, 2002
 24.  Festa A, Williams K, D’Agostino R, Jr., Wagenknecht LE, Haffner SM: The Natural Course of {beta}-Cell Function in 
Nondiabetic and Diabetic Individuals: The Insulin Resistance Atherosclerosis Study. Diabetes 55:1114-1120, 2006
 25.  Bogardus C, Tataranni PA: Reduced early insulin secretion in the etiology of type 2 diabetes mellitus in Pima Indians. 
Diabetes 51 Suppl 1:S262-S264, 2002
 26.  Pratley RE, Weyer C: The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabe-
tologia 44:929-945, 2001
 27.  Uusitupa M, Lindi V, Louheranta A, Salopuro T, Lindstrom J, Tuomilehto J: Long-term improvement in insulin sensitiv-
ity by changing lifestyles of people with impaired glucose tolerance: 4-year results from the Finnish Diabetes Prevention 
Study. Diabetes 52:2532-2538, 2003
 28.  Weyer C, Hanson K, Bogardus C, Pratley RE: Long-term changes in insulin action and insulin secretion associated with 
gain, loss, regain and maintenance of body weight. Diabetologia 43:36-46, 2000
 29.  Zethelius B, Byberg L, Hales CN, Lithell H, Berne C: Proinsulin and acute insulin response independently pre-
dict Type 2 diabetes mellitus in men--report from 27 years of follow-up study. Diabetologia 46:20-26, 2003 
The absence of an acuTe insulin response predicTs The onseT of Type 2 diabeTes  
in a caucasian populaTion wiTh impaired glucose Tolerance (igT): The hoorn IGT-STudy. 33
CHAPTER 3
determInants of chanGe In InsulIn  
secretIon over three years In ImpaIred 
Glucose tolerance:  
the hoorn IGt-study 
w. boorsma, g. nijpels, J.m. dekker, l.m. bouter, J.w.r. Twisk, r.J. heine 
Submitted for publication
34 deTerminanTs of change in insulin secreTion oVer Three years in impaired glucose Tolerance:  The hoorn IGT-STudy.CHAPTER 3
35deTerminanTs of change in insulin secreTion oVer Three years in impaired glucose Tolerance:  The hoorn IGT-STudy.
CHAPTER 3
determInants of chanGe In InsulIn secretIon over three years In ImpaIred 
Glucose tolerance:   
the hoorn IGt-study
w. boorsma, g. nijpels, J.m. dekker, l.m. bouter, J.w.r. Twisk, r.J. heine 
Submitted for publication
 
ABsTRACT
 
ObjECTivES Beta-cell dysfunction and insulin resistance are key defects in abnormal 
glucose tolerance. We investigated the three year changes in insulin secretion and insulin 
sensitivity in relation to glucose tolerance changes in persons with confirmed impaired 
glucose tolerance (IGT). 
SubjECTS aND mEThODS Of  Fifty persons, aged 45-74 and confirmed IGT (two sepa-
rate OGTTs), insulin sensitivity and first and second phase insulin responses, were mea-
sured with the hyperglycemic clamp at baseline and after three years. The disposition in-
dex was calculated as the product of first-phase insulin secretion and insulin sensitivity.
rESulTS Seven subjects converted to normal glucose tolerance (NGT), seven developed 
type 2 diabetes (DM2), while 36 continued to have IGT. In all subjects, insulin sensitivity 
decreased by an average of 35% (-48%; -22%). First-phase insulin secretion increased ap-
propriately in persons who remained IGT or converted to NGT. The persons who developed 
diabetes had 63% (-203% ; 78%) decrease in their disposition index. High serum gamma-
glutamyl transferase at baseline was associated with a decrease in the disposition index. 
CONCluSiONS Conversion to DM2 in persons with IGT was associated with the failure 
of first-phase insulin secretion to compensate for the lowering of insulin sensitivity. The 
decline in the disposition index was best predicted by a high serum level of gamma-
glutamyl transferase at baseline. 
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iNTrODuCTiON
Impaired glucose tolerance is a strong risk factor for the development of type 2 diabetes. 
About 30% of patients with impaired glucose tolerance develop diabetes within five to 
ten years of diagnosis, compared to only 5% of people with normal glucose tolerance 1 2. 
Compromised β-cell function and reduced insulin sensitivity are thought to be the key 
underlying defects 3-11, but how these defects relate to each other and the extent to which 
they contribute to the conversion from impaired glucose intolerance to diagnosed type 2 
diabetes is still not well understood 7 10-18. 
First-phase insulin secretion has been shown to be an independent early predictor of type 
2 diabetes 19 20. Now it has been well established that insulin secretion and insulin sensitiv-
ity are physiologically closely related. Therefore, when assessing beta cell function, it is 
important to adjust the measured  insulin secretion variable for the ambient insulin sen-
sitivity. 10 14 21. One method is to calculate an integrated measure of glucose tolerance: the 
disposition index. This index, the product of the measures of acute insulin response and 
insulin sensitivity, reflects the (hyperbolic) relationship between these variables. A lower-
ing of the disposition index has been associated with worsening of glucose tolerance 3 21 22. 
One longitudinal study assessed changes in insulin secretion and insulin sensitivity over 
five years using intravenous glucose tolerance tests and hyperinsulinemic-euglycemic 
clamps, in 48 Pima Indians 17 23. The main determinant of conversion to type 2 diabetes 
was a low disposition index. Similar findings were reported by others 24 25. 
The determinants of change in insulin secretion are not well known. A reduced first-phase 
insulin secretion can be acquired from a high-fat diet 26 27. Also, obesity 28 and an unfavor-
able body fat distribution have been shown to be related to decreased first phase insulin 
secretion, also when adjusted for insulin resistance 29 30. Furthermore the rate of conversion 
to type 2 diabetes has been shown to be dependent on age, ethnicity 28 31-33, family history 
of diabetes 34 35.
The main objective of our study was to relate the changes of insulin secretion and insu-
lin sensitivity, assessed with the hyperglycemic clamp method, in men and women with 
confirmed impaired glucose tolerance, to changes in glucose tolerance during a three-year 
follow-up. Our second objective was to identify the possible determinants of the observed 
changes in insulin secretion.  
 
 
SubjECTS aND mEThODS
Subjects Written informed consent was obtained from each participant for every step in 
the protocol, and the study was approved by the medical ethics committee of the VU 
University Medical Center. A sample of 12,093 45- to 74-year-old persons, taken from the 
population register of Hoorn, the Netherlands, received postal invitations to take a fasting 
blood glucose test. Of those, 6,651 (55%) persons visited the study center for the test. The 
3,147 persons who had a fasting plasma glucose level over 5.5 mmol/l underwent an oral 
glucose tolerance test. Of those, 554 persons had a two-hour plasma glucose value that ex-
ceeded 7.8 mmol/l in an oral glucose tolerance test that was repeated within two weeks. In 
1989-1991 a population-based cohort study of glucose metabolism was performed among 
2484 men and women of the municipality of Hoorn; the Hoorn study 36. In 1996-1998, 55 
persons were selected which were under 75 years of age, had a fasting plasma glucose 
between 6 and 7 mmol/l and a mean of two 2-hour post-load plasma glucose between 
7.8 and 11.1 mmol/l. Finally, a total 108 participants were considered impaired glucose 
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tolerant according to WHO ’85 criteria 37. They were selected to participate in a three-year 
intervention study, in which 54 subjects received acarbose (an alfa glucosidase inhibitor) 
and 54 received placebo 38. 
All participants underwent a hyperglycemic clamp at baseline, but only 57 underwent a 
second hyperglycemic clamp after 36 months of follow-up (51 subjects were not followed 
up because of withdrawal (37), poor compliance (9), death (4) or missing data (1)). Losses 
to follow-up differed between the intervention and control groups (36.1% vs. 13.3%). 
After excluding an additional seven subjects who were missing values for variables of 
interest (non-compliance, laboratory errors, missing samples), we included a total of 50 
subjects in this analysis, of which 24 subjects were on acarbose. Both at baseline and after 
a mean of 36 months, all subjects underwent two oral glucose tolerance tests, extensive 
physical examinations, and a hyperglycemic clamp. Oral glucose tolerance test. To mea-
sure fasting and two-hour post-load plasma glucose levels and fasting insulin levels, each 
subject underwent two standard 75 g oral glucose tolerance tests, performed within two 
weeks of each other, between 8 and 12 am, after at least 12 hours of fasting. 
Hyperglycemic clamp. All 50 participants underwent two hyperglycemic clamp tests (previ-
ously described 39). Each test began between 8:00 and 8:30 am, with the subject supine 
and in a fasting state. After arterialization of venous blood by warming the subject’s hand 
in a thermo-regulated box at 45°C, we measured insulin and glucose. We then adminis-
tered a priming infusion of 20% glucose solution, 150 mg/kg body mass, to acutely raise 
the subject’s blood glucose concentration to 10 mmol/l. We directly measured the blood 
glucose concentration at five minute intervals, and we administered a variable glucose 
infusion to maintain the subject’s plasma glucose concentration at 10 mmol/l for three 
hours. Blood samples for insulin level measurements were taken at two-and-a-half minute 
intervals for the first ten minutes and at five- to ten-minute intervals for the remaining 170 
minutes. Under stable hyperglycemic conditions, the amount of glucose infused equals the 
whole-body glucose disposal (M). That amount divided by the plasma insulin level during 
the same interval (160-180 min (I)) provides a measurement – M/I – of tissue sensitivity 
to insulin 39.
To measure first-phase insulin secretion, we used the trapezoid method to calculate 
the area under the curve of the first ten minutes of insulin secretion during the clamp 
(AUCins0-10) 
13. We determined the second-phase insulin secretion by calculating the mean 
insulin level during the last 20 minutes of the clamp (mean ins160-180). The disposition 
index, then, was the product of the measures of first-phase insulin secretion and insulin 
sensitivity (AUCins0-10 × M/I). 
Biometry. Body mass index was calculated as weight (in kilograms) divided by height (in 
meters), squared. Waist and hip circumference were measured to calculate the waist/hip 
ratio. Blood pressure was measured in the supine position with a random-zero sphygmom-
eter (Hawksley-Gelman Ltd, Lancing, UK); we used the average of two readings (Korotkoff 
5), taken at five-minute intervals, in our analyses.
Laboratory analyses. We determined the subjects’ fasting and two-hour post-load plasma 
glucose values using a hexokinase method (Boehringer Mannheim, Germany). During 
the clamp, we directly assessed blood glucose levels with a YSI analyzer (Yellow Springs 
Instruments, Ohio, USA). We measured fasting plasma specific insulin (mU/l) using an an-
tibody radio-immuno assay (Medgenix Diagnostics, Fleurus, Belgium). Cholesterol, high-
density lipoprotein cholesterol, and triglycerides were assessed using a caloric enzymatic 
test (Roche, Mannheim, Germany). Serum alanine-amino transferase, serum aspartate-
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amino transferase, and serum gamma-glutamyl transferase enzyme activity, expressed as 
U/l, was measured according to the method of the International Federation of Clinical 
Chemistry from 1985 40.  
sTATisTiCAL AnALysEs  
We first stratified baseline characteristics in tertiles of disposition index, expressing them 
as means with standard deviations or, for skewed data, medians and inter-quartile ranges. 
We used ANOVA to test for differences between the tertiles. Differences with p-values be-
low 0.05 were considered to be significant. We then assessed the absolute and the relative 
mean changes of insulin secretion (first- and second-phase) and disposition index and in-
sulin sensitivity over three years in relation to glucose tolerance after three years (WHO’99 
41). Logistic regression analyses were applied  to study associations of changes in insulin 
secretion and insulin sensitivity with conversion to type 2 diabetes. The models were ad-
justed for age, sex, acarbose use, and variables of interest. All variables are presented in 
their original units, but the odds ratios are presented in standardized steps, which differ in 
size depending on the particular variable. Because of the high incidence of type 2 diabetes 
in this population, the odds ratios probably slightly exaggerate the relative risk. We consid-
ered body mass index, waist/hip ratio, triglycerides, high-density lipoprotein cholesterol, 
liver enzymes (alanine-amino transferase, aspartate-amino transferase, gamma-glutamyl 
transferase), mean insulin levels, insulin sensitivity, plasma glucose levels, and HbA1c 
putative determinants of changes both in insulin secretion (first- and second-phase) and 
the disposition index. We tested all factors in linear regression analyses, adjusted for sex, 
age, acarbose use, and baseline value of the dependent variable. Additionally a model 
was constructed with adjustment for age, sex, acarbose use, baseline value of the depen-
dent variable, and insulin sensitivity. All models with p values <0.05 (two-tailed) were 
considered statistically significant. Models were checked for collinearity. A tolerance of 
<0.1 or a variance inflation factor of >10 were considered indications of collinearity. All 
associations of the regression analyses are reported as standardized betas. A standardized 
beta of –0.5 indicates that if the independent variable increases 1 standard deviation, the 
dependent (e.g. insulin secretion) decreases 0.5 standard deviations. We performed our 
statistical analyses with SPSS for Windows version 10.1.4.  
 
 
rESulTS
The participants’ mean age at baseline was 55.7 years; 45% were men. Baseline level 
means of fasting and post-load plasma glucose were 6.0 mmol/l and 7.9 mmol/l, respec-
tively. After three years, seven subjects had converted to normal glucose tolerance, while 
seven had developed type 2 diabetes; 36 continued to have impaired glucose tolerance. The 
mean first-phase insulin secretion (AUC
ins0-10) was 10.6 (4.9-18.9) mU l
-1min-1 at baseline; 
after three years, it had increased by 8.6 (4.9-12.4) mU l-1min-1. The second-phase insulin 
secretion (mean ins160-180 min) was 46.7 (35.9-73.7) mU l
-1 at baseline and then decreased 
by 11.9 (–26.1-2.4) mU l-1. The mean insulin sensitivity (M/I) began at 11.5 (6.9-16.9) mg 
kg-1 min-1 per mU  -1 and then decreased over three years by 5.6 (−8.1;–3.0) mg kg-1 min-1 
per mU l -1. As a consequence, the baseline disposition index was 107.6 (66.7-189.1) and 
increased by a mean of 5.0 (–35.6-45.6). Table 1 presents the baseline characteristics of the 
subjects according to their disposition indexes. Except for first phase insulin secretion, the 
clinical characteristics did not differ significantly between the tertiles.
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Table 1. clinical characteristics of 50 subjects at baseline, by tertiles of disposition index. 
Tertiles of disposition index (n) 16 18 17
disposition index 91.6 (20.8-163.4) 111.4 (48.4-251.6) 131.9 (79.9-286.7)
First-phase insulin secretion ( AuCins0-10) 
a 8.8 (2.2-17.7) 8.4 (4.7-14.7) 14.1 (9.3-26.9)
Second-phase insulin secretion (mean ins160-180) 54.6 (37.1-84.1) 43.9 (32.1-61.2) 47.0 (32.5-101.0)
Insulin sensitivity (M/I) 9.9 (5.5-15.4) 12.2 (8.7-18.0) 12.1 (6.3-16.5)
Age (in years) 53.9 (9.2) 56.2 (7.4) 56.9 (6.5)
Sex (% male) 53 23 53
Systolic blood pressure (mmhg) 144.4 (15.5) 138.8 (16.8) 139.3 (17.7)
diastolic blood pressure (mmhg) 90.7 (6.7) 90.7 (6.7) 89.4 (9.3)
hbA1c (%) 5.5 (0.6) 5.5 (1.5) 5.6 (0.5)
Fasting blood glucose (mmol/l) 6.1 (0.7) 6.0 (0.9) 5.9 (0.6)
Two-hour post-load glucose (mmol/l) 8.0 (0.4) 7.9 (0.5) 7.9 (0.6)
Body mass index (kg/m2) 28.2 (3.8) 26.8 (2.2) 28.9 (4.0)
Waist/hip ratio 0.9 (0.1) 0.9 (0.1) 0.9 (0.1)
Triglycerides (mmol/l) 1.9 (1.3-2.3) 1.7 (1.2-2.2) 1.7 (1.4-3.0)
hdL Cholesterol (mmol/l) 1.1 (0.3) 1.0 (0.2) 1.0 (0.2)
LdL cholesterol (mmol/l) 3.6 (0.9) 3.8 (1.0) 3.7 (1.0)
Serum aspartate-amino transferase (u/l) 13.0 (11.0-15.0) 14.0 (11.0-19.0) 11.0 (10.0-12.5)
Serum alanine-amino transferase  (u/l) 12.0 (12.0-16.0) 13.0 (11.0-19.3) 13.0 (9.5-15.5)
Serum gamma-glutamyl transferase (u/l) 24.3 (15.1) 34.2 (55.9) 22.9 (15.7)
  Values are means (sd) or medians (interquartile ranges) for skewed variables. a p-value < 0.05
Table 2 shows the relationships between the glucose tolerance status at the end of the 
follow-up and measures of insulin secretion and insulin sensitivity. Insulin sensitivity de-
creased similarly in the different groups. In the impaired and normal glucose tolerance 
groups first-phase insulin secretion after three years was adequately raised in response to 
a diminished insulin sensitivity, whereas in those converting to type 2 diabetes, first-phase 
insulin secretion failed to increase. Second-phase insulin secretion showed a similar pat-
tern. There was no statistically significant change in BMI in any of the glucose tolerance 
groups and the only decrease in BMI was in the normal glucose tolerance group.
As illustrated in Figure 1, the disposition index decreased only in those converting to type 
2 diabetes. A higher disposition index at baseline and a 3 year increase in disposition index 
was associated with a decrease of risk of developing diabetes by 46% and 43%, respec-
tively for 1 standardized step (borderline statistical significance).
Table 3 shows associations between baseline levels of putative determinants and changes 
in insulin secretion and the disposition index, adjusted for age, sex, and acarbose use. 
Waist/hip ratio showed a positive linear relationship with change in second phase insu-
lin secretion, which weakened after additional adjustment for insulin sensitivity. A high 
serum level of gamma-glutamyl transferase at baseline was significantly associated with 
a decrease in the disposition index. High serum levels of alanine-amino transferase and 
aspartate-amino transferase showed a similar, although not statistically significant, as-
sociation.
40 CHAPTER 3 deTerminanTs of change in insulin secreTion oVer Three years in impaired glucose Tolerance:  The hoorn IGT-STudy.
3
4
C
H
A
P
T
E
R
 2
T
H
E
 A
B
S
E
N
C
E
 O
F
 A
N
 A
C
U
T
E
 IN
S
U
LI
N
 R
E
S
P
O
N
S
E
 P
R
E
D
IC
T
S
 T
H
E
 O
N
S
E
T
 O
F
 T
Y
P
E
 2
 D
IA
B
E
T
E
S
  
IN
 A
 C
A
U
C
A
S
IA
N
 P
O
P
U
LA
T
IO
N
 W
IT
H
 IM
P
A
IR
E
D
 G
LU
C
O
S
E
 T
O
LE
R
A
N
C
E
 (
IG
T
):
 T
H
E
 H
O
O
R
N
 IG
T
-S
T
U
D
Y
.
3
5
T
H
E
 A
B
S
E
N
C
E
 O
F
 A
N
 A
C
U
T
E
 IN
S
U
LI
N
 R
E
S
P
O
N
S
E
 P
R
E
D
IC
T
S
 T
H
E
 O
N
S
E
T
 O
F
 T
Y
P
E
 2
 D
IA
B
E
T
E
S
  
IN
 A
 C
A
U
C
A
S
IA
N
 P
O
P
U
LA
T
IO
N
 W
IT
H
 IM
P
A
IR
E
D
 G
LU
C
O
S
E
 T
O
LE
R
A
N
C
E
 (
IG
T
):
 T
H
E
 H
O
O
R
N
 IG
T
-S
T
U
D
Y
.
G
lu
co
se
 t
o
le
ra
n
ce
 a
ft
er
 t
h
re
e 
ye
ar
s
N
or
m
al
 g
lu
co
se
 to
le
ra
nc
e
n 
= 
7
Im
pa
ire
d 
gl
uc
os
e 
to
le
ra
nc
e
n 
= 
36
T
yp
e 
2 
di
ab
et
es
n 
= 
7
C
on
ve
rs
io
n 
to
 ty
pe
 2
 d
ia
be
te
s
O
dd
s 
ra
tio
s 
(9
5%
 C
I)
B
as
el
in
e
T
hr
ee
-y
ea
r 
di
ffe
re
nc
e 
a
B
as
el
in
e
T
hr
ee
-y
ea
r 
di
ffe
re
nc
e 
a
B
as
el
in
e
T
hr
ee
-y
ea
r 
di
ffe
re
nc
e 
a
B
as
el
in
e
Th
re
e-
ye
ar
 d
iff
er
en
ce
 a
F
irs
t-
ph
as
e 
in
su
lin
 s
ec
re
tio
n 
( 
A
U
C
in
s0
-1
0)
13
.2
 (
10
.6
-1
9.
5)
14
.0
 (
6.
8)
1
10
.4
 (
4.
5-
19
.8
)
9.
2 
(1
4.
1)
 1
7.
4 
(4
.8
-3
3.
9)
0.
3 
(1
4.
4)
 
1.
24
 (
0.
59
-2
.6
0)
0.
38
 (
0.
14
-1
.0
1)
 3
S
ec
on
d-
ph
as
e 
in
su
lin
 s
ec
re
tio
n 
(m
ea
nI
16
0-
18
0)
60
.5
 (
42
.1
-6
9.
3)
14
.1
 (
40
.2
)
46
.7
 (
32
.6
-7
1.
9)
-1
4.
8 
(5
3.
0)
 
47
.9
 (
39
.3
-1
98
.3
)
-2
5.
1 
(5
7.
2)
 
1.
28
 (
0.
68
-2
.5
2)
0.
87
 (
0.
45
-1
.5
7)
In
su
lin
 s
en
si
tiv
ity
 (
M
/I)
10
.0
 (
5.
5-
23
.7
)
-5
.3
 (
6.
2)
 
12
.1
 (
7.
7-
16
.3
)
-5
.7
 (
10
.2
) 
1
9.
0 
(4
.1
-1
7.
3)
-4
.4
 (
6.
3)
 
0.
67
 (
0.
19
-2
.3
2)
1.
12
 (
0.
35
-3
.5
5)
D
is
po
si
tio
n 
in
de
x 
B
M
I (
kg
/m
2 )
10
7.
3 
(9
0.
8-
25
8.
1)
27
.4
 (
4.
9)
28
.0
 (
12
8.
4)
 
-1
.1
 (
2.
4)
 
11
7.
9 
(5
0.
8-
20
7.
0)
28
.0
 (
3.
5)
9.
9 
(1
54
.3
)
0.
6 
(1
.7
) 
2
79
.7
 (
66
.7
-1
39
.1
)
28
.0
 (
2.
4)
-5
0.
0 
(1
21
.1
) 
0.
5 
(2
.1
) 
0.
57
 (
0.
18
-1
.9
0)
0.
94
 (
0.
37
-2
.3
7)
0.
54
 (
0.
29
-1
.2
8)
 4
0.
75
 (
0.
30
-1
.9
1)
no
rm
al
 g
lu
co
se
 to
le
ra
nc
e 
= 
fa
st
in
g 
pl
as
m
a 
gl
uc
os
e 
< 
6.
1 
or
 tw
o-
ho
ur
 
po
st
-lo
ad
 p
la
sm
a 
gl
uc
os
e 
< 
7.
8;
 im
pa
ire
d 
gl
uc
os
e 
to
le
ra
nc
e 
= 
fa
st
in
g 
pl
as
m
a 
gl
uc
os
e 
6.
1–
7.
0 
or
 tw
o 
ho
ur
 p
os
t-l
oa
d 
pl
as
m
a 
gl
uc
os
e 
7.
8-
11
.0
; t
yp
e 
2 
di
ab
et
es
 =
 fa
st
in
g 
pl
as
m
a 
gl
uc
os
e 
> 
7.
0 
or
 tw
o-
ho
ur
 
po
st
-lo
ad
 p
la
sm
a 
gl
uc
os
e 
> 
11
.1
. V
al
ue
s 
ar
e 
m
ea
ns
 (s
d)
 o
r m
ed
ia
ns
 
(in
te
rq
ua
rti
le
 ra
ng
es
) f
or
 s
ke
we
d 
va
ria
bl
es
. o
dd
s 
ra
tio
s 
ar
e 
in
 s
ta
nd
ar
d 
de
via
tio
ns
 to
 fa
cil
ita
te
 c
om
pa
ris
on
s.
 o
ne
 s
ta
nd
ar
d 
de
via
tio
n 
at
 
ba
se
lin
e 
of
 fi
rs
t- 
an
d 
se
co
nd
-p
ha
se
 in
su
lin
 s
ec
re
tio
n 
ar
e 
12
 a
nd
 6
2 
m
u•
l-1
•m
in
-1
, r
es
pe
ct
ive
ly.
 in
su
lin
 s
en
sit
ivi
ty
 h
as
 a
 s
ta
nd
ar
d 
de
via
tio
n 
of
  9
 m
g•
kg
-1
•m
in
-1
 p
er
 m
u•
l-1
; t
he
 d
isp
os
itio
n 
in
de
x 
14
5 
m
g•
kg
-1
• 
m
in
-1
 a
nd
 b
m
i 3
.4
 k
g•
m
-2
. T
he
 s
ta
nd
ar
d 
de
via
tio
ns
 o
f c
ha
ng
e 
ar
e 
pr
es
en
te
d 
in
 ta
bl
e 
2.
 m
od
el
s 
ar
e 
ad
ju
st
ed
 fo
r a
ge
, s
ex
, a
nd
 a
ca
rb
os
e 
us
e.
 a
dd
itio
na
lly
, f
irs
t-p
ha
se
 in
su
lin
 s
ec
re
tio
n 
wa
s 
ad
ju
st
ed
 fo
r i
ns
ul
in
 
se
ns
itiv
ity
 a
. f
ol
lo
w-
up
 m
in
us
 b
as
el
in
e 
va
lu
es
; 1
 p
 <
 0
.0
1;
 2
 p
 <
 0
.0
5;
 3
 
p 
= 
0.
06
 4
 p
 =
 0
.1
9.
 
Fi
gu
re
 1
. r
el
at
ive
 th
re
e-
ye
ar
 c
ha
ng
es
 in
 m
ea
su
re
s 
of
 in
su
lin
 s
ec
re
tio
n 
an
d 
in
su
lin
 s
en
sit
ivi
ty
, b
y 
gl
uc
os
e 
to
le
ra
nc
e 
st
at
us
 a
fte
r t
hr
ee
 y
ea
rs
.  
ch
an
ge
 c
om
pa
re
d 
to
 b
as
el
in
e 
= 
(fo
llo
w-
up
 –
 b
as
el
in
e 
/ b
as
el
in
e)
 x
 
10
0%
. *
 p
 <
 0
.1
5,
 **
 p
 <
 0
.0
5
Ta
bl
e 
2.
 b
as
el
in
e 
va
lu
es
 a
nd
 m
ea
n 
th
re
e-
ye
ar
 d
iff
er
en
ce
s 
in
 5
0 
su
bj
ec
ts
, b
y 
gl
uc
os
e 
to
le
ra
nc
e 
st
at
us
 a
fte
r t
hr
ee
 y
ea
rs
.  
change compared to baseline (%)
normal
impaired
Type 2 diabetes
g
lu
co
se
 to
le
ta
nc
e 
st
au
s 
af
te
r t
hr
ee
 y
ea
rs
di
sp
os
it 
in
de
x
fi
rs
t p
ha
se
 in
su
lin
 s
ec
re
tio
n
se
co
nd
-p
ha
se
 in
su
lin
 s
ec
re
tio
n
in
su
lin
 s
en
sit
ivi
ty
25
0
20
0
15
0
10
0 50 0 -5
0
-1
50
-1
00
41deTerminanTs of change in insulin secreTion oVer Three years in impaired glucose Tolerance:  The hoorn IGT-STudy.
ch
an
ge
 =
 fo
llo
w-
up
 m
in
us
 b
as
el
in
e 
va
lu
es
; c
ha
ng
e 
a 
= 
ad
ju
st
ed
 fo
r a
ge
, s
ex
, a
nd
 a
ca
rb
os
e 
us
e;
 c
ha
ng
e 
b 
= 
ad
ju
st
ed
 fo
r a
ge
, s
ex
, a
ca
rb
os
e 
us
e,
an
d 
m
/i 
ra
tio
. h
dl
 =
 h
ig
h-
de
ns
ity
 lip
op
ro
te
in
; l
dl
 =
 lo
w-
de
ns
ity
 lip
op
ro
te
in
.
Au
C i
ns
0-
10
 c
ha
ng
ea
Au
C i
ns
0-
10
 ch
an
ge
b
m
ea
n 
in
s 1
60
-1
80
 c
ha
ng
ea
m
ea
n 
in
s 1
60
-1
80
 c
ha
ng
e b
dI
 c
ha
ng
ea
fi
rs
t-p
ha
se
 in
su
lin
 s
ec
re
tio
n 
(a
uc
in
s0
-1
0)
-
-
0.
10
 (-
0.
15
; 0
.3
5)
0.
07
 (-
0.
16
;0
.3
1)
-0
.2
4 
(-0
.5
5;
0.
08
)
in
su
lin
 s
en
sit
ivi
ty
 (m
/i)
-0
.1
7 
(-0
.4
5;
0.
11
)
-
-0
.3
4 
(-0
.5
9;
-0
.0
8)
-
0.
03
 (-
0.
27
;0
.3
2)
se
co
nd
-p
ha
se
 in
su
lin
 s
ec
re
tio
n 
(m
ea
n 
in
s 1
60
-1
80
)
-0
.2
4 
(-0
.5
2;
0.
04
)
-0
.4
1 
(-0
.7
2;
-0
.1
1)
-
-
-0
.2
2 
(-0
.4
9;
0.
06
)
sy
st
ol
ic 
bl
oo
d 
pr
es
su
re
 (m
m
hg
)
-0
.0
2 
(-0
.3
1;
0.
27
)
-0
.0
4 
(-0
.3
3;
0.
25
)
0.
09
 (-
0.
16
;0
.3
4)
0.
03
 (-
0.
21
;0
.2
7)
-0
.1
9 
(-0
.4
5;
0.
07
)
di
as
to
lic
 b
lo
od
 p
re
ss
ur
e(
m
m
hg
)
-0
.0
4 
(-0
.3
1;
0.
22
)
-0
.0
7 
(-0
.3
4;
0.
21
)
0.
02
 (-
0.
22
;0
.2
6)
-0
.0
2 
(-0
.2
6;
0.
21
)
-0
.1
7 
(-0
.4
3;
0.
09
)
hb
a1
c 
(%
)
-0
.1
0 
(-0
.3
7;
0.
16
)
-0
.0
9 
(-0
.3
5;
0.
18
)
0.
09
 (-
0.
15
;0
.3
2)
0.
10
 (-
0.
12
;0
.3
2)
-0
.1
2 
(-0
.3
8;
0.
14
)
fa
st
in
g 
bl
oo
d 
gl
uc
os
e 
(m
m
ol
/l)
0.
01
 (-
0.
30
;0
.3
3)
0.
03
 (-
0.
30
;0
.3
6)
-0
.0
1 
(-0
.2
4;
0.
23
)
0.
03
 (-
0.
20
;0
.2
6)
0.
13
 (-
0.
12
;0
.3
8)
Tw
o-
ho
ur
  p
os
t-l
oa
d 
gl
uc
os
e 
(m
m
ol
/l)
0.
07
 (-
0.
20
;0
.3
3)
0.
05
 (-
0.
22
;0
.3
2)
0.
15
 (-
0.
08
;0
.3
8)
0.
11
 (-
0.
10
;0
.3
3)
0.
04
 (-
0.
21
;0
.2
8)
bo
dy
 m
as
s 
in
de
x 
(k
g/
m
2 )
0.
02
 (-
0.
28
;0
.2
8)
0.
02
 (-
0.
29
;0
.3
2)
0.
09
 (-
0.
17
;0
.3
6)
-0
.0
3 
(-0
.2
8;
0.
22
)
0.
12
 (-
0.
15
;0
.3
8)
w
ai
st
/h
ip
 ra
tio
-0
.0
2 
(-0
.3
4;
0.
31
)
-0
.1
5 
(-0
.5
1;
0.
22
)
0.
26
 (0
.0
3;
 0
.4
8)
0.
22
 (-
0.
06
;0
.5
0)
-0
.1
3 
(-0
.4
6;
0.
19
)
Tr
ig
lyc
er
id
es
 (m
m
ol
/l)
-0
.0
8 
(-0
.3
5;
0.
29
)
-0
.1
2 
(-0
.3
9;
0.
16
)
0.
08
 (-
0.
15
;0
.3
2)
0.
04
 (-
0.
18
;0
.2
6)
-0
.1
0 
(-0
.3
4;
0.
15
)
hd
l 
ch
ol
es
te
ro
l (
m
m
ol
/l)
-0
.1
4 
(-0
.4
2;
0.
15
)
-0
.1
0 
(-0
.3
9;
0.
20
)
-0
.0
9 
(-0
.3
6;
0.
17
)
-0
.0
5 
(-0
.3
0;
0.
19
)
0.
03
 (-
0.
22
;0
.2
9)
ld
l 
ch
ol
es
te
ro
l (
m
m
ol
/l)
0.
02
 (-
0.
26
;0
.2
9)
-0
.0
3 
(-0
.3
1;
0.
25
)
-0
.1
4 
(-0
.3
7;
 0
.0
9)
-0
.2
1 
(-0
.4
3;
0.
00
)
0.
21
 (-
0.
04
;0
.4
5)
se
ru
m
 a
sp
ar
ta
te
-a
m
in
o 
tra
ns
fe
ra
se
 (u
/l)
-0
.0
4 
(-0
.3
1;
0.
23
)
-0
.0
4 
(-0
.3
1;
0.
24
)
0.
10
 (-
0.
14
; 0
.3
4)
0.
09
 (-
0.
13
;0
.3
2)
-0
.2
3 
(-0
.5
1;
 0
.0
6)
se
ru
m
 a
la
ni
ne
-a
m
in
o 
tra
ns
fe
ra
se
 (u
/l)
-0
.0
3 
(-0
.3
1;
0.
25
)
-0
.0
2 
(-0
.3
0;
0.
26
)
0.
10
 (-
0.
15
; 0
.3
5)
0.
11
 (-
0.
11
;0
.3
3)
-0
.2
5 
(-0
.5
2;
 0
.0
3)
se
ru
m
 g
am
m
a-
gl
ut
am
yl 
tra
ns
fe
ra
se
 (u
/l)
-0
.1
3 
(-0
.4
0;
0.
13
)
-0
.1
1 
(-0
.3
8;
0.
16
)
0.
10
 (-
0.
16
;0
.3
6)
0.
13
 (-
0.
09
;0
.3
5)
-0
.3
3 
(-0
.6
0;
 -0
.0
3)
Ta
bl
e 
3.
 p
ut
at
ive
 d
et
er
m
in
an
ts
 o
f c
ha
ng
e 
in
 fi
rs
t-p
ha
se
 in
su
lin
 s
ec
re
tio
n 
( a
uc
in
s0
-1
0)
, s
ec
on
d-
ph
as
e 
in
su
lin
 s
ec
re
tio
n 
(m
ea
n 
in
s1
60
-1
80
), 
an
d 
di
sp
os
itio
n 
in
de
x 
(d
i).
  
42 CHAPTER 3 deTerminanTs of change in insulin secreTion oVer Three years in impaired glucose Tolerance:  The hoorn IGT-STudy.
DiSCuSSiON
This prospective study in persons with confirmed impaired glucose tolerance demonstrated 
the potential of the disposition index in determining the change in glucose tolerance. A de-
cline of insulin sensitivity was observed, irrespective of the glucose tolerance status after 
the three year follow up. The disposition index decreased only in those persons converting 
to diabetes, who were not able to compensate for this decline by increasing their insulin 
secretion. In contrast, the persons which converted to normal glucose tolerance, showed 
the opposite. In addition, in those subjects who showed an increase in first-phase insulin 
secretion and the disposition index, the risk of developing type 2 diabetes was reduced. 
Of interest was our finding that a high gamma-glutamyl transferase was significantly as-
sociated with a decline of the disposition index. Alanine-amino transferase demonstrated 
a similar relationship. This supports the current view on the pathogenic role of ectopic fat 
accumulation in the development of both insulin resistance in the liver and possibly beta-
cell dysfunction 42. High serum alanine-amino transferase levels have shown to be related 
to both cardiovascular disease and in some studies also to incident diabetes.
sTudy’s LimiTATiOns And sTREnGTHs 
The statistical power of this study is limited because of the small number of subjects (N = 
50). Despite this fact, we found important results. This study originally was a randomized 
clinical trial designed to investigate the glucose-lowering effect of acarbose. Although it 
failed to have an effect on fasting glucose, HbA1c, insulin secretion and insulin sensitiv-
ity and conversion to type 2 diabetes, it lowered post load glucose 38. Therefore, in our 
analyses, we corrected for acarbose use. In this trial, 51 subjects who were lost to follow-
up did not have a second clamp test. To evaluate possible selection bias, we compared 
the baseline characteristics between subjects who completed the study and those who did 
not; we found no differences (data not shown). Our study population was a homogenous, 
enriched, group of patients with impaired glucose tolerance; the results of this study, 
therefore, cannot be extrapolated to persons with a normal glucose tolerance. 
Persons with impaired glucose tolerance are characterized by insulin resistance, hyperin-
sulinemia and elevated fasting and post load glucose levels 43. These defects, already pres-
ent in persons with impaired glucose tolerance explain their high risk for developing type 2 
diabetes. This is at the same time, the very reason to include these persons in intervention 
studies and mechanistic studies. 
 
We observed, in the whole group, a considerable decrease in insulin sensitivity over three 
years irrespective of each subject’s final glucose tolerance status. This could not be ex-
plained by changes in body mass index. Even though the inter-assay coefficient of varia-
tion of the insulin assays should have been under 10%, we cannot exclude the possibility 
of a change in the characteristics of the insulin assay (antibody sensitivity). Since the I 
component of the M/I ratio decreased only by 11.8%, whilst the M value decreased by 
52.7% in the whole group, one may assume that the found lowering of the insulin sensitiv-
ity is real and not a laboratory error. Thus, only a small part of the large decrease in insulin 
sensitivity can be attributed to a difference in the assay characteristics. 
 
This is the first study that prospectively analyzes the change in insulin secretion in a 
population of white patients with impaired glucose tolerance, using the reference method 
for insulin secretion assessment, the hyperglycemic clamp. The first insulin phase of the 
hyperglycemic clamp correlates well with the first insulin phase of the IVGTT minimal 
model technique 44, but has the advantage over the IVGTT, of measuring a second insulin 
phase as well. Furthermore, calculating insulin sensitivity from frequently sampled IVGTTs 
43deTerminanTs of change in insulin secreTion oVer Three years in impaired glucose Tolerance:  The hoorn IGT-STudy.
can be problematic 24. The group comprised men and women in equal numbers and there 
was a large variation in glucose tolerance status at follow-up. In the only previous longitu-
dinal study with repeated hyperinsulinemic-euglycemic clamp measures, 48 Pima Indians 
were followed for an average of five years, during which glucose tolerance deteriorated 
from normal to impaired to type 2 diabetes in 17 subjects, while remaining normal in 31 
subjects. In that study, the first-phase insulin secretion, measured during an intravenous 
glucose tolerance test, decreased by 51% in the converters from impaired glucose tolerance 
to type 2 diabetes and increased overall by 30% in the non-converters. At the same time, 
the maximally insulin-stimulated glucose disposal decreased by 19% during the transition 
from impaired glucose tolerance to type 2 diabetes and remained, on average, unchanged 
in the non-converters. As a consequence of these changes, the disposition index decreased 
by 47.5% in the converters and remained unchanged in the non-converters. Notwithstand-
ing the fact that the Pima population was younger and more obese, the results of these 
two studies very much accord with each other. Recently, the longitudinal change of beta-
cell function was studied with frequently sampled intravenous glucose tolerance tests 24. 
In that study, failure to increase insulin secretion led to impaired glucose tolerance, and a 
decrease in insulin secretion led to type 2 diabetes. Another recent study reported similar 
findings in high risk women 25. This is also in line with our results. 
 
 
DETErmiNaNTS Of ChaNgE iN iNSuliN SECrETiON
None of the tested putative determinants showed a statistically significant relationship 
with the change of first-phase insulin secretion. In our data, a higher level of gamma-
glutamyl transferase at baseline predicted (with borderline statistical significance) a de-
crease in the disposition index and therefore an eventual shift in glucose tolerance status. 
Gamma-glutamyl transferase is known to be a marker for intra-hepatic fat accumulation 
45. It and other liver enzymes have been shown to predict the incidence of type 2 diabetes 
in a number of prospective studies with 46 47 or without 48 adjustment for alcohol consump-
tion. The accumulation of fat in the liver is thought to reflect the fat accumulation in other 
organs, including the pancreas, with its possible lipotoxic effect on beta-cells 49 50. Our 
measures of changes in first-phase insulin secretion using the disposition index produced 
data that are also in keeping with the lipotoxicity theory. 
In conclusion, we have demonstrated that subjects with impaired glucose tolerance are 
likely to progress to type 2 diabetes when compensatory increase in insulin secretion fails, 
resulting in a decrease in the disposition index. We also found that gamma-glutamyl trans-
ferase predicted changes in the disposition index. 
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ABsTRACT
 
ObjECTivES To assess whether insulin sensitivity can explain the associations of leg fat 
mass and trunk fat mass with the cardiovascular disease risk profile in healthy European 
men and women. 
mEThODS aND prOCEDurES We studied 142 healthy men and women of a multi-
centre European study on insulin sensitivity, aged 30-60 years, from the centres in Hoorn, 
the Netherlands and Rome, Italy. Whole-body dual-energy X-ray absorptiometry was used 
to determine fat and lean soft tissue mass in the trunk and legs. Fasting glucose, insulin, 
and lipid levels were measured. Insulin sensitivity (M/I-ratio) was measured during a 
euglycemic-hyperinsulinemic clamp. Associations between fat-distribution and cardiovas-
cular disease risk factors were studied with linear regression analyses with adjustment for 
other body compartments, and subsequent adjustment for insulin sensitivity. 
rESulTS In men, larger leg fat mass was significantly and independently associ-
ated with lower triglyceride levels and higher HDL-cholesterol (p<0.10) and tended 
to be associated also with lower LDL-cholesterol, and lower fasting insulin levels. In 
women, larger leg fat mass was associated with favourable values of all cardiovascu-
lar disease risk factors, although the associations were not statistically significant. In 
both sexes, larger trunk fat mass was independently and significantly associated with 
unfavourable values of most cardiovascular disease risk factors and most associations 
did not markedly change after adjustment for insulin sensitivity.    
CONCluSiONS In a relatively young and healthy European population, larger leg fat 
mass is associated with a lower and trunk fat mass with a higher cardiovascular and meta-
bolic risk, which can not be explained by insulin sensitivity.
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iNTrODuCTiON
Obesity is a well known risk factor for both type 2 diabetes (DM2) and cardiovascular 
disease (CVD). More in particular, the distribution of body fat is associated with the risk of 
DM2 and components of the metabolic syndrome (MS). Insulin resistance (IR) is thought to 
be a key player in the association between fat distribution and the development of dyslipi-
demia, CVD and DM2 in adult humans 1 and even in children and adolescents 2.   
Waist and hip circumference, as estimates of fat distribution have been shown to have 
independent and opposite associations with glucose levels, dyslipidemia, IR and DM2 3 4. 
Recent studies showed that large hip circumferences were associated with lower risk of to-
tal mortality, cardiovascular mortality and morbidity, and CVD risk factors independently 
of waist circumference 3-8. Leg fat correlates inversely with coronary atherosclerosis 9. Fur-
thermore, trunk and leg fat have independent and opposite associations with fasting and 
post load glucose and IR in elderly populations 10 and have been shown to relate to CVD 
risk factors in the same way in Japanese 11 and Caucasian populations 4 12.   
In obese male subjects the relationship between lower body fat mass and a more favour-
able blood lipid profile persisted after adjustment for insulin sensitivity 13. However, it is 
not known if these relationships are present in healthy Caucasian men and women and, 
if present, if they can be explained by underlying differences in insulin sensitivity. In the 
present study, we used the gold standard technique, i.e. the hyperinsulinemic-euglycemic 
clamp, to investigate to what extent insulin sensitivity can explain the associations be-
tween body composition and CVD risk factors in healthy persons.
mEThODS aND prOCEDurES  
Study population   The RISC (Relationship between Insulin sensitivity and Cardiovascu-
lar disease risk) study is a prospective, observational, multi-centre cohort study whose 
rationale and methodology has been published previously 14. Briefly, participants were 
randomly recruited, from local populations of the participating countries. Participants 
were clinically healthy and aged between 30 and 60 years. Those with a history of car-
diovascular, pulmonary, kidney or malignant disease were excluded as well as those cur-
rently taking medications. After clinical examinations those with hypertension, diabetes, 
hypercholesterolemia, hypertriglyceridemia and ECG abnormalities were also excluded 14. 
The population was stratified by sex and age according to 10-year age groups. Baseline 
examinations began in June 2002 and were completed in July 2005. The present analysis 
is based on the cross-sectional baseline data of 80 Dutch and 62 Italian participants of the 
RISC-study, who satisfied all the inclusion criteria, had a hyperinsulinemic-euglycemic 
clamp study (clamp) of high quality and who underwent a dual energy X-ray absorptiom-
etry (DXA) scan.
Ethical considerations   The study protocol was approved by the Ethical Review 
Committee of the VU University Medical Centre in Amsterdam and Istituto di Me-
dicina Interna e Geriatria, Policlinico A Gemelli in Rome. All participants gave 
their written informed consent.        
 
Lifestyle and medical history questionnaire  Of the participants and their partners, in-
formation was collected on personal medical history and family history of CVD, stroke, 
hypertension and diabetes, smoking, alcohol habits. Physical activity was measured 
with the 7-day International Physical activity Questionnaire (IPAQ) 15. All medica-
tion was recorded. A modified version of the Rose questionnaire 16 and the Edinburgh 
claudication questionnaire 17 were used for exclusion of prevalent CVD. The lifestyle 
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questionnaire was prepared in English, translated into the 2 languages of the study 
and back-translated into English to ensure homogeneity.    
 
Physical examinations   Height was measured on a clinic stadiometer. Body weight 
and fat free mass were evaluated by the TANITA bioimpedance balance (Tanita Inter-
national Division, UK); waist, hip and thigh circumferences were measured by tape 
measure according to a standardised written protocol. BMI was calculated by weight 
divided by height squared (kg/m2). Sitting blood pressure and heart rate (OMRON 
705 cp, OMRON Healthcare Europe, The Netherlands) were measured three times 
over 10 min; the median value was used in the statistical analysis.    
 
Oral glucose tolerance tests (OGTT) Fasting blood samples were taken before and during 
a 75-g OGTT at 0, 30, 60, 90 and 120 min. Samples were transported on dry ice at pre-
arranged intervals to central laboratories 14.      
 
Clamp   On a separate day within one week after the OGTT, a euglycemic hyperinsu-
linemic clamp was performed in all subjects. Exogenous insulin was administered as 
a primed continuous infusion at a rate of 240 pmol·min–1·m–2 simultaneously with a 
20% dextrose infusion, adjusted every 5-10 min to maintain plasma glucose levels within 
0.8 mmol/l (±15%) of the target glucose level (4.5-5.5 mmol/l). The steady-state pe-
riod (for calculation of insulin sensitivity) was between 80-120 min. Additional blood 
samples were obtained at 20-min intervals for insulin and NEFA determination. The 
clamp procedure was standardised across centres by means of a demonstration video 
and ad hoc operating instructions. The crude data from each clamp were immediately 
transferred to the coordinating centre where they underwent quality control scrutiny ac-
cording to pre-set criteria. Insulin sensitivity was expressed as the ratio of the M-value 
Figure 1. standard regions of a dXa scan:  1, head; 2, trunk; 
3, arms; 4, legs. dXa = dual x-ray absorptiometry scan
1
2
3 3
2
4
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18 -averaged over the final 40 min of the 2 hour clamp -to the mean plasma insulin con-
centration measured during the same interval (M/I, in units of μmol.min-1.kgffm
-1 nm-1). 
The M-value was first normalized by fat free mass (measured by TANITA bio impedance 
balance), given that glucose uptake can only occur in cell mass (includes metabolically 
active part of adipose tissue) 18. The normalization by insulin level adjusts for minor 
differences in clamp insulin levels, given that within the physiological range, plasma 
insulin level is proportional to whole body glucose disposal 18. The glucose and insu-
lin areas under the curve were calculated by means of the trapezium rule 19.  
 
Lab assays Fasting plasma glucose (FPG) was analyzed using the Cobas integra system (Roche 
diagnostics, Basel, Switzerland). Fasting serum insulin concentrations were measured using 
solid-phase, two-site fluoro-immunometric assays (Auto DELFIA Insulin kit, Wallac Oy, Turku, 
Finland). Serum HDL-cholesterol (HDL), LDL-cholesterol (LDL) and triglyceride levels (TGs) 
were analysed with homogenous enzymatic colorimetric tests for modular analyzers (Roche 
diagnostics, Basel, Switzerland). Serum non-esterified fatty acids (NEFAs) were determined 
with an enzymatic colorimetric kit for modular (Randox, Crumlin, United Kingdom). 
          
Body composition  Whole-body DXA (dual energy X-ray absorptiometry) was performed 
using the fan beam technology (QDR-2000, software version 7.20D; Hologic, Brussels, Bel-
gium). The software provides estimates of lean tissue mass, fat mass, and bone mineral 
mass for the total body and for standard body regions (figure 1). With the use of specific 
anatomic landmarks, regions of the head, trunk, arms, and legs were distinguished 10. In 
the present analyses, we studied fat and lean soft-tissue mass from the trunk and legs. 
 
 
STaTiSTiCal aNalySES
In Table 1, clinical characteristics of 142 subjects are presented as means with standard de-
viations in categories of nationality and sex; for skewed data the medians and inter-quartile 
ranges are shown. Age-adjusted ANOVA was performed to assess whether the differences 
between the groups (according to sex and nationality) were significant.   
Linear regression analysis was used to examine the relationships between body composi-
tion measures and CVD risk factors (Table 2 and table 3). Associations did not change 
after adjustment for menopause and there was no interaction. Therefore we did not adjust 
for menopause in the models. Due to differences in body composition, all models were 
presented separately for men and women. To facilitate direct comparisons, results are 
reported as standardized betas. A standardized beta of 0.1 indicates that when the inde-
pendent variable increases by 1 standard deviation, the dependent variable increases by 
0.1 standard deviation. A p-value <0.05 (two-tailed) was considered statistically signifi-
cant. Regression models were checked for colinearity. A tolerance of <0.1 or a variance-
inflation factor of >10 were considered as indications of colinearity. Statistical analyses 
were performed with SPSS for Windows version 12.0.2.
 
 
 
rESulTS
The clinical characteristics of the subjects are shown in Table 1. When compared with wom-
en, men were about the same age, but the subjects of Rome were younger in general. Italian 
women had relatively low mean insulin sensitivity compared to Italian men (not statistically 
different) and they had a larger proportion of physical inactivity (statistically significant). 
Although there was a low prevalence of the Metabolic syndrome 20 (Table 1), larger leg 
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dutch Italian
Men (35) Women (45) Men (28) Women (34)
Age (years) 48.9 ± 8.2 45.7 ± 7.5 b 39.3 ± 7.2 40.2 ± 8.1
height (cm) 179.1 ± 6.1a b 168.2 ± 6.1 b 176.8 ± 7.3 a 162.3 ± 6.1
BMI (kg/m2) 26.1 ± 2.3 24.9 ± 3.2 26.6 ± 3.0 25.3 ± 3.9
Waist (cm) 93.6 ± 7.2 a 81.5 ± 8.7 87.7 ± 9.5 a 74.5 ± 15.1
hip (cm) 99.0 ± 9.0 a b 101.3 ± 6.6 b 92.4 ± 4.7 94.3 ± 9.2
Leg f at (%) 24.1 ± 4.7 a b 43.4 ± 8.3 b 17.8 ± 7.4 a 33.0 ± 8.0
Trunk fat (%) 23.6 ± 6.2 a 31.3 ± 10.4 21.0 ± 5.9 a 29.7 ± 9.5
Leg fat (kg) 6.1 ± 1.6 a b 10.3 ± 3.3 b 4.6 ± 1.9 a 7.3 ± 3.6
Lean leg tissue (kg) 18.9 ± 2.2 a 13.1 ± 1.9 b 21.0 ± 3.8 a 14.0 ± 2.1
Trunk fat (kg) 9.9 ± 3.2 10.8 ± 4.8 8.3 ± 3.0 a 9.3 ± 3.6
Total fat (kg) 21.1 ± 6.6 a b 14.9 ± 5.7 b 26.0 ± 9.9 a 20.1 ± 10.3
Mean systolic blood pressure (mmhg) 124.3 ± 12.4 a b 111.5 ± 11.6 114.7 ± 9.0 109.0 ± 10.4
Mean diastolic blood pressure(mmhg) 76.5 ± 7.2 a 69.0 ± 8.0 75.0 ± 6.2 a 70.0 ± 7.2
hdL-cholesterol (mmol/l) 1.3 ± 0.3 a b 1.6 ± 0.4 1.1 ± 0.3 a 1.5 ± 0.3
LdL-cholesterol (mmol/l) 3.4 ± 0.8 3.0 ± 0.8 3.1 ± 0.7 2.9 ± 0.8
Triglycerides (mmol/l) 1.18 (0.83-1.56) a 0.81 (0.72-1.08) 1.08 (0.73-1.54) a 0.70 (0.55-0.95)
neFAs (mmol/l) 0.46 (0.34-0.55) b 0.54 (0.42-0.61) b 0.41 (0.29-0.53) 0.76 (0.53-0.82)
Fasting blood glucose (mmol/l) 5.6 ± 0.4 a b 5.3 ± 0.4 b 4.9 ± 0.9 a 4.4 ± 0.6
Insulin sensitivity (M) 3.3 ± 1.0 3.2 ± 0.9 4.0 ± 1.5 2.8 ± 1.1
Insulin sensitivity (Mffmass) 50.2 ± 14.7
 a b 69.1 ± 18.8 61.7 ± 23.6 a 61.4 ± 23.0
Insulin sensitivity (Mffmass/I-ratio) 129.5 ± 54.7 169.2 ± 51.8 118.7 ± 61.9 116.4 ± 54.2
Fasting insulin (pmol/l) 36.2 ± 20.5 32.4 ± 12.9 46.4 ± 25.0 41.6 ± 25.2
Smokers  n (%) 12 (34.3) a 9 (20.9) b 10 (32.3) a 14 (29.8)
Activity (IPAQ score) -inactive n (%) 6 (18.8) a 2 (4.9) b 6 (21.4) a 15 (34.1)
-minimally active n (%) 14 (43.8) a b 22 (53.7) 11 (39.3) a 18 (40.9)
-health enhancing activity n (%) 12 (37.5) a 17 (42.5) b 11 (39.3) 11 (25.0)
MS prevalence n (%) 10 (17.2) a b 0 (0) b 3 (7.7) 2 (3.2)
Table 1. clinical  characteristics of dutch and italian men and women of the risc study
a: significant difference between sexes, within nationality (p<0.05). b: significant difference between nationalities, within
gender (p<0.05).
fat was associated with a lower prevalence of the metabolic syndrome (statistically not 
significant), while the association of larger trunk fat mass with a higher prevalence 
Table 2. associations (standardized betas) between body composition (trunk lean mass and leg lean mass 
not shown in the models) and cVd risk factors in men.
Men model 1 Men model 2 Men model 3 Men model 4
LFM TFM LFM TFM LFM TFM LFM TFM
Fasting glucose -0.12 0.02 -0.12 0.02 -0.35* 0.04 -0.36* -0.02
Fasting insulin 0.01 0.09 -0.10 0.01 -0.33 0.30 -0.42 0.18
hdL-cholesterol 0.29 -0.50*** 0.35* -0.45** 0.19 -0.53** 0.25 -0.45**
LdL-cholesterol -0.23 0.19 -0.24 0.18 -0.23 0.19 -0.24 0.18
Triglycerides -0.48** 0.70*** -0.56*** 0.63*** -0.90*** 1.04*** -0.98*** 0.94***
neFAs 0.15 0.13 0.14 0.11 0.15 0.13 0.14 0.11
Systolic blood pressure -0.27 0.15 -0.23 0.19 -0.15 0.19 -0.10 0.27
model 1 is adjusted for the other body compartments, age and centre. model 2 is model 1, additionally adjusted for insulin sensitivity. 
model 3 is adjusted for the other body compartments, age, centre, smoking and physical activity. model 4 is model 3, additionally adjusted 
for insulin sensitivity. * = p<0.10, ** = p<0.05, *** = p<0.01. lfm; leg fat mass, Tfm; Trunk fat mass.
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of the metabolic syndrome was statistically significant (data not shown).   
In men, larger LFM was significantly associated with lower TGs, independent of other 
body compartments. The association became a bit stronger after adjustment for insulin 
sensitivity (Table 2). Although not statistically significant, larger LFM was also associated 
with lower FPG and blood pressure levels and with higher HDL (p<0.10). Larger TFM was 
significantly associated with higher TGs and with lower HDL. These associations did not 
markedly change after adjustment for insulin sensitivity.    
In women (Table 3), larger LFM was associated with more favourable HDL, LDL and TGs, 
although not statistically significant. These associations did not markedly change after 
adjustment for insulin sensitivity. Larger TFM was significantly associated with higher 
FPG, fasting insulin and TGs, higher systolic and diastolic blood pressure and lower HDL. 
These associations did not markedly change after adjustment for insulin sensitivity, except 
for TGs, which association with trunk fat became statistically non-significant. Adjustment 
for height did not change any of the associations above (data not shown) and there was 
no interaction with nationality.
 
 
DiSCuSSiON  
Although this study is limited due to a small sample size, it still yields interesting observa-
tions. The present study in healthy subjects confirms the known associations of leg and 
trunk fat with glucose and lipid concentrations. To our knowledge, we are the first to 
show that these associations are not explained by whole body insulin sensitivity, when 
measured with the euglycemic clamp technique. These findings are in agreement with 
previous studies which used alternate measures of body composition 3-9, or the DXA scan 
8-11. Most of these previous studies were in elderly populations, or in elderly and obese 
populations. Only one recent study in Japanese men and women 11 reported similar find-
ings in the young and the old (20-79 years). Buemann et al 13 found similar results in male 
obese subjects, when they used the Matsudas-index to estimate the level of whole body 
insulin sensitivity (the Matsudas-index is calculated from plasma glucose and serum insu-
lin levels, measured during an OGTT and corresponds relatively well with the euglycemic 
clamp 21). The unfavourable associations between trunk fat and CVD risk factors were 
also present and consistent among sexes in our study. Again, these associations could not 
be explained by the level of insulin sensitivity. Normalization of insulin sensitivity for fat 
free mass is still under debate. To evaluate the possible differences between the different 
WoMen model 1 WoMen model 2 WoMen model 3 WoMen model 4
LFM TFM LFM TFM LFM TFM LFM TFM
Fasting glucose -0.06 0.37** -0.04 0.34* -0.08 0.36** -0.06 0.34*
Fasting insulin -0.02 0.56*** 0.12 0.34* 0.10 0.51*** 0.27 0.25
hdL-cholesterol 0.18 -0.55*** 0.10 -0.42** 0.28 -0.64*** 0.21 -0.53**
LdL-cholesterol -0.11 0.01 -0.13 -0.04 -0.09 -0.05 -0.11 -0.02
Triglycerides -0.20 0.51** -0.08 0.32 -0.16 0.45** -0.02 0.23
neFAs 0.09 0.02 0.09 0.02 0.01 0.04 0.03 0.01
Systolic blood pressure 0.02 0.40* 0.03 0.38* 0.02 0.41** 0.03 0.39*
diastolic blood pressure -0.34 0.62*** -0.34 0.61*** -0.27 0.62*** -0.27 0.61***
Table 3. associations (standardized betas) between body composition (trunk lean mass and leg lean mass 
not shown in the models) and cVd risk factors in women.
model 1 is adjusted for the other body compartments, age and centre. model 2 is model 1, additionally adjusted for insulin sensitivity. 
model 3 is adjusted for the other body compartments, age, centre, smoking and physical activity. model 4 is model 3, additionally adjusted 
for insulin sensitivity. * = p<0.10, ** = p<0.05, *** = p<0.01. lfm; leg fat mass, Tfm; Trunk fat mass.
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methods (the normalization of the M value for fat mass (Mffmass) or the correction for insu-
lin level (Mffmass/I-ratio), we repeated analyses with uncorrected M-values and M/I-ratios 
(data not shown). These analyses showed that the strength and the direction of the found 
associations remained unchanged and were therefore virtually independent of the used 
corrections, for fat free mass or for steady state insulin level. 
Study limitations  
Dual-energy  X-ray absorptiometry cannot discriminate between different fat depots. It 
is therefore not possible to draw conclusions from the present study with regard to the 
difference in associations between subcutaneous leg fat and CVD risk factors or between 
intra or intermuscular leg fat and CVD risk factors. However, in the lean; total leg fat in the 
thigh measured by DXA represents almost exclusively subcutaneous leg fat (90% subcuta-
neous, 8% subfascial and 2% intermuscular) 22, in contrast to total fat in the trunk which 
is 35-40% visceral fat and 60-65% subcutaneous fat 23 24. The present analyses is based on 
cross-sectional data and it is not known if the same results will be found when this group 
is studied prospectively.
Body composition and CVD risk factors   
Snijder et al. found that most likely subcutaneous thigh fat accounts for the favourable 
effects of leg fat on CVD risk factors rather than intra-muscular fat 25. Research on li-
podystrophy, has demonstrated that conditions which involve the absence of subcuta-
neous fat, are associated with IR 26-29. The differences in amount of subcutaneous fat 
mass between men and women (leg fat percentage was twice as high in women when 
compared to men), may partly explain the differences in the associations between leg 
fat and insulin sensitivity for either gender. The mechanism by which the subcutaneous 
leg fat adds to a favourable CVD risk profile is still under debate. Previous studies have 
reported differences in metabolic, genetic and hormonal characteristics between subcu-
taneous and visceral fat tissue. When compared with visceral adipocytes (fat cells), sub-
cutaneous adipocytes have low catecholamine stimulated lipolysis rates and are more 
sensitive to insulin 30-33. It has been suggested that subcutaneous adipose tissue acts as 
a ‘metabolic sink’, metabolizing and storing excess free fatty acids in both fasting 34 35 
and postprandial states 36. This may prevent ectopic fat accumulation in liver, muscle 
and beta-cell and thus eventually prevents IR, impaired insulin secretion, impaired glu-
cose metabolism,  hyperlipidemia and increased CVD risk. In addition, it is known that 
visceral fat contains more macrophages which are both more active and secrete more 
Interleukin-6 and Tumor Necrosis Factor-α than subcutaneous fat, which increases the 
C-reactive protein levels. This produces a chronic low inflammatory state which adds to 
the CVD risk 37. It is not known if similar pathways also can be found in subcutaneous 
thigh or trunk fat depots and if the associations are present in the opposite direction. 
In conclusion, in healthy European men and women the associations between body com-
position and CVD risk factors, can not be explained by insulin sensitivity.
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ABsTRACT
 
ObjECTivES It has been hypothesized that insulin resistance is a major independent 
determinant of cardiovascular disease (CVD). Our aim was to investigate whether whole 
body insulin sensitivity was associated with ECG abnormalities independently of other 
CVD risk factors.
DESigN Cross-sectional study. 
SubjECTS aND mEThODS We studied 1,129 metabolically healthy European men and 
women, aged 30-60 years, with a broad range of both insulin sensitivity and body weight. 
ECG abnormalities were defined as having Q/QS or ST-T abnormalities in the resting ECG. 
Whole body insulin sensitivity was measured by hyperinsulinemic-euglycemic clamp.
Logistic regression analysis was used to study determinants of ECG abnormalities.
rESulTS Insulin sensitivity was associated with Q/QS abnormalities with an Odds-Ratio 
(95% CI) of 0.56 (0.34-0.91) per 1-SD, although not independently of waist circumference. 
Waist, BMI, total body fat (measured by impedance) and the metabolic syndrome were 
associated with Q/QS abnormalities. The odds ratio for Q/QS abnormalities with waist 
circumference was 2.33 (1.49-3.64), which was independent of demographic factors and 
other CVD risk factors. Furthermore the association between waist and Q/QS abnormali-
ties was not mediated by insulin sensitivity. No associations with ST-T abnormalities were 
observed.
CONCluSiONS In our healthy European population whole body insulin sensitivity was 
associated with ECG abnormalities but not independently of waist.
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iNTrODuCTiON
Electrocardiographic (ECG) -abnormalities are predictors of CVD events, morbidity and 
mortality in symptomatic and asymptomatic men and women 1-3. ECG abnormalities have 
been shown to be related to obesity 4 and to the metabolic syndrome (MS) 5. The ECG 
abnormalities which have been associated with obesity in previous studies, include Q/
QS patterns and ST-T abnormalities, which are signs of previous myocardial infarction or 
ischemia 6 7.
Insulin resistance (IR) is thought to be a key player in the association between obesity and 
fat distribution, and the development of CVD in adult humans 8 and even in children and 
adolescents 9. It has been hypothesized 10 that insulin resistance itself is a major independ-
ent determinant of cardiovascular disease (CVD). Conclusive evidence for the direct role 
of insulin resistance as a CVD risk factor is, however, lacking. Insulin resistance has been 
shown to be associated with coronary artery disease (CAD) measured by resting ECG in 
type 2 diabetic patients 11. Prospective studies 12-14 have reported an association between 
insulin resistance and incident CVD. However, only one of these studies included direct 
measures of insulin resistance 15 and in one of them, the association was lost when ad-
justed for established CVD risk factors. In three studies, an independent association was 
found between whole body glucose disposal and CAD, but these studies were small and in 
selected populations 16-18. Indirect evidence comes mainly from studies in which an asso-
ciation between hyperinsulinemia and CVD was found. In a large epidemiological study 19 
which used a frequently sampled intravenous glucose tolerance test (FS-IVGTTs) to assess 
insulin resistance, a high prevalence of CAD was associated with insulin resistance, inde-
pendently of other risk factors, but this population included a substantial number of sub-
jects with impaired glucose tolerance (23%) and type 2 diabetes (32%). In the RISC study, 
insulin sensitivity was assessed by a hyperinsulinemic euglycemic clamp data, ECGs were 
classified according to the Minnesota code and indices of body fat were obtained from 
1,129 healthy Europeans.
We investigated the relationship between insulin sensitivity and ST-T and Q/QS (ECG) 
abnormalities. Furthermore we studied the relationship between indices of body fat and 
ECG abnormalities and whether insulin sensitivity could explain the relationship between 
body fat and ECG abnormalities. 
 
SubjECTS aND mEThODS
Study population   The RISC study (Relationship between Insulin sensitivity and Cardiovas-
cular disease risk) is a prospective, observational, multi-centre cohort study whose ration-
ale and methodology has been published previously 20. Briefly, participants were recruited 
from local populations of the 19 recruiting centres, between June 2002 and July 2005. Par-
ticipants were clinically healthy and aged between 30 and 60 years. Those with a history 
of cardiovascular, pulmonary, kidney or malignant disease were excluded as well as those 
currently taking medications for diabetes, hypertension, lipid lowering and obesity. After 
clinical examinations those with hypertension (BP>140/>90 mmHg), diabetes (fasting 
glucose/post load glucose >7.0 /11.1 mmol/l), hypercholesterolemia (>7.8 mmol/l) or 
hypertriglyceridemia (> 4.6 mmol/l) were also excluded 20. ECG exclusion criteria includ-
ed: acute injury or ischemia or pericarditis, atrial flutter or fibrillation, tachycardia (heart 
rate > 130 bpm), sustained ventricular tachycardia, three premature ventricular contrac-
tions in a row, acute myocardial ischaemia: ST elevation > 1 mm (especially in leads III, 
aVL, aVF, V1-V4), sinus arrest (pause > 3 s), Mobitz type II AV block and a 3rd degree AV 
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block. The RISC population was stratified by sex and age according to 10-year age groups. 
The present analysis is of 1129 participants of the RISC-study, who satisfied all the inclu-
sion criteria, had an ECG recorded and a hyperinsulinemic-euglycemic clamp (clamp).
 
Ethical considerations   The study protocol was approved by the Ethical Review Commit-
tees of all study centres. All participants gave their written informed consent. 
 
Lifestyle and medical history questionnaire  Personal medical history and family history 
of CVD, stroke, hypertension and diabetes, as well as smoking, and alcohol habits were 
assessed by questionnaire. Physical activity was measured with the 7-day International 
Physical Activity Questionnaire (IPAQ). All medications were recorded, both prescribed 
(including hormone replacement therapy and oral contraceptives), and self-medications 
such as vitamin supplements and homeopathy. A modified version of the Rose question-
naire and the Edinburgh claudication questionnaire were used for exclusion of prevalent 
CVD. The lifestyle questionnaire was prepared in English, translated into the languages of 
the study and back-translated into English to ensure homogeneity.
 
Physical examinations   Height was measured on a clinic stadiometer. Body weight and fat 
mass were evaluated by the TANITA bio impedance balance (Tanita International Division, 
UK); waist, hip and thigh circumferences were measured by tape measure according to a 
standardised written protocol. BMI was calculated by weight divided by height squared 
(kg/m2). Waist-to-hip ratio was calculated. Sitting blood pressure and heart rate (OMRON 
705 cp, OMRON Healthcare Europe, The Netherlands) were measured three times over 10 
min, after 5 min of rest; the median value was used in statistical analysis. A resting 12 
lead ECG was recorded and centrally interpreted according to the Minnesota code 21 by an 
experienced cardiologist (MT-G), who was blinded to all clinical information. ECG-abnor-
malities were defined by the presence of Q/QS (Minnesota; 1.1-1.3) or ST-T abnormalities 
(Minnesota; 4.1-4.2, 5.1-5.2). The Sokolow-Lyon index 22, corresponding to Minnesota 
codes 3-1, 3-3, was used to identify left ventricular hypertrophy (LVH) by calculating the 
sum of S wave in V1 and R wave V5 or R wave in V6 (≥ 3.5 mV) and/or R wave in aVL 
(≥ 1.1 mV).
 
Oral glucose tolerance tests (OGTT)  Blood samples were taken before and during a 75-g 
OGTT at 0, 30, 60, 90 and 120 min. Samples were transported on dry ice at pre-arranged 
intervals to central laboratories 20.
 
Clamp   On a separate day within one week after the OGTT, a euglycemic hyperinsulinemic 
clamp was performed in all subjects. Exogenous insulin was administered as a primed 
continuous infusion at a rate of 240 pmol·min–1·m–2 simultaneously with a 20% dextrose 
infusion, adjusted every 5-10 min to maintain plasma glucose levels within 0.8 mmol/l 
(±15%) of the target glucose level (4.5-5.5 mmol/l). The steady-state period (for calcula-
tion of insulin sensitivity) was between 80-120 min. The clamp procedure was standard-
ized across centres by means of a demonstration video and precise operating instructions. 
The crude data from each clamp were immediately transferred to the coordinating centre 
where they underwent quality control scrutiny according to pre-set criteria. Insulin sensi-
tivity was expressed as the ratio of the M-value - averaged over the final 40 min of the 2 
hour clamp and normalized by fat-free mass - to the mean plasma insulin concentration 
measured during the same interval (M/I, in units of μmol.min-1.kgffm
-1 nM-1) 23. The glucose 
and insulin areas under the curve were calculated by means of the trapezium rule 24. Insu-
lin resistance was defined as the lowest 25% of the M/I distribution.
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Laboratory assays Fasting plasma glucose was analyzed using the Cobas integra system 
(Roche diagnostics, Basel, Switzerland). Fasting serum insulin concentrations were meas-
ured using solid-phase, two-site fluoro-immunometric assays (Auto DELFIA Insulin kit, 
Wallac Oy, Turku, Finland). Serum HDL-cholesterol, total-cholesterol and triglycerides 
were analyzed with homogenous enzymatic colorimetric tests for modular analyzers (Ro-
che diagnostics, Basel, Switzerland). LDL-cholesterol was estimated by the Friedwald for-
mula. 
Definition of the metabolic syndrome  The metabolic syndrome was defined according to 
the AHA/NHLBI criteria 25. For a person to have the metabolic syndrome three or more of 
the following five factors have to be present: central obesity (defined as waist circumfer-
ence > 102 cm for men and > 88 cm for women), TG  ≥ 1.7 mmol/L, HDL cholesterol < 
1.03 mmol/L in males and < 1.29 mmol/L in women, raised blood pressure: systolic BP ≥ 
130 or diastolic BP ≥ 85 mm Hg, fasting plasma glucose (FPG) ≥ 5.6 mmol/L. 
 
 
STaTiSTiCal aNalySES
Quantitative data are expressed as means with standard deviations (skewed variables as 
medians with inter quartile ranges) and categorical data as percentages. Age-adjusted 
ANOVA tested for statistically significant differences between the means of continuous 
variables, and skewed variables (triglycerides, MI-ratio, physical activity and alcohol con-
sumption) were log-transformed. A χ2-test compared differences for categorical variables. 
Test for trend was used to investigate if there was a linear trend of the frequencies of ECG 
abnormalities over the tertiles of variables of interest. Logistic regression was used to es-
timate the relationships between variables of interest and the presence of ECG abnormali-
ties, controlling for potential confounding variables. Associations were expressed as odds 
ratios (ORs) with their 95% confidence interval (CI) per 1-SD increase in the independent 
variable involved. The independence of the associations was evaluated if variables did 
not exhibit excessive co-linearity with each other, after adjustment for centre. Model 1 
(demographic factors) was adjusted for centre, sex and age. Model 2 was additionally 
adjusted for insulin sensitivity, or for waist when insulin sensitivity is the independent 
variable.  Model 3 (CVD risk factors) is model 1, adjusted for smoking, total-cholesterol, 
systolic blood pressure and menopause.  Due to the differences in distribution of variables 
of interest between the two groups of participants with ECG abnormalities, we analyzed 
Q/QS abnormalities and ST-T abnormalities separately. Statistical analyses used SPSS for 
Windows version 12.0.2.
 
 
rESulTS
The characteristics of the 1,129 participants are presented according to the presence of Q/
QS and ST-T abnormalities in Table 1. The prevalence of ECG abnormalities was 5.6%. 
The prevalences of Q/QS and ST-T wave abnormalities were 3.1% and 2.5% respectively. 
In general men and women with ECG abnormalities (Q/QS and ST-T combined) had less 
favourable values of cardiovascular risk factors than those without. Within the group with 
ECG abnormalities, subjects with predominantly Q/QS abnormalities, differed from the 
subjects with ST-T abnormalities with respect to their metabolic and CVD risk profile. On 
average they were more overweight, had higher systolic blood pressure, lower HDL and 
higher TG levels and post load glucose levels (all P < 0.05). Furthermore they were more 
insulin resistant and physically less active. Within the group with Q/QS abnormalities 
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no eCG abnormalities
Q/QS ST-T
n (%) 1066 35 (3.1) 28 (2.5)
Age (years) 43.4 ± 8.2 42.0 ± 8.3 42.6 ± 8.6
Sex (% men) 44.3 a 74.3 b 35.7
Menopause (% of women) 12.4 8.6 10.7
Waist (cm) 86.2 ± 12.8 95.9 ± 10.0 b 84.0 ± 11.3
Waist –to-hip ratio 0.86 ± 0.11 0.91 ± 0.11 b 0.84 ± 0.08
BMI (kg/m2) 25.4 ± 4.0 28.3 ± 3.6 b 24.3 ± 3.4
Tanita fat (%) men 21.7 ± 6.4 24.9 ± 4.7 b 20.5 ± 3.6
Tanita fat (%) women 32.2 ± 7.6 37.6 ± 7.9 b 30.0 ± 9.8
Systolic BP (mmhg) 116.5 ± 12.1 120.8 ± 8.0 118.0 ± 12.0
diastolic BP (mmhg) 74.0 ± 7.7 75.5 ± 7.7 74.8 ± 8.5
hdL-cholesterol (mmol/l) 1.42 ± 0.38 1.20 ± 0.30 b 1.57 ± 0.34
Total-cholesterol (mmol/l) 4.80 ± 0.85 4.86 ± 0.86 4.45 ± 0.73
Triglycerides (mmol/l) 0.92 (0.68-1.27) 1.12 (0.85-1.86) b 0.72 (0.58-1.08)
Fasting glucose (mmol/l) 5.1 ± 0.6 5.1 ± 0.5 5.1 ± 0.5
Post load glucose (mmol/l) 5.7 ± 1.5 6.0 ± 1.3 5.6 ± 1.3
Fasting insulin (pmol/l) 35.1 ± 19.1 40.5 ± 20.2 35.9 ± 23.9
M/I-ratio (μmol.min-1.kgffm
-1 nM-1) 127.7 (91.6-175.9) 107.6 (79.5-125.6) b 165.1 (96.9-219.7)
Insulin resistance (%) 22.5 22.9 17.2
Smoking   (smoker/ex-smoker) 26.7/ 26.3 18.2/ 24.2 25.0/ 28.6
Alcohol (grams/day) 47.7 (15.0-105.0) 61.0 (18.8-129.9) 49.3 (26.4-119.9)
Activity (IPAQ total MeTS) 1677.0 (693.0-3960.0) 946.5 (338.3-2466.0) b 2167.5 (954.0-4752.0)
MS prevalence  (%) 9.3 22.9 b 0.0
Median heart rate (bpm) 68.4 ± 10.3 68.7 ± 10.5 68.9 ± 11.9
eCG abnormalities
Table 1. clinical characteristics
asignificant difference between group with no ecg abnormalities and group with ecg abnormalities (p<0.05). 
bsignificant difference between  groups with Q/Qs abnormalities (minnesota; 1.1-1.3) and  sT-T abnormalities (minnesota; 4.1-4.2, 5.1-5.2) 
(p<0.05).
there were also more men and more subjects with  MS. In the group with Q/QS abnormali-
ties we identified three persons with left axis deviation and 1 with right axis deviation. We 
did not detect persons with LVH according to the Sokolow-Lyon index.
We observed statistically significant linear trends (P<0.05) of Q/QS abnormalities over 
sex specific tertiles of BMI, waist circumference, total body fat (%) and for insulin sensi-
tivity, the M/I ratio, but not fasting insulin or waist-to-hip ratio (Fig 1A).  We did not find 
statistically significant linear trends of ST-T abnormalities over the tertiles of any of these 
variables (Fig.1B). 
Figure 1A. frequencies (%) of Q/Qs abnormalities 
according to tertiles  of body mass index (bmi), waist 
circumference (waist), waist to hip ratio (w/h ratio), 
total body fat as percentage (fat (%)), fasting plasma 
insulin (fpi) and insulin sensitivity (m/i) * p for trend 
statistically significant at the 0.05 level.
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Figure 1B. frequencies (%) of sT-T abnormalities 
according to tertiles  of body mass index (bmi), 
waist circumference (waist), waist to hip ratio (w/h 
ratio), total body fat as percentage (fat (%)), fasting 
plasma insulin (fpi) and insulin sensitivity (m/i) * p 
for trend statistically significant at the 0.05 level.
A high insulin sensitivity was associated with a low prevalence of Q/QS abnormalities 
when adjusted for CVD risk factors. However, the association was not independent of 
waist circumference (odds ratio of 0.97 (0.58-1.63)), BMI or total body fat (data not 
shown). Also, Waist-to-hip ratio, insulin resistance and fasting insulin were not independ-
ently associated with Q/QS abnormalities. BMI, waist and total body fat (%) were posi-
tively associated with Q/QS abnormalities (Table 2), independently of demographic factors 
(model 1), insulin sensitivity (model 2) and CVD risk factors (model 3). The associations 
were statistically significant. Subjects with the MS were also more likely to have Q/QS 
abnormalities. When we deleted the persons with left axis deviation from the analysis 
the results did not materially change (data not shown). To investigate if the strength and 
direction of the association between insulin sensitivity and Q/QS abnormalities was de-
pendent on the degree of insulin resistance we analyzed the relationship between insulin 
sensitivity and Q/QS abnormalities separately in the insulin resistant group (N = 282). A 
higher insulin sensitivity was associated with a lower prevalence of Q/QS abnormalities 
with an odds ratio of 0.74 (0.52-1.05), when adjusted for waist. In contrast, high insulin 
sensitivity was weakly, and not statistically significant, associated with a high prevalence 
of STT abnormalities.
Q/Qs sT-T
Independent variable model 1 model 2 model 3 model 1
BMI 1.95 (1.34-2.74)*** 1.88 (1.29-2.73)*** 1.94 (1.33-2.84)*** 0.76 (0.49-1.19)
Waist 2.33 (1.49-3.64)*** 2.23 (1.37-3.63)*** 2.25 (1.38-3.68)*** 0.85 (0.52-1.39)
Total body fat 1.94 (1.31-2.88)*** 1.83 (1.20-2.80)*** 2.00 (1.30-3.10)*** 0.74 (0.50-1.10)
Waist-to-hip ratio 1.26 (0.86-1.84) 1.18 (0.79-1.76) 1.24 (0.78-1.98) 0.94 (0.57-1.53)
Insulin sensitivity 0.56 (0.34-0.91)** - 0.56 (0.34-0.92)** 1.48 (0.99-2.20)
Insulin resistance (y/n) 1.14 (0.50-2.64) - 1.10 (0.46-2.63) 1.37 (0.50-3.74)
Fasting insulin 1.33 (0.95-1.85) 1.19 (0.81-1.75) 1.33 (0.95-1.87) 1.34 (0.87-2.04)
MS ATP-III (y/n) 3.06 (1.36-7.43)** 2.92 (1.14-7.50)** - -
Systolic blood pressure 1.24 (0.99-1.90) 0.94 (0.87-1.01) - 1.35 (0.87-2.10)
Table 2. odds ratios (95% ci) of prevalence of ecg abnormalities per 1-sd increase in independent  
variable
model 1 is adjusted for centre, age, sex. model 2 is model 1 plus adjustment for insulin sensitivity. model 3  is model 1 plus adjustment for 
cVd risk factors (menopause, smoking, total-cholesterol, blood pressure).  **(p < 0.05), ***(p<0.01).
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DiSCuSSiON
This is the largest epidemiological study to date in which whole body insulin sensitivity 
has been measured by hyperinsulinemic-euglycemic clamp and studied in relation with 
ECG abnormalities. We did not find evidence that insulin sensitivity is a strong independ-
ent determinant of Q/QS abnormalities after either waist or total body fat was taken into 
account, nor did it act as a mediator in the relationship between body fat and ECG abnor-
malities. 
 
Some previous studies found a strong  association with insulin resistance 26 27 and fasting 
insulin 28 29.  However, these studies did not use the reference method for the assessment of 
whole body insulin sensitivity. Moreover, most of these study populations were selected, 
high risk populations. The subjects were very insulin resistant 30 31, or had a large number 
of subjects with impaired glucose tolerance 32 or hypertension 33. The present study was 
of low CVD-risk individuals. Although in our subgroup analysis with insulin resistant 
individuals, the association between high insulin sensitivity and low prevalence of Q/QS 
abnormalities was not much stronger, it seemed to be less dependent on waist.  
The finding that body fat is associated with Q/QS abnormalities, independently of other 
major CVD risk factors is in agreement with previous studies 34 35. In contrast to De Bacquer 
et al. 36 we did not find an association between indices of body fat and ST-T abnormalities, 
in agreement with Frank et al 37.
Strengths of the study include a well defined sample of more than 1,000 healthy men and 
women, insulin resistance measured by the reference method and ECG’s centrally coded 
by an experienced cardiologist, blinded for other information. However, there are some 
limitations of the present study that need discussion. 
 
First of all, this study is cross-sectional. To assess the role of insulin resistance in the gen-
esis of ECG abnormalities, the RISC cohort will be followed prospectively, thus enabling 
such analyses in the future. Second, our study population was a relatively young and 
healthy group of European men and women. The prevalence of Q/QS and ST-T abnor-
malities we found were in line with the prevalences that de Bacquer et al. found in their 
population based sample in the age group 25-75 years 38. Furthermore there was a large 
variation in body fat and insulin sensitivity, which is necessary to study these associations. 
Third, compared to body fat indices such as BMI and waist, insulin sensitivity, determined 
by the M/I ratio, displayed a large variability which can be attributed to physiological 
variability (day-to-day and diurnal changes 39) and precision of the test. The coefficient 
of variation of the hyperinsulinemic euglycemic clamps may range from 6-15% 40 41. The 
random test-retest differences of fasting insulin can be 22% 42. This is expected to lead to 
random misclassification with respect to individuals’ mean levels and this may result in 
weaker estimates of associations. Finally, in this study we could not confirm that the Q/
QS abnormalities were specifically due to previous (silent) myocardial infarct (MI). This 
makes the findings harder to interpret clinically. However, the exclusion of LVH, left axis 
deviation and bronchopulmonary disease makes it more likely that (silent) MI was the 
cause of the ECG abnormalities. 
 
In conclusion, in this large population of healthy men and women from all over Europe, 
insulin sensitivity was associated with ECG abnormalities. However, this association was 
explained by waist.
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ABsTRACT
 
ObjECTivES To study the association between insulin resistance and microalbuminuria 
in a low CVD risk population. 
DESigN Cross-sectional study. 
SubjECTS aND mEThODS We studied 1,207 healthy European men and women, aged 
30-60 years, without diabetes or hypertension. Whole body insulin sensitivity was mea-
sured by hyperinsulinemic-euglycemic clamp and micro albuminuria (albumin-to-creati-
nine  ratio 2-30 mg/mmol) was calculated from the mean of two spot urine samples. Insu-
lin resistance was defined as the lowest 25% of the insulin sensitivity distribution. Logistic 
regression analysis was used to study the independence of the association between insulin 
resistance and microalbuminuria.  
rESulTS The prevalence of microalbuminuria was 3.1%. Subjects with microalbuminuria 
had a lower mean whole body insulin sensitivity (means (interquartile range) 96.0 (75.1-
147.4) vs. 128.4 (93.0-176.7, P-value 0.02) compared to subjects without microalbuminu-
ria. Logistic regression analysis showed that the association between insulin sensitivity and 
microalbuminuria was non-linear and was best described by categorizing it into quartiles. 
Insulin resistance (upper 25% of the distribution) increased the odds ratio ((OR), 95% CI) 
of having microalbuminuria by 4.13 (1.59-10.70), independently of fasting insulin, triglyc-
erides, fasting glucose, blood pressure, HDL-cholesterol and waist circumference.  
CONCluSiONS Insulin resistance was associated with a higher prevalence of microalbu-
minuria, independently of overweight or other CVD risk factors, which suggests that there 
may be a direct link. 
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iNTrODuCTiON
Microalbuminuria is a well known risk marker for cardiovascular and renal disease in type 
2 diabetic patients 1 2 and in non-diabetic persons 3-6. The risk for cardiovascular (CVD) 
disease is independent of renal function, hypertension and diabetes and is already present 
at low levels of microalbuminuria 7-9. Furthermore, according to the 1999 definition of the 
MS by the World Health Organization (WHO), microalbuminuria may be regarded as part 
of the metabolic syndrome (MS) 7.
The determinants of microalbuminuria are not fully known. However, cross-sectional 
evidence suggests that insulin resistance contributes to the development of microalbu-
minuria in persons with diabetes type 2, impaired glucose tolerance and hypertension, 
when insulin resistance was estimated by HOMA 10-13 or by hyperinsulinemic euglycemic 
clamp 11 14 15. In one study with non-diabetic subjects, insulin resistance was associated 
with microalbuminuria, when insulin resistance was assessed with frequently sampled 
intravenous glucose tolerance tests (FSIVGTTs) and minimal model analysis 16. However, 
in this study there was an overrepresentation of impaired glucose tolerant (IGT) subjects 
and hypertensive subjects. We evaluated whether this relationship exists already in a nor-
motensive population.
 
In the present study we investigated the association between insulin resistance, measured 
by hyperinsulinemic euglycemic clamp, and microalbuminuria in a general healthy popu-
lation. As microalbuminuria and insulin resistance may be a consequence of CVD, the 
RISC population was selected for a very low CVD risk, by excluding subjects with hyper-
tension, prior cardiovascular disease or diabetes or treatment by lipid lowering drugs. 
 
 
rESEarCh  DESigN aND mEThODS  
Study population The RISC study (Relationship between Insulin sensitivity and Cardiovas-
cular disease risk) is a prospective, observational, multi-centre cohort study. The rationale 
and methodology has been published previously 17. Briefly, participants were recruited 
from local populations of the participating countries. Participants were clinically healthy 
and aged between 30 and 60 years. Those with a history of cardiovascular, pulmonary, 
kidney or malignant disease were excluded as well as those currently taking medications 
for diabetes, hypertension, dyslipidaemia or obesity. After clinical examinations those with 
hypertension (systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg), 
diabetes (fasting plasma glucose ≥7.0 mmol/l or post load glucose ≥ 11.1 mmol/l), hyper-
cholesterolemia (Total cholesterol ≥ 7.8 mmol/l) and hypertriglyceridemia (triglycerides ≥ 
4.6 mmol/l) were also excluded 17. Baseline examinations began in June 2002 and were 
completed in July 2005. The present analysis is based on the baseline data of 1, 207 par-
ticipants of the RISC-study, who satisfied all the inclusion criteria, and had a hyperinsu-
linemic-euglycemic clamp study (clamp) of high quality.
Ethical considerations   The study protocol was approved by the Ethical Review Com-
mittees of all the study centres involved in the participating countries. All participants 
gave their written informed consent.       
 
Lifestyle and medical history questionnaire  Of the participants and their partners, informa-
tion was collected on personal medical history and family history of CVD, stroke, hyperten-
sion and diabetes, smoking, alcohol habits. Physical activity was measured with the 7-day 
International Physical activity Questionnaire (IPAQ) 18. All medication was recorded, both 
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prescribed (including hormone replacement therapy and oral contraceptive), and self-med-
ication such as vitamin supplements and homeopathy. A modified version of the Rose ques-
tionnaire 19 and the Edinburgh claudication questionnaire 20 were used for exclusion of prev-
alent CVD. The lifestyle questionnaire was prepared in English, translated into the languag-
es of the study and back-translated into English to ensure homogeneity.   
 
Physical examinations   Height was measured on a clinic stadiometer. Body weight was eval-
uated by the TANITA bio impedance balance (Tanita International Division, UK); waist, hip 
and thigh circumferences were measured by tape measure according to a standardised written 
protocol. BMI was calculated by weight divided by height squared (kg/m2). Sitting blood pres-
sure and heart rate (OMRON 705 cp, OMRON Healthcare Europe, The Netherlands) were mea-
sured three times over 10 min; the median value was used in statistical analysis.   
 
Oral glucose tolerance tests (OGTT)  Fasting blood samples were taken before and dur-
ing a 75-g OGTT at 0, 30, 60, 90 and 120 min. Samples were transported on dry ice at 
pre-arranged intervals to central laboratories 17.     
 
Clamp   On a separate day within one week after the OGTT, a euglycemic hyperinsulinemic 
clamp was performed in all subjects. Exogenous insulin was administered as a primed 
continuous infusion at a rate of 240 pmol·min–1·m–2 simultaneously with a 20% dextrose 
infusion, adjusted every 5-10 min to maintain plasma glucose levels within 0.8 mmol/l 
(±15%) of the target glucose level (4.5-5.5 mmol/l). The steady-state period (for calcula-
tion of insulin sensitivity) was between 80-120 min. Additional blood samples were obtained 
during the clamp for insulin and NEFA determination. The clamp procedure was standard-
ized across centres by means of a demonstration video and detailed operating instructions. 
The crude data from each clamp were immediately transferred to the coordinating centre 
where they underwent quality control scrutiny according to pre-set criteria. Insulin sen-
sitivity was expressed as the ratio of the M-value -averaged over the final 40 min of the 2 
hour clamp and normalized by fat-free mass- to the mean plasma insulin concentration 
measured during the same interval (M/I, in units of μmol.min-1.kgffm
-1 nM-1) 21. The glucose 
and insulin areas under the curve were calculated by means of the trapezium rule 22. Insulin 
resistance was defined as the lowest 25% of the M/I distribution (sex-specific).  
 
Lab assays Fasting plasma glucose was analyzed using the Cobas integra system (Roche 
diagnostics, Basel, Switzerland). Fasting serum insulin and pro-insulin concentrations 
were measured using solid-phase, two-site fluoro-immunometric assays (Auto DELFIA 
Insulin kit, Wallac Oy, Turku, Finland). Serum HDL-cholesterol, LDL-cholesterol and 
triglycerides were analysed with homogenous enzymatic colorimetric tests for mod-
ular analyzers (Roche diagnostics, Basel, Switzerland).     
 
Urinalysis semi-quantitative tests (Bayer Multistix 10 SG urinalysis strips) were used 
for the detection or measurement of glucose, bilirubin, ketones, specific gravity, blood, 
PH, protein, uribilinogen, nitrate and leucocytes. If urine nitrate or leucocyte posi-
tive (indicating infection) collection was repeated after treatment.    
 
Urinary albumin was analysed using MA (micro albumin) antiserum for Beckman Array sys-
tems on a Beckman array 360 protein analyser, programmed and used according to instruc-
tions of the manufacturer. For calibration, the Beckman Coulter urine protein calibrator for 
immunochemistry systems was used. The assigned values are traceable to the IFCC reference 
preparation CRM 470. Single samples are analysed according to the manufacturer’s instruc-
tions. At the beginning and at the end of the series two quality control samples were measured. 
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The coefficient of variation for the between run imprecision was 5.0 % (at a mean  concentra-
tion of 11.4 mg/l) and  5.0% (at a mean  concentration of 72.6 mg/l).     
 
Urinary creatinine was analysed using Jaffé creatinine reagent (Roche) on a modular P 
system (Roche). The assay is programmed and calibrated according to the manufacturer’s 
instructions using the rated blanked assay method. Single samples are analysed according 
to the instruction of the manufacturer. Quality control samples are measured daily. The 
coefficient of variation for the between run imprecision was < 2.0 % at a mean concentra-
tion of 6.1 respectively 11.0 mmol/l.
Calculation of urinary albumin- creatinine ratio To increase precision the urinary albumin-
creatinine ratio (ACR) was measured on two separate occasions from overnight first-void-
ed (just out of bed) urine samples. In case of dipstick values for blood of 200 or more, the 
observation was considered unreliable, and not considered for the analyses. When albu-
minuria was under limit of detection of the assay (2 mg/l), the value was set at zero mg/l. 
The mean ACR of the duplicates was taken, where there were two values.  Microalbuminu-
ria was defined when the mean ACR was between 2 and 30 mg/mmol, overt proteinuria 
when the mean ACR was over 30 mg/mmol 23.
sTATisTiCAL AnALysEs  
Quantitative data are expressed as means with standard deviations (skewed variables 
as medians with inter-quartile ranges) and categorical data as percentages. ANOVA 
was performed to test for statistically significant differences between continuous vari-
ables, the skewed variables (M/I-ratio, fasting insulin, triglycerides and physical activ-
ity) were log-transformed first. When variances were unequal among the groups to 
test (Levene’s test), differences were evaluated by Mann-Whitney-U test. The χ2-test 
was used for testing categorical variables. Logistic regression was used to estimate 
the relationships between variables of interest and the presence of microalbuminuria. 
Associations were expressed as odds ratios (ORs) with their 95% confidence intervals 
(CI) per 1-SD increase in the independent variable involved. First we investigated the 
character of the associations between independent variables and microalbuminuria by 
inspecting the frequencies of microalbuminuria over tertiles and quartiles of the inde-
pendent variables and by testing for linear trend.  The independence of the association 
of insulin resistance was tested by adjusting for the well known risk factors associated 
with insulin resistance and was evaluated only if variables did not exhibit excessive 
co-linearity which each other, after adjustment for centre. Model 1 (demographic fac-
tors) was adjusted for centre, sex and age. Statistical analyses were performed with 
SPSS for Windows version 12.0.2.
rESulTS 
Baseline characteristics of  1,207 subjects are presented in Table 1, according to the pres-
ence of  microalbuminuria. The prevalence of microalbuminuria was 3.1%. The subjects 
with microalbuminuria were more insulin resistant (51% were in the lowest insulin sensi-
tivity quartile), had a lower systolic blood pressure and higher triglyceride levels. 
Figure 1 shows the prevalence of microalbuminuria according to quartiles of insulin sen-
sitivity. The highest prevalence was clearly in the lowest quartile (those who were insulin 
resistant), and there was no difference in the frequency of microalbuminuria in partici-
pants who were not resistant. Logistic regression analysis showed that insulin resistance 
was associated with a higher prevalence of microalbuminuria independently of demo-
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Microalbuminuria no Microalbuminuria P value
n (%) 37 (3.1) 1170 (96.9)
Age (years) 45.1 ± 8.7 43.6 ± 8.3 0.27
Sex (%male) 43.2 45.5 0.46
Menopause (%) 12.7 13.5 0.52
Waist (cm) 86.7 ± 13.9 86.7 ± 12.7 0.99
MI-ratio (μmol.min-1.kgffm
-1 nM-1) 96.0 (75.1-147.4) 128.4 (93.0-176.7) 0.02
Insulin resistance (lowest 25%) 51.0 23.3 0.001
Fasting insulin (pmol/l) 31.5 (23.8-59.0) 31.0 (21.0-44.0) 0.07
Median SBP (mmhg) 113.2 ± 11.5 117.1 ± 12.1 0.05
Median  dBP (mmhg) 74.1 ± 7.1 74.4 ± 7.8 0.99
hdL-cholesterol (mmol/l) 1.46 ± 0.43 1.42 ± 0.38 0.54
LdL-cholesterol (mmol/l) 3.02 ± 0.73 2.89 ± 0.79 0.35
Triglycerides (mmol/l) 1.07 (0.85-1.45) 0.93 (0.68-1.27) 0.01
FPG (mmol/l) 5.1 ± 0.8 5.1 ± 0.5 0.74
Post load glucose (mmol/l) 6.1 ± 1.7 5.7 ± 1.5 0.17
Smoking   (never/smoking/ex) 56.8/21.6/21.6 46.4/27.0/26.6 0.46
Activity (IPAQ total MeTS) 1485.0 (346.5-3492.0) 1677.0 (693.0-3960.0) 0.37
Table 1. clinical characteristics according to presence of microalbuminuria
graphic factors, Table 2. The 25% most insulin resistant subjects continued to have a more 
than fourfold higher odds-ratio of having microalbuminuria than insulin sensitive subjects 
(higher 75%), independently of other risk factors. The odds ratio did not substantially 
change (remained four or higher) when adjusted for waist, fasting insulin, systolic blood 
pressure, diastolic blood pressure, triglycerides, HDL-cholesterol and fasting glucose (data 
not shown). Fasting insulin and triglycerides were also associated with microalbuminuria. 
Finally we studied possible interactions between risk factors by adding interaction terms 
for insulin sensitivity and systolic blood pressure, triglycerides, waist, fasting insulin; these 
interactions were not significant, indicating that the association between insulin sensitiv-
ity and microalbuminuria did not differ for high levels compared to low levels of systolic 
blood pressure, waist, fasting insulin and triglycerides.
 
Figure 1. frequency (%) of microalbuminuria 
according to quartiles of insulin sensitivity.
Values are means (sd), medians (inter-quartile ranges) for skewed variables or percentages.
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DiSCuSSiON
We found that insulin resistance was strongly associated with microalbuminuria, inde-
pendently of high blood pressure or other CVD risk factors. Until now there has been 
little literature on euglycemic clamp estimated insulin sensitivity and microalbuminuria 
in healthy general populations. However our findings are in agreement with the findings 
of the IRAS study 24. In the IRAS study (1995) persons with normal glucose tolerance and 
impaired glucose tolerance were investigated with FS-IVGTTs. It was found that insulin 
resistance was associated with microalbuminuria, independently of other risk factors. In 
their study hypertension (>140/90 mmHg), which was highly prevalent in the IRAS popu-
lation (32.3%), was an even stronger risk factor for microalbuminuria. In diabetic subjects 
in most studies the same associations were found 8 12 25. In most previous studies in NGT 
subjects the systolic blood pressure was higher in subjects with microalbuminuria and 
hypertension was positively associated with a higher prevalence of microalbuminuria 24 26 
27. However, in the present study we excluded all subjects with SBP ≥ 140 mmHg and DBP 
≥ 90 mmHg, which may explain the reverse association between systolic blood pressure 
and microalbuminuria in our study. This is in line with the existence of a strong associa-
tion between systolic blood pressure and microalbuminuria. The conditions in the present 
study are unique in that sense and may provide evidence for the hypothesis that there is 
a direct link between insulin resistance and microalbuminuria, regardless of the degree of 
systolic blood pressure in the non hypertensive range. 
 
The finding that insulin resistance is associated with microalbuminuria independent-
ly of waist is not in agreement with the results from the DESIR study 28. In that study 
increased waist circumference was the strongest predictor for the development of mi-
croalbuminuria. However, differences between study populations, method of measure-
ment of insulin sensitivity (HOMA-IR versus euglycemic clamp) and microalbuminuria 
(single urinary albumin concentration of >20 mg/l or proteinuria by dipstick versus 
duplicate ACR 2-20 mg/l) may explain the discrepancy.    
What could be the potential mechanisms relating insulin resistance to microalbuminuria? 
Insulin resistance has been related to endothelial dysfunction 29 30 and microalbuminu-
ria has been regarded as an indicator of endothelial dysfunction 31. Furthermore, insulin 
resistance is thought to adversely effect proximal tubular re-uptake of albumin 32. An-
other mechanism might be that insulin resistance and hyperinsulinemia cause glomerular 
hypertension and hyperfiltration (increase in GFR), resulting in albumin ultra-filtration 
and excretion 33. However we found no strong association between insulin resistance and 
GFR, or between GFR and microalbuminuria (data not shown). This could mean that 
* insulin sensitivity = m/i value (m = amount of metabolized glucose/i = average plasma insulin concentration) 
** p<0.05.
Table 2. odds ratios (95% ci) for  having microalbuminuria.
risk factor
Insulin sensitivity  
Insulin resistance
Fasting plasma insulin
Waist
Systolic blood pressure
diastolic blood pressure
Triglycerides
hdL-cholesterol
Fasting plasma glucose
Standardized odds ratio (95%CI)
0.55 (0.34-0.89) 
4.02 (1.92-8.36)
1.14 (1.01-1.29)
1.27 (0.84-1.92)
0.73 (0.50-1.07)
1.14 (0.79-1.64) 
1.41 (1.07-1.85)
0.90 (0.61-1.33)
1.63 (0.64-4.19)
p-value
0.02
< 0.001 
0.03
0.26
0.10
0.50
0.02
0.60
0.65
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in normo-tensive, relatively lean subjects these associations do not (yet) exist. We also 
investigated the role of triglycerides as a mediating factor between insulin resistance and 
microalbuminuria. Triglycerides are known as a marker of insulin resistance in obesity and 
diabetes 34 and in populations with a low CVD risk, as is recently confirmed in the RISC 
study 35. However, triglycerides did not explain the association between insulin resistance 
and microalbuminuria. This is in agreement with findings in previous studies with type 
2 diabetic patients in fasting and post-prandial conditions 36 37, but has not been found in 
two previous studies with non-diabetic native Indians and in healthy normoalbuminuric 
adults 38 39. In the latter study salt sensitivity and blood pressure were associated with high 
(but still) normal albumin excretion, whereas hyper-triglyceridemia and hyperinsulinemia 
were not. 
The low CVD risk participants in the RISC study, as well as the large sample size, cre-
ate a reliable design to address the present research question. However, there are 
some limitations that need discussion.       
 
First of all, this study is cross-sectional. To assess the possible role of insulin resistance 
in the pathogenesis of microalbuminuria, this group should be followed prospectively. 
Second, another issue in this analysis is that our study population was a relatively healthy 
and non hypertensive group of European men and women. The prevalence of  microalbu-
minuria we found was 3.1%, which is low compared to the 6.9%,  Hillege et al. previously 
reported 27. However, in their population based sample (microalbuminuria category 30-300 
mg L-1) of non diabetic and non-hypertensive individuals in the age group 28-75 years 27 the 
cardiovascular and metabolic health status was less favourable. Hyperlipidemia was pres-
ent in 26.3% of the population and 7.7% had a history of myocardial infarction and 2.0% 
a history of stroke. Other studies reported  prevalences from 4.7% for men and 11.1% for 
women 26 to 8.9% 40 and 9.4% 41 for men and women together. Again, these populations 
either had a higher mean age or where generally less healthy.
In conclusion, insulin resistance was associated with a higher prevalence of microalbu-
minuria, independently of blood pressure, overweight, triglycerides and fasting insulin 
in the general population with a low CVD risk, which suggests that there maybe a direct 
link. 
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CHAPTER 7.1
General dIscussIon:   
summary of the results and methodoloGIcal consIderatIons
w. boorsma
In this thesis we have presented the results of a population based prospective cohort 
study on the role of insulin secretion and insulin sensitivity in the development of type 2 
diabetes in persons with impaired glucose tolerance. In addition, the relationship between 
insulin sensitivity and cardiovascular disease in a large population of  healthy persons was 
studied. In the present chapter the main findings will be summarized and the method-
ological aspects will be discussed.
maiN fiNDiNgS 
insuLin sECRETiOn, insuLin sEnsiTiviTy And Risk OF COnvERsiOn TO TyPE 2 
diABETEs in iGT suBjECTs.       
The Hoorn IGT-Study population consisted of persons detected through population screen-
ing in the general population of Hoorn, the Netherlands. Their glucose tolerance status 
was assessed by performing two consecutive OGTTs. At baseline and during follow-up a 
hyperglycaemic clamp was performed to estimate beta-cell function and insulin sensitiv-
ity. In addition, changes in glucose tolerance status and in particular the occurrence of 
diabetes was assessed. In persons with IGT, insulin secretion and insulin sensitivity were 
both found to be important for conversion in previous studies in other populations (for 
example in Pima Indians). We compared the predictive value of  insulin secretion, i.e. the 
early phase insulin secretion (first phase insulin secretion following i.v. glucose adminis-
tration), insulin resistance and the disposition index (a value determined by the product 
of insulin secretion and insulin sensitivity), for conversion to type 2 diabetes in Caucasian 
IGT subjects (chapter 2). Furthermore we investigated the changes in insulin secretion 
and insulin sensitivity in relation to conversion to type 2 diabetes in IGT persons during 3 
years of follow up (chapter 3). Finally, we were interested in putative determinants of the 
changes in insulin secretion and insulin sensitivity (chapter 3).
 
In 101 Caucasian IGT persons, the cumulative incidence of type 2 diabetes was 34.7% 
during a mean follow up of 4.2 years. The strongest predictor for conversion to type 2 dia-
betes was the absence of a first phase insulin peak. The presence of a “peak” was defined 
as the presence of an insulin value, which was significantly higher than the mean of the 
“flat” first insulin peaks. Other predictors, such as first phase insulin secretion (area under 
the curve), or the disposition index, were also predictive but more dependent on insulin 
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resistance. Furthermore, a smaller subgroup (50 IGT persons) of the IGT study popula-
tion demonstrated a large decrease in insulin sensitivity. However, the change in insulin 
secretion determined the change of glucose tolerance status, and thus the conversion to 
T2DM. In those whose glucose tolerance improved or stayed the same, a compensatory in-
crease of insulin secretion was observed. In those converting to diabetes no compensatory 
increase of insulin secretion was observed. Consequently the disposition index, express-
ing the interplay between insulin secretion and insulin sensitivity in sustaining normal 
glucose tolerance, decreased. In the search for a putative determinant of the change in 
insulin secretion we found that high levels of liver enzymes (gamma-glutamyl transferase, 
alanine-amino transferase) were predictive of a decrease in the disposition index. As these 
liver enzymes are markers for non alcoholic fatty liver disease, this may suggest fat ac-
cumulation in the liver.
insuLin sEnsiTiviTy,  BOdy COmPOsiTiOn And  CARdiOvAsCuLAR disEAsE Risk in 
THE GEnERAL POPuLATiOn.
The RISC Study aims at establishing the role of insulin resistance in the pathophysiol-
ogy of cardiovascular disease. The population comprises some 1200 men and women 
from all over Europe, aged 30-60 years. Insulin sensitivity was measured with the hy-
perinsulinemic euglycemic clamp technique. Cardiovascular disease risk was estimat-
ed by lipid and glucose profile, ischemic ECG-abnormalities, body composition (DXA) 
and microalbuminuria. The present cross-sectional analyses were based on the baseline 
measurements. First we wanted to know if insulin sensitivity could partly or fully ex-
plain the known associations between body fat and CVD risk factors (glucose levels, 
lipid levels, blood pressure), as previous research has repeatedly reported associations 
between insulin sensitivity and body fat and between insulin sensitivity and CVD risk 
factors (chapter 4). Second, we wanted to know if insulin sensitivity could explain the 
well known associations between body fat and ischemic ECG abnormalities (chapter 
5). Third, insulin resistance has previously been associated with microalbuminuria (a 
marker for endothelial dysfunction). We wanted to know if this association was also 
present in a relatively young and healthy population (chapter 6).     
 
In a subpopulation of 142 Dutch and Italian men and women we confirmed the opposite 
associations of leg and trunk fat mass, as measured by DXA, with CVD risk markers. This 
has previously been found in less healthy and in an elderly populations. Larger leg fat 
mass was associated with a more favourable CVD risk profile. In men larger leg fat mass 
adjusted for other body compartments was associated with lower TG’s. Larger trunk fat 
mass was associated with a less favourable CVD risk profile. In men  and women it was 
associated with a lower HDL and higher TG’s and in women only it was associated with 
higher fasting insulin, higher fasting glucose and higher blood pressure. Whole body insu-
lin sensitivity did not explain the associations of leg fat mass or trunk fat mass with CVD 
risk factors. Only in women insulin sensitivity attenuated to a modest extent some of the 
associations.
  
Whole body insulin sensitivity was associated with ECG abnormalities, but not indepen-
dently of estimates of body fat. BMI and waist and body fat percentage (measured by bio-
impedance), were strongly associated with Q/QS abnormalities and mostly explained the 
association between insulin sensitivity and Q/QS abnormalities. 
 
Insulin sensitivity was strongly associated with the prevalence of microalbuminuria, in-
dependently of glomerular filtration rate, blood pressure, body weight and fasting insulin. 
Triglycerides were also strongly associated with microalbuminuria, although not indepen-
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dently of insulin sensitivity. The existence of this association in a non-hypertensive, low 
CVD risk population suggests a direct mechanistic link between insulin sensitivity and 
microalbuminuria.
 
mEThODOlOgiCal CONSiDEraTiONS 
In this thesis the natural course of type 2 diabetes and the link between insulin sensitivity 
and cardiovascular disease are described. In a prospective cohort study (chapters 2 and 
3) a well defined group of persons is followed prospectively. The population at baseline 
is free of the disease under study (outcome measure), but the individual subjects differ 
in levels of exposure to potential causes (determinants) of the disease. These potential 
causes of the disease are measured before the actual onset of the disease, allowing as-
sessment of the temporal relationship and causal inference. However, to establish a true 
causal relationship between determinant and outcome, more requirements have to be 
fulfilled 1. In a cross-sectional design (chapters 4, 5 and 6), the outcome (disease) and 
the exposure to the potential causes (determinants) are measured at the same time. This 
makes the design less suitable to draw conclusions on causal inference and interpretations 
must be made with caution. However, both designs can be used to provide new clues for 
a suspected causal relationship.        
To produce acceptable evidence, according to Feinstein 2, comparisons within a study 
should be fair or unbiased, also known as the internal validity of the comparison. What 
is learned from research should be suitable for extrapolation and application elsewhere 
beyond the restriction and immediate focus of the research; external validity. Validity de-
mands that the study repeatedly produces the same results, which are a correct reflection 
of the real events. Bias can produce overestimation or underestimation of the true associa-
tion and it can even change the direction of an effect. Selection bias, information bias and 
confounding can be a threat to the internal validity of a study 3. These systematic errors 
involve i.e. choosing the wrong study design, errors in the execution of a design or errors 
in the analysis of the data. Furthermore, random errors are a threat to the precision of the 
study. They are dependent on measurement error (variation in individual measurement) 
and sampling error (magnitude of the population sample). Increasing the precision can be 
achieved by increasing the sample size of the population, decreasing the measurement er-
ror and using the most efficient design (increasing the quantity of information per subject; 
matching; for example)3. The validity of our studies will be discussed below.
THE HOORn iGT-sTudy POPuLATiOn
The two studies described in chapter 2 and 3 were population based prospective cohort 
studies. The relatively small number of subjects in chapter 2 (N = 109) was sufficient to 
analyse the conversion to DM2 in IGT subjects. However, in chapter 3 the small population 
size limited the interpretation of  the borderline significant associations between deter-
minants and insulin secretion. Needless to say that the evidence would have been more 
straight forward or convincing if we had a bigger sample size. Selection bias is present 
when there is a systematic difference in the chance of getting selected for a study. Since 
all participants were identified by a total population screening with a high participation 
rate, selection bias is not likely to be a threat to the validity here. This selection procedure 
produced a very specific group. The IGT subjects were identified by a screening for IGT 
in the general population through a random selection procedure 4. They were then asked 
to participate in the DAISI study 5. The DAISI study (see also appendix) was a random-
ized clinical trial studying the glucose lowering effect of acarbose (an alpha-glucosidase 
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inhibitor). The study described in chapter 2 used only the data on 109 subjects which did 
not receive acarbose (placebo and control group). The study described in chapter 3 used 
the data of 50 participants of which half received acarbose and the other half placebo. 
Due to the randomization procedure, exposure to the determinants of interest is likely 
to have been evenly distributed over the groups and most forms of selection bias should 
have been ruled out. However, attrition bias; bias due to selective loss to follow up could 
be of importance. In the study in chapter 4, fifty-one subjects were lost to follow up. The 
drop-out rate was higher in the subjects that were using acarbose. We did not have the in-
formation from a second clamp test of these subjects so we did not know if these subjects 
differed systematically from the ones remaining in the study. However, we do know that 
they did not systematically differ in exposure to determinants of interest at baseline. The 
IGT subjects were selected for their high risk of developing T2DM within a few years. A 
limitation of this design is that the results from these analyses can only be extrapolated to 
other Caucasian IGT populations of the same age.
THE RisC sTudy POPuLATiOn
The studies described in chapter 4, 5 and 6 used baseline data of a large international 
multi-centre prospective cohort study, which methods have been previously published 6. 
The large sample size of this study produced a relatively high statistical power necessary to 
adequately address our research questions. The main research question of the RISC Study 
is to test the hypothesis that there is a direct link between insulin resistance and cardio-
vascular disease in a low-risk European population. The recruitment of healthy volunteers 
from the general population, through random sampling and invitation by means of the 
local municipal registries eliminated most forms of selection bias. The population sample 
was stratified according to age and sex. Although we cannot rule out the possibility that 
subjects ‘willing to undergo a clamp test’, are generally healthier than non-responders, it 
poses no problem for testing the hypothesis stated above. In chapter 4 only the data of 
the Dutch and Italian sub cohort was used. When we compared the variables of interest 
between the two sub samples, we found no international differences. However to exclude 
possible confounding by unknown variables, we adjusted for centre in all analyses in 
chapters 4, 5 and 6. The results of these studies can be extrapolated to the healthy general 
European population with the same age and a low CVD risk.
mEAsuRinG insuLin sECRETiOn 
In the Hoorn IGT-Study, insulin secretion and insulin sensitivity were both assessed with 
the  hyperglycaemic clamp technique 7-9. The hyperglycaemic clamp is the reference meth-
od for the assessment of the first and second phase of insulin secretion 8 10. Although it 
is not the reference method for the assessment of insulin sensitivity, the correlation be-
tween insulin sensitivity measured by hyperglycaemic clamp and the reference method, 
the hyperinsulinaemic-euglycaemic clamp 8 11, is high 7-9 12 13. An important condition for the 
measurement of insulin sensitivity in hyperglycemic or euglycemic clamp is to shut off the 
hepatic glucose production in the liver. Obviously the measured insulin sensitivity would 
be underestimated if glucose was still produced by the liver. To avoid misclassification (in-
formation bias); tests should be accurate and the results reproducible. The variation in test 
variables should be less than the biological variation (in this case the variation in steady 
state glucose during the last 20 minutes of the clamp). In our study the CV (coefficient of 
variation) of the glucose level during the steady state phase of the hyperglycaemic clamp 
was 6,6% (chapter 2 and 3). We considered a CV of < 5 very good and a CV 5-10 accept-
able. A limitation of the hyperglycaemic clamp is that it only estimates glucose stimulated 
insulin secretion. Other stimulants of insulin secretion, like incretin-hormones (GLP-1 and 
GIP) that are produced in the gut, are known to contribute importantly to insulin secre-
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tion. Therefore, results should be interpreted with this restriction in mind. Also, different 
glucose levels are being applied to provoke an insulin response. The insulin responses can 
therefore only be compared within, and not between studies 10. A feature that may also 
indicate the health of a beta-cell is potentiation (speed of the insulin response), which is 
also not measured 10. 
 
Of importance is that insulin secretion can only be interpreted in relation to insulin sensi-
tivity 14. In order to take this into account the disposition index (DI) was proposed. The DI, 
which is the mathematical product of insulin secretion and insulin sensitivity is a method 
to assess underlying capacity of the insulin secretory system 15. It is designed with the as-
sumption that insulin secretion and insulin sensitivity are reciprocally related. However 
not with all indices (OGTT, IVGTT) or in all populations this is the case 11. To properly 
construct the DI, the insulin secretion and sensitivity should be measured at the same time 
but they also should be independent measures 16 17. Ideally in a control group the shape of 
the relationship should be checked. 
dETERminAnTs OF insuLin sECRETiOn
In chapter 3, except for insulin sensitivity and insulin secretion and their change in 3 years, 
we also measured putative determinants of the change in insulin secretion in relation to 
conversion to DM2. These variables included demographic variables (age and sex),. An-
thropometric variables (BMI (height and weight)) and waist-to-hip ratio), and clinical and 
biochemical variables such as systolic blood pressure, fasting plasma glucose, HbA1c, Trig-
lycerides, HDL-cholesterol and liver-enzymes (ASAT, ALAT and GGT). Many risk factors 
show a considerable amount of within person variability. This variation, including both 
imperfections of measurement instruments or protocols and biologic fluctuations, causes 
regression dilution bias. Example of a determinant which normally does not have much 
within person variability is BMI. Example of one that has a high variability is systolic blood 
pressure. In order to make realistic estimates of potential exposure effects of determinants 
of interest at baseline, regression dilution must be taken into account. The best way to con-
trol for it is to take an average of two or more measurements of the determinant at baseline 
and take the mean. Furthermore it is important to control the circumstances under which 
measurements take place. In our study duplex measurements were performed of determi-
nants with large within person variability, such as  blood pressure, as well as the most of 
the other biochemical variables. 
mEAsuRinG insuLin sEnsiTiviTy
In the RISC Study, insulin sensitivity was measured with the hyperinsulinemic-euglycemic 
clamp, which is the reference method for insulin sensitivity assessment 8. The clamp pro-
cedure was standardized across centres by means of a demonstration video and ad hoc 
operating instructions. The crude data from each clamp were immediately transferred to 
the coordinating centre where they underwent quality control scrutiny according to pre-
set criteria. Plasma glucose levels had to be maintained within 0.8 mmol/l (±15%) of 
the target glucose level (4.5-5.5 mmol/l) during the clamp. The steady-state period (for 
calculation of insulin sensitivity) was between 80-120 min. The within and inter-assay 
CV’s for insulin, were both <4.3%. To calculate insulin sensitivity, first the whole body 
glucose disposal during the clamp (M) was normalized by fat free mass (Mffm), given 
that the glucose uptake can occur only in lean tissue (cell mass). The M value was also 
corrected by the steady state plasma insulin level (I) to correct for the minor differences 
in clamp insulin levels. There are other possible normalizations, such as resting rate of 
expenditure of energy (Mree), which is a quantitative measure of the total metabolically 
active cell mass 18, as long as it is measured during the clamp. M values uncorrected for 
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fat free mass generally overestimate the insulin sensitivity in men compared to that in 
women 11, whereas normalizing M by bodyweight (Mbw) exaggerates the insulin resistance 
of the obese 19. Although the euglycemic clamp has a better reproducibility than all other 
methods, the  M/I-ratio displays a large within-person variability. This variability can be 
attributed to physiological variability (day-to-day and diurnal changes 20 21) and precision 
of the test. The coefficient of variation values of the hyperinsulinemic euglycemic clamps 
may range from 6-15% 22-24. For comparison, the random test-retest differences of fasting 
insulin can be 22%, which is mainly attributable to biological variation, since the assay 
variation is small 25. This is expected to lead to random misclassification with respect to 
individuals habitual levels. This results probably, though not certainly 26, in weaker esti-
mates of associations through, “bias towards the null”. 
mEAsuRinG BOdy COmPOsiTiOn, LiFE sTyLE-FACTORs And Cvd Risk FACTORs
In the RISC Study, not only anthropometric variables such as waist, hip, and BMI were 
measured, but also fat and muscle tissue mass was estimated by dual X-ray absorptiometry 
(DXA) scan (chapter 5). The DXA scan is a good alternative to the more accurate but more 
expensive CT or MRI scans to measure soft tissue body compartments directly, although 
estimation of total abdominal fat can be underestimated by 10% 27. Reported CV’s are 
4.3% for lean soft mass 28, 7.8% for total fat mass 29, at the mid-thigh and 3.9% for total 
abdominal fat 27. However, these CV’s are presumably dependent on the degree of obesity. 
DXA scanners work with presumptions regarding densities of tissues. It is not very well 
known whether the differences in fat content in adipose tissue reported in literature are 
attributable to different characteristics of the study populations, as for example race, age, 
and obesity level. Waist circumference was an alternative for the prediction of abdominal 
fat we used, which has a CV of  2.3% and is considered just as effective 27 in epidemiologi-
cal studies. Also standardized lifestyle questionnaires were used to assess medical history, 
medication, smoking and alcohol use 30, the level of activity 31 and cardiovascular diseases 
such as claudication and angina pectoris 32 33. These questionnaires were translated into 
the 11 languages of the project and then back-translated to English to ensure homogeneity 
6. Biochemical variables were measured in a central laboratory, using standardized tests 
with inter-assay CV of 5.0% for urinary albumin, <2.0% for urinary creatinine,  <5% 
for NEFA, <2.0% for Total cholesterol, <2.0% for HDL-cholesterol and <2.0% for trig-
lycerides.
ECG ABnORmALiTiEs
In chapter 5, resting 12 lead ECG’s were coded centrally according to the Minnesota code 
34 by an experienced cardiologist, who was blinded for other information, to reduce the 
chance of  differential misclassification. Minnesota coding was based on visual measure-
ment of the ECG complex. Classification of ECG changes depends on differences as small 
as 0.01 s in the width of the Q wave or of 0.5 mm in the degree of ST segment depression; 
therefore, only ECGs of high quality were accepted 35. ECG-abnormalities were defined by 
the presence of  Q-wave and/or ST-T abnormalities (Minnesota codes; 1.1-1.3, 4.1-4.2, 
5.1-5.2). 
miCROALBuminuRiA
Microalbuminuria in chapter 6 was measured using a standardized test with inter-assay 
coefficient of 5.0% for urinary albumin and < 2.0% for urinary creatinine. The coefficients 
of variation (CV’s) of these assays are relatively small compared to intra-individual CV’s. 
Urinary Albumin excretion may fluctuate by 35-60% from day to day 36 37 and is influenced 
by multiple factors, including; physical exercise, protein rich meals, elevated blood pres-
sure 38. To increase precision  the urinary ACR was measured on two separate occasions 
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from overnight first-voided urine samples.  In case of dipstick values for blood of 200 or 
more, the observation was considered unreliable, and not considered for the analyses. 
When albuminuria was under limit of detection of the assay (2 mg/l), the value was set at 
zero mg/l.  The mean ACR of the duplicates was taken, where there were two values.  With 
mean ACR >2-30 mg/mmol microalbuminuria was defined.  With mean ACR of 30 mg/mmol 
or more overt proteinuria was defined 39. The gold standard to determine microalbuminuria 
is a concentration of 30-300 mg of albumin in two out of three 24 hour-urine samples, col-
lected in a period of at least 1, but preferably 6 months 40. However, these collections have 
been criticised to be troublesome and sometimes inaccurate 41 and for research purposes 
the ACR has been suggested as the method of choice 42. An overnight ACR  >2.0 mg/mmol 
predicts an overnight excretion rate of >30 μg/min very well (sensitivity 96%, specificity 
99.7%) 43.
COnFOundinG And EFFECT mOdiFiCATiOn
For most diseases multiple (at least more than one) determinants have to be present at 
some time in the pathogenesis of the disease to actually cause the disease, which is also 
known as multi-causality model 44. The tool to study multiple putative determinants of a 
disease is multiple regression analysis. Often the variables under study are highly associ-
ated with each other and also with the disease but are not involved in the causal pathway. 
These potential confounders can distort the association and should be adjusted for in the 
analysis if the investigator is interested in the magnitude of the effect of the main deter-
minant only. A problem is that it is difficult to determine whether a potential confounder 
is involved in the causal pathway. Adjustment for it when it is actually a mediator would 
lead to underestimation of the true effect of the main determinant. Interaction is present 
when the effect of one determinant on the disease is different when another determinant 
is also present. 
 
The latter determinant is called an effect modifier. In most of the analyses we were inter-
ested in independent associations of the main determinant (i.e. insulin sensitivity and mi-
croalbuminuria in chapter 6). One would expect that adjustment for a confounder would 
lead to a increase in the estimated regression coefficient (negative or positive) and an 
accidental adjustment for a mediator would result in a decrease in the estimated regres-
sion coefficient of the main determinant. In case of uncertainty, we always presented 
the adjusted and the unadjusted models. In chapter 4 we used multiple linear regression 
analysis to investigate trunk fat and leg fat mass separately from each other and from other 
body compartments (lean mass), when we studied the associations with CVD risk factors. 
However, the adjustment of highly correlated  body compartments (trunk fat and leg fat 
i.e.) for each other, could result in associations which are in fact statistical artefacts due to 
multi-colinearity. To avoid this problem there is a rule of thumb that says that it is unwise 
to include two independent variables in a model if their correlation exceeds 0.9. Another 
criterion is the presence of disproportionate large estimated coefficients accompanied by 
very large estimated standard errors. We always made sure these criterions were checked. 
In all analyses we investigated effect-modification by suspect variables (i.e. sex), by add-
ing product terms to the models and by checking stratified analyses. 
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CHAPTER 7.2
General dIscussIon:   
pathophysIoloGIcal InterpretatIon and suGGestIons for future research  
w. boorsma
In the present chapter we will discuss the main findings in relation to known pathophysi-
ological mechanisms and formulate new hypotheses. Also suggestions for future research 
will be given.
WhaT DiD WE fiND iN ThE hOOrN igT STuDy?
Insulin secretion and hyperglycaemia
IGT subjects are characterized by insulin resistance, slightly elevated fasting glucose levels 
and elevated post load glucose levels. At baseline of our study there were abnormalities 
in the insulin secretion pattern.  The absence of an insulin peak at baseline conferred a 
5-fold risk of conversion to T2DM within 8 years. In this IGT population it was the stron-
gest predictor for conversion (chapter 2). Although this particular finding can not be com-
pared with the findings of any other study due to the way we analyzed the insulin peak, 
diminished (first phase) insulin secretion in general (measured by HOMA, minimal model 
or IV-GTT) is a well known predictor of T2DM 1-3. A low disposition index, which was the 
second best predictor, is a well known predictor for T2DM conversion 4 5 in Pima Indians. 
Insulin resistance
We also found (chapter 3) that insulin sensitivity decreased considerably in the whole group 
irrespective of glucose tolerance status. This decrease could not be explained by weight 
change. This is in line with previous research in other populations 4 and in Caucasian IGT 
subjects 2. Other known determinants for T2DM development and insulin resistance are 
weight gain 6-8, ethnicity 9-11, familial predisposition 12 13 and age 14. In our study the Caucasian 
IGT subjects experienced almost no weight gain. No other explanations for the estimated 
change in insulin sensitivity could be found. Even though the inter-assay coefficient of vari-
ation of the insulin assays should have been under 10%, we cannot exclude the possibility 
of a change in the characteristics of the insulin assay (antibody sensitivity). Since the I com-
ponent of the M/I ratio decreased only by 11.8%, whilst the M value decreased by 52.7% in 
the whole group, one may assume that the found lowering of the insulin sensitivity is real 
and not a laboratory error. Thus, only a small part of the large decrease in insulin sensitiv-
ity can be attributed to a difference in the assay characteristics. In those who converted to 
T2DM, there was almost no compensating increase in insulin secretion, which resulted in a 
decrease in disposition index, and likely contributed to the worsening of glucose tolerance. 
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Beta-cell lipotoxicity?
The lowering of the  DI, mostly due to a loss of first phase insulin secretion, was associ-
ated with higher plasma concentrations of gamma glutamyl transferase, a liver-enzyme, 
at baseline (chapter 3). We cannot attribute this finding specifically to non-alcoholic fatty 
liver disease, but it is in accord with the lipotoxicity theory. Gamma-GT is known to be a 
sensitive but non-specific marker for intra-hepatic fat accumulation 15 as is ALAT 16. Intra-
hepatic fat accumulation is thought to reflect ectopic fat storage, including, amongst other, 
fat accumulation in the pancreas. This fat storage results in insulin resistance  in liver and 
muscle 17-20, and in the pancreas it is thought to contribute to defects in insulin secretion 
21-23. Statistical associations may be the reflection of other underlying (unmeasured)  pro-
cesses or pathways. For example, abnormalities in the secretion of or sensitivity to differ-
ent incretin hormons 24 25 may play an important role. Incretins, and in particular GLP-1 are 
important for the stimulation of insulin release,  inhibition of glucose output in the liver 
and at the level of the brain they regulate food intake by enhancing satiety. Moreover, in 
animal models they have been shown to increase beta-cell proliferation and survival 24. 
However, human studies have not been able to confirm this observation.
 
WhaT DiD WE fiND iN ThE riSC STuDy?
ABdOminAL FAT And LiPOTOxiCiTy
More abdominal fat, measured by dual-x-ray-absorptiometry (DXA) scan, was strongly as-
sociated with unfavourable levels of most CVD risk factors (chapter 5). We know that ab-
dominal visceral fat makes up 35-40% of the total abdominal fat and is situated inside the 
abdominal cavity where it covers and surrounds the guts. It differs from subcutaneous fat 
in metabolic, genetic and hormonal terms. Large visceral adipocytes, storing an increased 
mass of triglycerides, become resistant to the anti-lipolytic effects of insulin. This further 
contributes to increased non esterified fatty acids (NEFA) levels, which in turn may lead 
to ectopic fat storage in other organs 19 20 26-28. Ectopic fat storage may have detrimental ef-
fects on insulin sensitivity and beta-cell function in IGT and T2DM. The enhanced quanti-
ties of NEFAs that are delivered into the portal vein and then into the liver, lower hepatic 
insulin clearance and promote gluco-neogenesis. In addition to the known associations 
between abdominal fat and risk factors for cardiovascular disease which are also referred 
to as the Metabolic Syndrome (low HDL-cholesterol, high triglycerides, high systolic blood 
pressure), we found a strong independent association between waist and ischemic ECG-
abnormalities. This association was independent of insulin resistance (chapter 5). The 
potential mechanism to explain this association is not known. A speculative mechanism 
may include an atherogenic metabolic profile, resulting in atherosclerosis and possibly 
also lipid accumulation in the heart muscle 29 30. 
LEG FAT And LiPOTOxiCiTy
In contrast to abdominal fat, larger leg fat mass was associated with more favourable 
levels of CVD risk factors (chapter 4). Total leg fat in the thigh consists almost exclusively 
of  subcutaneous  fat (90%). It has been suggested that the subcutaneous leg fat depot 
acts as a “sink” for circulating NEFAs 31-34. Subcutaneous fat adipocytes, when compared 
with visceral fat adipocytes, have low catecholamine stimulated lipolysis rates and are 
more sensitive to insulin. The storing of excess NEFAs results in lower circulating lipid 
levels and may prevent insulin resistance, impaired insulin secretion, hyperlipidemia and 
increased CVD risk. However, the rate at which NEFAs can be removed from the circula-
tion has a threshold and the whole system depends on the balance between the rate of 
97general discussion:  PAThoPhySIoLoGICAL InTerPreTATIon And SuGGeSTIonS For FuTure reSeArCh. 
NEFA release and the maximum clearance rate of the mitochondrion in the adipocyte. If 
the release rate exceeds the clearance rate, the lipid concentration becomes toxic for the 
mitochondrion and the system collapses. This results in redistribution of NEFAs over other 
tissues and high NEFA levels 27.
insuLin REsisTAnCE nOT THE sinGLE dRivinG FORCE?
Our hypothesis was that insulin sensitivity is an important mediating factor between body 
composition and metabolic or CVD risk profile. However, that was not what we found in 
these  cross-sectional analyses of subjects with a low CVD risk. Although our own analy-
ses and a previous report 35 showed that in the RISC study sample, insulin sensitivity was 
associated with BMI and with CVD risk factors (post load glucose, triglycerides,  LDL and 
HDL cholesterol) it does not explain the associations between BMI and CVD risk factors. 
Indeed of the three factors; insulin resistance, insulin secretion and waist, no one factor 
stands out alone and each factor makes it’s own independent contribution to the metabolic 
risk cluster as defined in the metabolic syndrome. However, one has to keep in mind that 
the RISC population is young and metabolically relatively healthy. In the RISC follow up 
study, the importance of some of these associations will become clear for the development 
of clinical conditions, such as; type 2 diabetes, dyslipidaemia and hypertension 36.
insuLin REsisTAnCE And miCROALBuminuRiA
Although abdominal fat was more strongly associated with almost all the CVD risk fac-
tors, insulin resistance was independently associated with microalbuminuria (chapter 6). 
There are a number of potential mechanisms linking insulin resistance to microalbuminu-
ria. Insulin resistance is thought to adversely affect proximal tubular re-uptake of albu-
min 37. Furthermore insulin resistance and hyper-secretion cause glomerular hypertension 
and hyperfiltration 38, which also contribute to microalbuminuria. A different underlying 
mechanism would be endothelial dysfunction. Microalbuminuria has been regarded as an 
indicator of endothelial dysfunction 39 40. The vascular endothelium is a large paracrine 
endocrine and autocrine organ which plays an important role in vascular homeostasis 41-43. 
This homeostasis is dependent on the coordination and balance of vascular tone, smooth 
muscle cell proliferation, inflammation, coagulation and fibrinolysis 44 45. Dys-functioning 
of the vascular endothelium is recognized as an early step in the development of athero-
sclerosis 46-49. Also, insulin resistance has been suggested to be a consequence of endothe-
lial dysfunction 50. 
rElEvaNT pOSSiblE uNDErlyiNg mEChaNiSmS
ECTOPiC FAT, LOw GRAdE inFLAmmATiOn And Cvd
Adiposity has been found to be very strongly associated with elevated pro-inflammatory 
markers. BMI is related to C-reactive protein (CRP), fibrinogen and Tumour Necrosis Fac-
tor alpha (TNF-α) 50 51. Also about 30% of the total IL-6 production originates from adipose 
tissue 50 52. IL-6, a pro-inflammatory interleukin, modulates the CRP production in the liver 
and CRP can be regarded as the marker of a chronic inflammatory state 53-55. A substantial 
amount of the adipose tissue TNF-α production comes from infiltrating macrophages. TNF-
alpha contributes to insulin resistance by a.o. inhibiting the insulin signalling pathway.  
“vAsOCRinE siGnALLinG”
A hypothesis that may explain the concomitant occurrence of insulin resistance and en-
dothelial dysfunction is the one by Yudkin et al, who suggest that “vasocrine”-signalling 
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from the peri-arteriolar fat, 56 results in endothelial dysfunction and insulin resistance (fig-
ure 1). In lean rats, insulin stimulates nutritive flow in muscle arteries. However, in obesity, 
vaso-regulatory peri-arteriolar fat accumulates, resulting in diminished insulin induced 
vasodilatation or even vasoconstriction 57, exacerbating insulin resistance. Perivascular 
fat deposits are distributed widely throughout the arterial circulation. In times of caloric-
excess and inactivity, epicardial fat (coronary arteries), peri-renal fat (renal arteries) and 
pelvic fat depots (femoral arteries), enlarge with potentially adverse consequences. Out-
side to inside signalling of the perivascular fat together with overproduction of cytokines 
(see visceral fat above) may lead to inflammation, and atherosclerosis. 
Figure 1. “Vasocrine” signalling from perivascular fat. a hypothesis based on  excess production of Tnf-alpha, crp and nefa’s by 
periarteriolar adipocytes in obesity. adipocytokines produced by peri-vascular adipocytes [1] inhibit  insulin signalling (insulin resistance), 
leaving unopposed vasocontrictor effects of endothelin-1 [2]. reduced insulin mediated increase in nutritive blood flow will contribute to 
insulin resistance.  high circulating levels of Tnf-alpha and crp [3] produce low grade inflammation [4] of the intima. in the renal arteries 
[5] this leads to microalbuminuria [6]. high circulating levels of nefa [7] and Tg   [8] will contribute to the endothelial dysfunction. eventu-
ally these mechanisms will lead to decreased blood flow and atherosclerosis [9].
“sLEEP And APPETiTE”
The brain plays an important role in energy-homeostasis 58 59. A recent study showed  that 
suppression of slow wave sleep (non-REM sleep) induced a substantial decrease in insulin 
sensitivity in healthy individuals 60, explained by an increase in activity of the sympathetic 
nervous system. In another study 61, the relationship between short sleep (4 hours per 
night for 6 days) and ghrelin and leptin levels was investigated. Grehlin reflects the total 
amount of fat and inhibits food intake while leptin increases appetite and food intake. 
Morning glucose levels were higher, daytime grehlin levels were decreased, while daytime 
leptin was increased. This altered balance may have explained the observed increase of 
appetite. Other (epidemiological) studies reported an association between short sleep du-
ration and high BMI and even type 2 diabetes 62-64.
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impliCaTiONS fOr CliNiCal praCTiCE
In the Hoorn IGT study we confirmed that IGT persons are at an increased risk for T2DM- 
development. A large number will convert in a few years. The most important determinant 
of conversion in this high risk population is the inability to increase the insulin secretion 
in case insulin resistance worsens. Diabetes may be postponed by addressing insulin re-
sistance in order to decrease the “burden” on a compromised insulin secretory system. 
Weight reduction 65, increase in physical activity, reduced fat intake etc. have all shown 
to be beneficial. Our results suggest that another target for intervention may be beta-cell 
function, which eventually determines the conversion to diabetes. The focus on beta-cell 
function  has already led to the development of drugs that stimulate glucagon-like pep-
tide-1 (GLP-1) receptors (GLP-1 analogues) or inhibit the clearance of native GLP-1 and 
gastric inhibitory peptide (GIP) (dipeptidyl-peptidase-4 (DPP-4) inhibitors). These com-
pounds stimulate beta-cell function in a glucose dependent fashion 66. However, whether 
these compounds will be able to ameliorate the natural history, i.e. the progressive decline 
of beta-cell function remains to be established. 
 
Our results also confirm that fat distribution is an important determinant of several CVD 
risk factors in a low CVD risk population. Increased trunk fat mass was associated with 
unfavourable changes in the CVD risk factor profile, including: HDL-cholesterol, triglycer-
ides, fasting insulin, blood pressure, Q/QS (ECG) abnormalities, in both men and women. 
Several studies have found a direct link between abdominal weight loss and normalization 
of the metabolic profile 65. To avoid accumulation of intra-abdominal fat, sufficient and 
regular physical exercise should be promoted as well as moderate intake of high energy 
dense food and drinks. Recent evidence also suggests that (work related) stress and low 
quality sleep should be avoided.
 
 
SuggESTiONS fOr fuTurE rESEarCh
The focus on the improvement  of beta-cell function is crucial as it is the main determi-
nant of conversion to T2DM 67. As beta-cell function and mass are difficult to measure 
in humans, future research should be focused on identifying biomarkers or methods to 
quantify insulin secretion and beta-cell mass reliably. Although insulin sensitivity plays an 
important role in the pathophysiology of IGT and T2DM, it may not play the central role. 
The development of insulin sensitizers may not be the way forward, unless beta-cell health 
is favourably affected. Our research confirms that lifestyle change and early prevention 
are important targets, as they have an effect on overweight and fat distribution. On top of 
behaviour and environmental factors the genetic susceptibility is important. The role of 
genes and its interaction with the environment largely remains to be elucidated. 
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ABsTRACT
 
aimS/hypOThESiS We hypothesized that acarbose would delayed conversion from im-
paired glucose tolerance (IGT) to type 2 diabetes by alleviating postprandial hyperglyce-
mia. Our study’s main objective was to investigate the effect of acarbose in IGT-persons on 
their two-hour plasma glucose level and beta-cell function.  
SubjECTS aND mEThODS The study included a random sample of 45–70-year-old 
residents of Hoorn, Netherlands, with mean fasting plasma glucose <7.8 mmol/L and 
mean two-hour plasma glucose of 8.6–11.1 mmol/L (measured by two successive oral 
glucose tolerance tests). After a qualification period, participants were randomized to ac-
arbose treatment or placebo. Insulin secretion and insulin sensitivity was measured by 
hyperglycaemic clamp. After a three-year treatment, analyses were performed of both the 
intention-to-treat and the per-protocol groups.  
rESulTS Of the 12,093 residents who received postal invitations, 118 participants were 
randomized. The mean difference of the post-load plasma glucose after three years, was 
-1.16 mmol/L (95% CI: -2.03; -0.17). The absolute risk reduction for diabetes was 6% (95% 
CI : -9% ;21%). No effect was seen on insulin secretion and insulin sensitivity.   
CONCluSiONS In patients with IGT, treatment with acarbose was associated with ben-
eficial effects on two-hour plasma glucose levels but not with improvement of beta-cell 
function.
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iNTrODuCTiON
Approximately 11% of all Caucasians aged 40 and older suffer from impaired glucose 
tolerance 1-3. The World Health Organization distinguishes this glucose intolerance 
category for its two-fold risk of cardiovascular disease 4-9. Moreover, approximately a third 
of persons with impaired glucose tolerance develop type 2 diabetes within five to ten 
years 10-14. The main patho-physiological abnormalities responsible for impaired glucose 
intolerance include a compromised beta-cell response to hyperglycemia, with a loss of the 
first-phase insulin secretion, and reduced insulin sensitivity, both in muscle and liver. 
In a previous large multi-center intervention trial in persons with impaired glucose 
tolerance (STOP-NIDDM), acarbose, an alpha-glucosidase inhibitor, delayed conversion to 
type 2 diabetes 15-20. However, those results have been disputed as questions arose about 
the study’s methods, analyses, and interpretations. Not only the post-prandial glucose 
levels decreases, but also the fasting glucose levels 20-22. It was therefore questioned if 
acarbose also improves insulin secretion or insulin sensitivity. 
Our single-center trial, started before the STOP-NIDDM results were published, studied 
the effect of chronic lowering of postprandial glucose excursions on beta-cell function and 
insulin sensitivity. Our primary objectives were to investigate the effects of acarbose on the 
distribution of the two-hour plasma glucose level following an intake of 75g of glucose, the 
incidence of conversion to type 2 diabetes, on insulin secretion induced by hyperglycemia, 
and on insulin sensitivity. 
 
 
maTErialS aND mEThODS
In a randomized, double-blind, placebo-controlled, parallel-group study, we compared 
acarbose with placebo in patients with impaired glucose tolerance. The three-year 
intervention was preceded by three pre-randomization study phases: an initial screening, 
a six-week qualification period, and a wash-out period. The ethical committee of the VU 
University Medical Center approved the protocol. All participants gave written informed 
consent.
We defined the primary outcome measure as the plasma glucose level two hours after 
oral intake of 75g glucose after three years of treatment (OGTT). Assuming that the mean 
two-hour post-load glucose level in patients with impaired glucose tolerance, when treated 
with placebo, increases 0.25 mmol/L in three years, that the mean level in patients treated 
with acarbose decreases 0.25 mmol/L in three years 21 22, and that the standard deviation 
of the levels is stable in both groups and remains equal to the standard deviation in the 
comparable subpopulation of the Hoorn Study survey [0.67 mmol/L] 3, we determined that 
we would need 47 participants in each treatment group to demonstrate the resulting 0.5 
mmol/L difference as statistically significant with alpha (two-sided) = 0.05 and beta = 
0.05. Thus, we needed complete data from 94 participants to provide sufficient statistical 
power.
Using the population register of the town of Hoorn in the Netherlands, we mailed invitations 
to take a blood glucose test to 12,093 randomly selected 45–74-year-old persons. Of those, 
6,651 (55%) visited the study center. We immediately excluded anyone who had: diseases 
or conditions likely to prevent completion of the study, known uncorrected endocrine 
disorders, documented gastrointestinal diseases, cholesterol >10 mmol/L or triglycerides 
>10 mmol/L, treatment with lipid lowering medication (with the exception of statins), a 
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myocardial infarction within the previous six months, impaired liver function (AST/ALT 
>50 units/L), or impaired kidney function (creatinine >150 mmol/L).
Of the remaining participants, the 3,147 with fasting plasma glucose levels >5.5 mmol/L 
underwent an oral glucose tolerance test. That test identified 554 participants with two-
hour plasma glucose levels >7.8 mmol/L; they returned two weeks later for a second test. 
In the end,  171 participants met the inclusion criteria: a mean fasting plasma glucose level 
<7.8 mmol/L, a mean two-hour plasma glucose level of 8.6–11.1 mmol/L, an HbA1c level 
≤7.0% and aged 45–70 years. These 171 participants were selected for the qualification 
period. The mean two-hour plasma glucose level of 8.6–11.1 mmol/L as inclusion criterion 
was chosen because of the higher incidence of  conversion of diabetes 14.
At the start of the study, the World Health Organization (WHO) definition of 1985 classified 
T2DM as a fasting plasma glucose value of  ≥7.8 mmol/l and/or a two-hour plasma glucose 
value of  ≥11.1 mmol/l 22 and Impaired Glucose Tolerance (IGT) as a fasting plasma glucose 
value of  < 7.8 mmol/l and/or a two-hour plasma glucose value of  ≥ 7.8 and <11.1. In 
1999, during the study, the WHO lowered the fasting plasma glucose value criterion for 
T2DM to  ≥7.0 and for IGT a fasting glucose value <7.0 (the two-hour plasma glucose 
value remained unchanged) 23. 
As the qualification period began, participants started with one tablet acarbose per day 
in week 1 and two tablets per day in week 2, they reached the maintenance dose of 
50 mg three times each day in week 3 and continued that dose through week 6. We 
selected this dose because previous studies had demonstrated that it significantly 
lowered postprandial blood glucose with fewer side-effects than a dose of 300 mg/day 
20-22. Participants were instructed to take their tablets with the first bite of a meal.   
 
At the end of the qualification period, participants were considered eligible for the wash-
out period and subsequent trial if they met the following criteria: having complied with 
the study procedures, having taken more than 80% of the prescribed medication during 
the qualification period’s third through sixth weeks (as determined from returned tablet 
blisters), and having reported no adverse effects that that could threaten future compliance. 
All eligible participants received placebo tablets for the four-week wash-out period.
 
After the qualification and wash-out periods, study numbers were randomly assigned to 
the placebo or the acarbose group, generated by a computer at Bayer’s biometric unit. 
The numbers were assigned in ascending order in sequence of the subject’s entry into 
the intervention study. The identity of the treatment groups was concealed until the final 
statistical analysis.
The intervention period lasted three years and one month. After an initial two weeks of 
up-titration, participants received either the maintenance dose of three 50 mg tablets of 
acarbose per day or placebo. Placebo tablets matched the acarbose tablets in size, shape, 
and color. Counts of tablets remaining at the end of each three month treatment period 
were recorded in a drug inventory form as an indication of compliance. 
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Figure 1. overview of subject disposition
postal invitation
n = 12,093
first screening
n = 6,651
ogTT (fpg > 5.5 mmol/l)
n = 6,651
subjects randomized
n = 118
completers
n = 36
completers
n = 30
placebo
n = 58
acarbose
n = 60
subjects enrolled
post-load glucose 
> 8.5 and < 7.8 mmol/l
n = 171
drop-outs
n = 22
  Primary reason:
  adverse event (n=8)
  consent withdrawn (n=1)
  death (n=3)
  lack of efficacy (n=6)
  lost to follow-up (n=1)
  non-compliance (n=3)
drop-outs
n = 30
  Primary reason:
  adverse event (n=22)
  consent withdrawn (n=2)
  death (n=1)
  lack of efficacy (n=2)
  non-compliance (n=3)
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mEaSurEmENTS
At the start of the intervention, we measured participants’ height, weight and body mass 
index 23. Fasting plasma glucose was measured every three months, and participants took 
an OGTT twice at intervals of 18 months. Tablets were not taken on the morning of these 
measurements. 
Fasting and two-hour post-load plasma glucose levels were measured with a hexokinase 
method (Boehringer, Mannheim, Germany). Plasma-specific insulin (milli-units/L) was 
measured by an immuno-radiometric assay (Medgenix Diagnostics, Fleurus, Belgium), 
and intact proinsulin (milli-units/L) by an immuno-radiometric assay based on antibodies 
(Dako, Cambridgeshire, United Kingdom). Total cholesterol, HDL cholesterol, and 
triglycerides were measured by enzymatic methods (Roche, Mannheim, Germany).
At the start of the intervention, participants underwent a hyperglycemic clamp after at 
least 12 hours of fasting. Lying down, they were administered a priming infusion of saline 
(0.9%) and glucose (20%). Blood was sampled through a cannula inserted into a vein on 
the back of the hand of the opposite arm. The hand was placed in a thermo-regulated box 
at 45° C to arterialize the venous blood. After infusion of a bolus of glucose (150 mg/kg), 
blood glucose was measured with a glucose analyser (Yellow Springs Instrument, Inc., 
Yellow Springs, OH, USA) at 2.5 minute intervals. Blood glucose was maintained for 170 
minutes at a hyperglycemic level of 10 mmol/L. Insulin samples were taken at 2.5 minute 
intervals during the first ten minutes and at 5–10 minute intervals for the remaining 160 
minutes.
We estimated beta-cell function by assessing the first phase insulin secretion in the first 
10 minutes of the clamp, calculating (using the trapezoidal rule) the area under the curve 
(AUCins0-10) of the insulin levels of the first ten minutes of the clamp. We also estimated 
insulin sensitivity. Under stable conditions of constant hyperglycemia, the amount of 
glucose infused (mg/kg/minute) equals the amount of metabolized glucose (M). We 
calculated (again, using the trapezoidal rule) the area under the curve of the glucose 
infusion rate during the last 20 minutes of the clamp. The M value divided by the average 
plasma insulin concentration (I) during the same interval – the M/I ratio – provides a 
measurement of tissue sensitivity to insulin (mg/kg/minute per milli-units/L). Finally, as 
a measurement of beta-cell function adjusted for insulin sensitivity, we calculated the ratio 
between the first insulin secretion phase and the M/I.
Participation in the intervention was terminated for any of the following reasons: refusal 
to cooperate, emergence of inter current illness, serious side-effects, or unacceptably high 
glucose levels.  We took final data measurements at the end of the treatment period or 
when a participant converted to diabetes. For participants who withdrew early, we tried 
to determine the reason for termination and to carry out as many scheduled follow-up 
measurements as possible, giving highest priority to the primary efficacy measure. In cases 
of loss to follow-up, we tried to determine the reason for the loss and to obtain a final 
assessment of the primary measure of efficacy.
 
 
STaTiSTiCal aNalySiS
We performed analyses of both the intention-to-treat and the per-protocol populations. We 
removed participants from the per-protocol analysis if a treatment code was broken, lab 
results were unacceptable, or data essential to statistical analyses were missing. 
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Using t tests, we compared fasting plasma glucose, two-hour post-load plasma glucose, 
HbA1c, and lipid levels between the treatment groups. We performed primary efficacy 
analyses for both the intention-to-treat and per-protocol groups. In cases where a patient 
needed blood glucose lowering treatment, we used the two-hour post-load level measured 
prior to the start of the treatment. We compared the mean differences between both fasting 
and two-hour post-load levels at the start of the intervention and the last visit (t tests). We 
performed multiple regression analysis with the last fasting and two-hour post-load levels 
as the dependent variables, and the following independent variables: an indicator variable 
for the treatment contrast (0 = placebo; 1 = acarbose), the baseline fasting and two-hour 
post-load plasma glucose levels, age, and sex. The effects of acarbose treatment on levels 
of insulin secretion and insulin sensitivity as measured by the clamp were evaluated using 
linear regression analysis, with acarbose as the indicator variable, adjusted for the baseline 
value, age, and sex. Finally, we calculated the rate of conversion to diabetes with relative 
risk reduction, attributable risk, and absolute risk reduction. 
 
 
rESulTS
Of the 171 participants who entered the qualification phase, 53 were ineligible to continue; 
therefore, 118 participants were randomized. From these participants, 25 persons (21.2%) 
had a fasting glucose value >7.0 mmol/l, and had T2DM according to the WHO99 
criterion. By the end of the intervention, 52 participants had dropped out for various 
reasons, leaving 66 participants with complete data sets for the per-protocol analysis. 
Table 1 summarizes the participants’ demographic data. The treatment groups showed no 
important differences, with the exception of a statistically significant difference in their 
levels of HbA1c [acarbose 5.9% (95% CI: 5.77%; 6.03%) versus placebo 5.6% (95% CI: 
5.44%; 5.76%); p < 0.05). 
Variable
Placebo
n=58
Acarbose
n=60
non-randomized 
n=53
Age (years) 56.5 ± 7.0 58.5 ± 7.9 56.7 ± 8
Sex (% male) 50.0 50.8 42.0 
Body mass index (kg/m2) 29.5 ± 3.8 28.4 ± 3.9 28.8 ± 4.1
Waist/hip ratio 0.89 ± 0.07 0.89 ± 0.09 0.89 ± 0.09
Fasting glucose (mmol/L) 6.5 ± 0.6 6.6 ± 0.5 6.5 ± 0.6
Two-hour post-load glucose (mmol/L) 9.5 ± 0.7 9.6 ± 0.7 9.7 ± 0.8
hbA1c (%) 5.6 ± 0.6 5.9 ± 0.5 5.7 ± 1.1
Current smoker (%) 23.3 24.6 44.0
Table 1. demographic characteristics of study participants at screening
all data (except sex and smoking status) given as arithmetic mean ± (standard deviation).
Tables 2 and 3 summarize the course of plasma glucose, plasma insulin, and lipid levels by 
comparing mean values at baseline and end of treatment. The two-hour post-load plasma 
glucose showed a decrease in the acarbose group. Fasting total triglycerides increased 
in participants on placebo and decreased in participants on acarbose. Table 3 shows the 
results of the regression analyses. In the intention-to-treat analysis, but not in the per-
protocol analysis, acarbose showed a statistically significant effect on the two-hour post-
load levels. 
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Table 3 also shows the results of the regression analysis of the clamp-derived variables of 
insulin secretion and insulin sensitivity at baseline and after three years. For this analysis, 
52 participants (27 placebo, 25 acarbose) underwent a hyperglycemic clamp twice. Five 
of these participants had converted to type 2 diabetes. No statistically significant effect of 
acarbose could be determined. 
The rate of conversion to diabetes according to the former WHO criterion (WHO85) in the 
placebo group was 24.1% and in the acarbose group 18.3%. The relative risk was 0.76 
(95% CI: 0.38;1.53), the attributable risk: -0.14 (95% CI: -0.46; 0.21), and the absolute risk 
reduction 6% (95% CI: -9; 21). 
The number of drop-outs due to adverse events was much higher with acarbose than with 
placebo (36.7% versus 13.8%). Acarbose had a significantly higher rate of side-effects, 
most affecting the gastrointestinal system: abdominal pain (13.1% versus 3.3%), diarrhea 
(19.7% versus 1.7%), and flatulence (44.3% versus 3.3%). None of the documented 
gastrointestinal adverse events were regarded as serious. One participant in the acarbose 
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Table 2. Descriptive course of test results 
Placebo group Acarbose group
Two-hour post-load plasma glucose (mmol/L)
Baseline
       mean value 9.51 ± 0.66 (58) 9.58 ± 0.74 (60)
Last visit (per-protocol)
mean value 
mean difference acarbose vs placebo
  -0.49 (95% CI: -0.56; 1.56)
8.57 ± 2.31 (36) 8.13 ± 2.41 (30) 
Last visit (intention-to-treat)
mean value 
mean difference acarbose vs placebo
-1.16 (95% CI: -2.03; -0.17)**
9.28 ± 2.71 (58) 8.18 ± 2.33 (60) 
Fasting plasma glucose (mmol/L)
Baseline
       mean value 6.50 ± 0.61 (58) 6.59 ± 0.56 (60)
Last visit (per-protocol)
mean value 
mean difference acarbose vs placebo
-0.06 (95% CI: -0.46;0.34)
6.38 ± 0.99 (36) 6.34 ± 0.77 (30) 
Last visit (intention-to-treat)
mean value 
mean difference acarbose vs placebo
-0.16 (95% CI: -0.48;0.15)
6.58 ± 1.05 (58) 6.39 ± 0.77 (60)
Fasting total triglycerides (mmol/L)
Baseline
mean value 2.09 ± 1.03 (53) 2.34 ± 1.58 (49)
Last visit (per-protocol)
Mean value 2.25 ± 1.43 (36) 2.19 ± 1.38 (30)
Last visit (intention-to-treat)
mean value
       mean difference acarbose vs placebo
       -0.57(95% CI: -1.08; -0.06)**
2.45 ± 1.52 (53) 2.12 ± 1.22 (49)
Note: All data given as arithmetic mean ± standard deviation (n). **p<0.05
Table 3 also shows the r sults of the regression analysis of the clamp-derived var ables of
insulin secretion and insulin sensitivity at baseline and after three year . For this analysis,
52 participants (27 placebo, 25 acarbose) underwent a hyperglycemic clamp twice. Five 
of these participants had converted to type 2 diabetes. No statistically significant effect of 
acarbose could be determined. 
The rate of conversion to dia etes according to the former WHO criterion (WHO85) in the
placebo group was 24.1% and in the acarbose group 18.3%. The relative risk was 0.76 
(95% CI: 0.38;1.53), the attributable risk: -0.14 (95% CI: -0.46; 0.21), and the absolute risk 
reduction 6% (95% CI: -9; 21). 
The number of drop-outs due to adverse events was much higher with acarbose than with
placebo (36.7% versus 13.8%). Acarbose had a significantly higher rate of side-effects,
most affecting the gastrointes inal syst m: ab ominal pain (13.1% versus 3.3%), di rhea
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Table 3 also shows the result  of the regression analysis of the clamp-derived variables of
insulin secretion and insulin ensitivity at baseline and after three years. For this analysis,
52 participants (27 placeb , 25 acarbose) un erwent a hypergly emic clamp twice. Five
of these participants had c nverted to type 2 iabetes. No statisti ally significant effect of
acarbose could be determined. 
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group died from colon carcinoma approximately eight months after a last treatment, but 
the death was not considered related to this treatment. 
 
 
DiSCuSSiON
In this study, we evaluated the effects of a three-year treatment with acarbose in patients 
with impaired glucose tolerance. The results partially support our initial hypothesis. In 
both the per-protocol and intention-to-treat analyses, acarbose lowered the mean two-
hour post-load plasma glucose; in the intention-to-treat analysis the difference between 
acarbose and placebo was statistically significant. We also observed a statistically 
significant and clinically relevant decrease in total triglycerides in the acarbose group. We 
found no differences with regard to fasting glucose, HbA1c, or conversion to diabetes. Nor 
did we observe any beneficial effects of acarbose treatment on insulin secretion or insulin 
sensitivity. The frequency and pattern of observed adverse events did not deviate from 
the already known safety profile of acarbose, which is associated with gastrointestinal 
complaints. These results support those of the STOP-NIDDM trial 18-20.
Despite screening of a large population (12,093), we identified only 118 eligible participants 
for the trial, due to a high drop-out rate. The main reason for this pre-mature drop-out 
was gastro-intestinal side-effects. This phenomenon limits the use of acarbose. Because 
of the rate of premature drop-outs (higher than in other acarbose studies), we had data 
for only 66 participants for the per-protocol analysis. This did not meet the requirement 
of 47 participants in each treatment group necessary for sufficient statistical power. We 
believe that this lack of power is the main reason that our results were not statistically 
significant in this analysis. Another limitation of this study is that we could not calculate a 
power-analysis on insulin secretion or insulin sensitivity, because of a lack of information 
on a meaningful difference in both measures and unknown standard deviations of these 
measures in this population. However, if a decrease of HbA1c and two-hour post-load 
glucose values would be explained by insulin secretion or insulin sensitivity, a statistically 
significant change should have occurred. Finally, there was small but significant HbA1c 
difference between the acarbose and control group at baseline, although there was no 
significant difference between the post-load glucose levels.  Several other studies have 
looked at preventing or delaying conversion of impaired glucose tolerance to type 2 
diabetes. All of these studies had to screen large populations to find sufficient numbers of 
eligible participants 15-20. In addition to the difficulty of finding participants, it is also very 
difficult to motivate patients with impaired glucose tolerance to comply with treatment 
protocols, especially when they are not yet suffering hyperglycemia-related complaints. 
These are but two limitations of this kind of prevention study. 
The STOP-NIDDM and a Chinese multicenter study are the other trials that analyzed 
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Dependent Added variables Beta (95% CI)
Post-load plasma glucose (mmol/L) Baseline post-load glucose, age, sex -1.18 (-2.11; -0.24)**
Fasting plasma glucose (mmol/L)
First insulin secretion phase
Insulin sensitivity*
Disposition index
Baseline fasting glucose, age, sex
Baseline first insulin secretion, age, sex
Baseline insulin sensitivity, age, sex
Baseline disposition index, age, sex
-0.16 (-0.46; 0.15)
-5.07 (-11.96; 1.81)
1.34 (-2.28; 4.96)
-7.28 (-80.56; 66.0)
Table 3. Linear regression analysis with acarbose as independent variable
* Insulin sensitivity = M/I value (M = amount of met bolized glucose/I = average plasma insulin concentration) 
** p<0.05.
group died from colon carcinoma approximately eight months after a last treatment, but 
the death was not considered related to this treatment. 
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acarbose as a diabetes prevention treatment. In contrast with our study, the STOP-NIDDM 
trial showed a delay in the conversion to diabetes 18-20. In that study, the maintenance 
dose of acarbose was twice the dose in our study; this factor, among others, may explain 
the inconsistent results. However, a systematic review of alpha-glucosidase inhibitors 
concluded that dosages higher than 150 mg/day had no better effect on glycemic control 23. 
Moreover, the STOP-NIDDM results have been questioned because that study used a 
modified intention-to-treat analysis and there was a considerable difference in participants 
who already had diabetes at baseline. The Chinese study found no effect of acarbose on 
the prevention of the development of type 2 diabetes 24.
No other study has presented data on the effects of acarbose on insulin sensitivity and 
insulin secretion with clamp-derived measures. We hypothesized that acarbose would have 
a positive effect on insulin secretion and thus beta-cell function by delaying the gastro-
intestinal absorption of glucose and ameliorating postprandial hyperglycemia. However, 
we found no such effect. This concord with an acarbose intervention study with patients 
with early diabetes 25.
In summary, our study showed that acarbose lowers two-hour post-load plasma glucose, 
but failed to show that it delays conversion to type 2 diabetes. We observed no effect of 
acarbose on insulin secretion or insulin sensitivity. 
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iNTrODuCTiON  
Diabetes mellitus, a disease known from ancient times, has reached epidemic proportions 
in the previous decade, with more than 194 million affected people worldwide. Global 
estimations predict a further increase of almost 50% for the year 2010, with the greatest 
increase in the developing countries of Africa, Asia and South America. Type 2 diabetes 
mellitus (T2DM) accounts for some 90% of the adult onset diabetes. A large part of the 
medical and socio-economic burden of the disease is caused by the diabetes associated 
complications. Cardiovascular morbidity is 2 to 4 fold greater in type 2 diabetic patients, 
compared to non-diabetic persons. Micro-vascular complications include renal disease, 
retinopathy and neuropathy. 
Both genetic predisposition and environmental factors are involved in the pathogenesis of 
T2DM. A positive family history confers a 2 to 4 fold risk for type 2 diabetes and 15-25% of 
first degree relatives of patients with type 2 diabetes develop impaired glucose tolerance or 
diabetes. Besides the general ageing of the population in many societies, which is strongly 
associated with the increase in T2DM, there are other factors which contribute to the 
development of T2DM.      
An abundance of food, an increased energy density of the food and a more sedentary 
lifestyle have led to an increased prevalence of obesity, which is a strong risk factor for 
the development of T2DM. In particular upper body fat distribution is associated with 
an unfavourable metabolic and cardiovascular disease risk profile in both men and 
women. In addition to high fasting and post load glucose levels, which are used for the 
diagnosis, T2DM and precursor conditions are more or less characterised by a cluster of 
impaired insulin release, insulin resistance, an altered lipid profile, abdominal obesity 
and consequently a high risk for cardiovascular disease. This cluster of characteristics is 
also known as the Metabolic Syndrome. Although it is generally accepted that all these 
components aggregate in insulin resistant persons and all contribute to the pathogenesis 
of T2DM and the cardiovascular risk, for many of these components it is not clear what 
the independent contributions are. It is also not clear if these associations already exist in 
a population with a low cardiovascular disease (CVD) risk and to what degree they are 
dependent on insulin resistance. Our main research questions were;
 Is insulin secretion a better predictor for conversion to type 2 diabetes than 
 insulin sensitivity? 
 What happens to the insulin secretion in relation to the insulin sensitivity during 
 3 years of follow up?
 What determines the change of insulin secretion and insulin sensitivity in subjects 
 with impaired glucose tolerance (IGT)?
 Can insulin sensitivity explain the relationships between body fat distribution 
 and cardiovascular disease risk?
 Is insulin sensitivity associated with ECG abnormalities, independent of other 
 CVD risk factors?
 Is insulin resistance independently associated with microalbuminuria?
  
 
STuDy DESigN
The Hoorn IGT-Study was a prospective cohort study in which we investigated the role 
of insulin secretion and insulin sensitivity in the onset of type 2 diabetes in persons with 
IGT during a mean of 4 years of follow up. We also investigated putative determinants of 
change in insulin secretion (chapter 2 and 3).  
The RISC Study is an ongoing prospective cohort study of 1500 persons, in 14 European 
•
•
•
•
•
•
120 summary & samenVaTTingsummARy
countries, with a low CVD risk. It is designed to investigate the role of insulin sensitivity 
in the pathogenesis of cardiovascular disease. In chapter 4, 5 and 6 three baseline studies 
(cross-sectional) are presented.
 
 
maiN fiNDiNgS aND DiSCuSSiON
In chapter 2 we presented the results of a prospective study of Caucasian, confirmed IGT 
persons and we found that insulin sensitivity, second phase insulin secretion and the 
disposition index were no independent predictors of T2DM conversion. The strongest 
predictor was the absence of a first insulin peak (the first and fast insulin release in 
response to a glucose load), when measured by hyperglycemic clamp.   
In chapter 3 we investigated the 3-year changes in insulin sensitivity and  insulin secretion 
in a subgroup of the same IGT persons. Seven persons developed T2DM, thirty-six remained 
IGT and seven converted to normal glucose tolerance (NGT). All categories were subject 
to a decrease in insulin sensitivity, although the T2DM group experienced the largest 
decrease (>60%). The main difference between the categories was the difference in the 
change in insulin secretion. The persons who became NGT or remained IGT, both had an 
increase in insulin secretion of 140-160%. The increase in the T2DM category was next to 
nil. This was expressed in a decreasing disposition index (an integrated measure of glucose 
tolerance). The only determinant we found that was associated with a decrease in the 
disposition index  was gamma-glutamyl-transferase (GGT), which is known to be a marker 
of intra-hepatic fat accumulation. This finding supports a present pathophysiological 
hypothesis, which suggests a direct link between ectopic fat accumulation and impaired 
insulin release.  
In chapter 4 we found associations of leg and trunk fat mass with CVD risk markers, 
which have previously been found in less healthy or more elderly populations. After 
adjustment for overall body fat, larger leg fat mass was associated with a more favorable 
CVD risk profile. In men it was associated with lower triglycerides (TG’s). Larger trunk 
fat mass was associated with a less favourable CVD risk profile. In men and women it 
was associated with a lower HDL-cholesterol (HDL) and higher TG’s and in women only 
it was associated with higher fasting insulin, higher fasting glucose and higher blood 
pressure. However, we could not find a mediating or confounding role of whole body 
insulin sensitivity in these associations. This suggests a more direct influence of body fat 
on CVD risk profile. Furthermore, whole body insulin sensitivity was associated with ECG 
abnormalities independent of demographic factors, but not independently of estimates of 
body fat (chapter 5).    
In chapter 6, we present the results of analyses on the association between insulin resistance 
and microalbuminuria. Insulin resistance was strongly associated with the prevalence of 
microalbuminuria, independently of heart rate, glomerular filtration rate (GFR), blood 
pressure, overweight and fasting insulin and TG’s. High TG’s were also associated with 
microalbuminuria, although not independent of insulin sensitivity. The existence of this 
association in a non-hypertensive, low CVD risk population; suggests a direct mechanistic 
link between insulin sensitivity and microalbuminuria.
 
 
iN CONCluSiON   
Although insulin resistance is regarded as an important determinant of conversion to 
T2DM and the most important clustering factor for the cardiovascular risk factors present 
in the metabolic syndrome, our data suggest other factors are also important. First of all, 
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in Caucasian IGT persons, impaired fast insulin release seemed to be a better predictor 
for T2DM conversion than insulin resistance. Secondly, from our studies in the “healthy” 
Europeans, we found that in all associations between different types of body fat and 
indicators of CVD, there was no, or very little,  mediating or confounding role of insulin 
sensitivity. This was true for HDL-cholesterol, Triglycerides, blood pressure and even 
ECG abnormalities. However, we did find a strong association between insulin resistance 
and microalbuminuria and this has to be investigated further. Since the study was cross-
sectional, conclusions on cause and consequence can’t be drawn. Therefore, much can 
be expected from the results of the follow up study of this population. What became 
clear in this study, is that even in a low risk population the detrimental influence of 
abdominal fat on the metabolic and CVD profile is already present. This underscores the 
idea that overweight is an important target in the prevention of CVD and should always 
be addressed, even in a young and healthy population. Thus, insulin resistance surely is 
an important factor in the pathogenesis of both type 2 diabetes and CVD. However, it is 
one among others.
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Diabetes mellitus is een ziekte die al beschreven werd in de oudheid. In de afgelopen 
eeuw nam het aantal mensen met diabetes wereldwijd sterk toe en dat resulteerde in 194 
miljoen mensen met diabetes in 2003. Type 2 diabetes neemt ongeveer 90% in van alle 
diabetesvormen en wordt in de volksmond ook wel “ouderdomssuikerziekte” genoemd.  
Patiënten met type 2 diabetes hebben met name problemen met het regelen van hun 
bloedglucose en hun bloedvetten. Dit geeft op den duur een verhoogde kans op hart– en 
vaatziekten. De kans op bijvoorbeeld een hartinfarct bij mensen met type 2 diabetes is 
twee tot vier keer zo groot als bij mensen zonder diabetes. De gangbare gedachte is dat 
een combinatie van te veel eten, te weinig bewegen en erfelijke aanleg voor de ziekte zorgt 
voor stoornissen in glucose- en vetstofwisseling. 
Er is al heel veel onderzoek gedaan naar de oorzaak  van diabetes. Het is echter nog niet 
duidelijk wat de belangrijkste factor is voor het ontstaan van type 2 diabetes en daaraan 
gerelateerde hart- en vaatziekten. Enerzijds wordt verminderde insulinegevoeligheid als 
de belangrijkste factor genoemd, terwijl een andere theorie zegt dat het een veranderde 
insulineproductie is. Het doel van het onderzoek in dit proefschrift is de bijdrage van 
insulineproductie door de alvleesklier en de insulinegevoeligheid van het lichaam, aan 
het ontstaan van type 2 diabetes en hart– en vaatziekten te onderzoeken. Tevens werd 
gekeken naar de invloed van overgewicht, beweging en andere factoren. 
 
 
ONDErzOEkSOpzET 
Er zijn twee groepen vrijwilligers onderzocht. In de “Hoorn IGT-studie” zijn mensen 
onderzocht die een licht gestoorde glucosestofwisseling (impaired glucose tolerance (IGT)) 
hadden. Zij werden gemiddeld gedurende 4 jaar gevolgd. Er werd vervolgens gekeken wie 
type 2 diabetes kreeg en of dat werd veroorzaakt door een verminderde insulineproductie 
of door een verminderde insulinegevoeligheid. Overgewicht en vetten in het bloed werden 
ook gemeten. 
In de “RISC-studie” zijn gezonde mensen onderzocht, tussen de 30 en de 60 jaar oud. De 
RISC studie (Relationship between Insulin sensitivity and Cardiovascular disease) is een 
internationale studie waarin  mensen uit verschillende Europese landen zijn onderzocht 
om het verband te bekijken tussen insulinegevoeligheid en hart– en vaatziekten.
 
 
ONDErzOEkSrESulTaTEN EN DiSCuSSiE
In hoofdstuk 2 laten we zien dat een gestoorde snelle insulineproductie de belangrijkste 
voorspeller was voor het krijgen van type 2 diabetes bij mensen met IGT. Verminderde 
insulinegevoeligheid was niet voorspellend. Omdat het beschrijven van de insulineproductie 
op deze manier nog niet eerder gedaan is, is dit een nieuwe bevinding die we nog niet 
precies kunnen vergelijken met resultaten uit ander onderzoek.
In hoofdstuk 3 beschrijven we de veranderingen van de insulineproductie en de insuline 
gevoeligheid in het lichaam gedurende drie jaar. We hebben gekeken of er verschillen 
samenvatting
“InsulIn; sense and sensItIvIty”
InsulInesecretIe en InsulIneGevoelIGheId In relatIe tot type 2 dIabetes  
en hart- en vaatzIekten
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waren tussen personen die type 2 diabetes hadden gekregen, personen die IGT werden, 
en personen die weer een normale glucosestofwisseling hadden gekregen. We zagen dat 
bij iedereen de insulinegevoeligheid afnam. Bij de mensen wiens glucosestofwisseling 
normaliseerde  of hetzelfde (IGT) bleef, nam de insulineproductie toe. Alleen bij de mensen 
die type 2 diabetes ontwikkelden nam de insulineproductie niet toe. Wij concludeerden 
daarom dat, in deze fase, een toename van de insulineproductie bepaalt of personen 
type 2 diabetes krijgen. Verder bestudeerden we de factoren die met de verandering van 
insulineproductie samenhingen. We vonden een relatie tussen hoge spiegels van een 
leverenzym (GGT), wat mogelijk wijst op opstapeling van vet in de lever en gebrek aan 
toename van de insulinesecretie.  
In hoofdstuk 4 laten we zien dat bij gezonde Italianen en gezonde Nederlanders die 
meededen aan de RISC studie, een  relatie bestaat tussen de hoeveelheid opgeslagen vet 
in de benen en in de buik en het risico op hart– en vaatziekten. Een grotere hoeveelheid 
vet in de benen had vooral een gunstige relatie met het hart- en vaatziekten risicoprofiel 
(lagere triglyceriden in het bloed bij mannen; bij vrouwen had het een gunstige relatie met 
alle risicofactoren voor hart- en vaatziekten).  Een grotere hoeveelheid vet in de buik en 
rondom de buik ging gepaard met ongunstige waarden van bijna alle risicofactoren voor 
hart- en vaatziekten, bij zowel mannen als vrouwen. Deze relaties konden niet verklaard 
worden door een hoge of een lage insulinegevoeligheid van het lichaam. Mogelijk zijn dit 
directe effecten van het vetweefsel zelf.  
In hoofdstuk 5  beschrijven we dat bij  alle RISC deelnemers  verminderde insulinegevoeligheid 
een verband heeft met een verhoogde kans op ECG-afwijkingen. Echter, deze relatie werd 
beter verklaard door het hebben van overgewicht.  
In hoofdstuk 6 worden de resultaten getoond van een onderzoek naar het verband tussen 
insulinegevoeligheid en microalbuminurie (uitscheiding van kleine hoeveelheden eiwit 
in de urine). Microalbuminurie  heeft een relatie met het verminderde functioneren van 
de vaatwand (endotheeldysfunctie) en geeft een verhoogde kans op nierziekte. In ons 
onderzoek liet verminderde insulinegevoeligheid van het lichaam een sterke relatie zien 
met microalbuminurie. 
 
CONCluDErEND, 
kunnen we zeggen dat insulineproductie en insulinegevoeligheid beide factoren zijn die 
invloed hebben op het krijgen van type 2 diabetes. Echter, een veranderd patroon van snelle 
insulineafgifte lijkt de beste voorspeller voor het krijgen van type 2 diabetes bij mensen 
met een al gestoorde glucosestofwisseling. Als voorwaarde om de glucosestofwisseling te 
kunnen normaliseren bij een verminderde insulinegevoeligheid, leek het vermogen tot een 
toename van de insulineproductie belangrijk. 
Bij mensen met een laag risico op hart– en vaatziekten bevestigen we eerder onderzoek 
dat een relatie vond tussen meer buikvet en een minder gunstig hart– en vaatziekten 
risicoprofiel. Beenvet had daarentegen een gunstige relatie. Deze relaties konden niet 
verklaard worden door een hoge of lage insulinegevoeligheid. Lage insulinegevoeligheid 
had wel een sterke relatie met microalbuminurie, wat wijst op beginnende vaatschade. 
Blijkbaar zijn voor de ontwikkeling van type 2 diabetes en hart– en vaatziekten meerdere 
factoren van belang naast insulinegevoeligheid.
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